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Introduction
introDuction
Intensive care patients are subject to many factors that may influence the patients’ state of 
comfort or distress. Pain is the main cause of distress experienced by many adult intensive 
care patients [1], which can be caused by different factors like underlying disease, prolonged 
immobility and standard routine nurse care such as mobilization or chest drain removal [2]. 
In previous studies, 45-83% of conscious intensive care patients rated their pain intensity as 
moderate to severe, at rest as well as during procedures [3-5]. Also most sedated mechani-
cally ventilated patients experience some degree of pain even in the absence of surgical inci-
sions or trauma [6-7]. Researchers have recognized that pain and inadequate pain relief are 
major causes of physiological adversity and emotional stress [2,8-9], disorientation and sleep 
deprivation [2]. As a result, adequate use of analgesics may decrease morbidity and mortality 
[10] and improve the quality of life in intensive care patients [3].
Pain aSSeSSment in intenSiVe care PatientS
In order to manage pain adequately, effective methods for the recognition, evaluating and 
monitoring of pain are essential. Although regular assessment and documentation of pain 
and response to therapy is recommended by the Society of Critical Care Medicine (SCCM) 
[2] and the Netherlands Society of Intensive Care (NVIC) [11], a previous study revealed that 
the observed rates of assessment during procedural pain in mechanically ventilated patients 
remain below 40% [12]. Besides, 35% to 55% of the nurses have been reported to underrate 
patients’ pain [1,13]. Additionally, pain assessment in intensive care patients may be compli-
cated by mechanical ventilation and decreased consciousness as a result of the severity of 
illness and the use of sedatives in these patients, particularly when high doses of sedatives 
are administered [3-4]. Every patient in the intensive care unit will pass different phases of 
consciousness from deep sedation in the first stage of the disease or after surgery to a fully 
conscious and communicative patient. Apart from conscious patients and deeply sedated 
patients, a third group can be identified, i.e. conscious sedated (mechanically ventilated) 
patients. Current intensive care unit practice strives to restrict sedation to a conscious level 
whenever possible, in agreement with the landmark report [14] that showed that ventilated 
patients benefit from daily interruption of sedative infusions. The suitability of the pain as-
sessment instrument depends on the psychometric characteristics of the available pain 
scales, the sedation state of the patient and the ability for abstraction and comprehension of 
the patient at the moment of pain assessment.
In conscious patients, self-report is still the ‘gold standard’ for pain assessment according 
to the guidelines of the International Association for the Study of Pain [2]. So far, the numeric 
rating scale (NRS; range 1 to 10) and the visual analogue scale (VAS; range 1 to 100) have 
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been validated for acute pain only. Both scales are not validated in mechanically ventilated 
patients in the intensive care unit [15]. However, in sedated patients, the self-report of the 
patient is usually not available [16-17]. For these patients, several observational pain scales 
are available. The behavioral pain scale (BPS; range 3-12) for example, was developed spe-
cifically for measuring the severity of pain in sedated, mechanically ventilated, unresponsive 
patients [18], and consisted of three pain related behaviours; facial expression, upper limbs 
movements and compliance of mechanical ventilation. In conscious sedated mechanically 
ventilated patients, self-reporting using the NRS or VRS-4 (range 1-4) may be complicated 
or unreliable in these patients due to their temporarily limited capacities of abstraction and 
concentration, and lack of comprehension [1-2]. From this point of view, it is of interest which 
health care worker (nurse, physician or consultant) should score pain in case the patient can-
not communicate verbally. While the attending nurse is involved in daily care of the patient, 
the physician seems to have a more distant relation to the patient. Until now, the most ap-
propriate health care worker, who should score pain in case the patient is not able to report 
pain is not known. Furthermore, it is unknown which pain assessment instrument is most 
adequate in intensive care patients.
Pain management for intenSiVe care PatientS after carDiac 
Surgery
When pain is measured with appropriate pain scales, this will result in the ability to man-
age pain adequately. Despite the high incidence of pain, physicians may be uncomfortable 
treating pain using opioids, because of impaired mental status and altered pharmacokinetics 
and pharmacodynamics of analgesics as result of organ system dysfunction in intensive care 
patients [3]. Additionally, opioid analgesia is commonly associated with adverse effects, 
including hypotension and respiratory depression, and worse outcomes as increased me-
chanically ventilator days and depressed neurological status [19]. Puntillo et al. [4] confirmed 
this observation in an observational study, in which 64% of the patients did not even receive 
analgesics before or during a painful procedure, such as wound care or drain removal. How-
ever, preventing pain is more effective than treating established pain. When patients receive 
drugs on an ‘as needed’ basis, they may receive less than the prescribed dose and encounter 
significant delays in treatment [2]. Thus, analgesics should be administered on a continuous 
or scheduled basis, with supplemental bolus doses as required. On the other hand, higher 
doses of continuous infusions of analgesics may result in more side effects as respiratory 
depression, constipation or nausea. Therefore, a pain management plan and therapy goal 
should be established for each patient and re-evaluated as the clinical condition changes 
[2]. While to date, the implementation of protocols improves with a more patient-orientated 
regime for analgesia and sedation, a trend is observed away from a hypnosis-based approach 
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towards an analgesia-based approach. Although these changes may improve pain and se-
dation practice, further efforts are needed for widespread implementation of pain scoring 
systems and analgesia protocols [20-21].
morPHine anD Paracetamol analgeSia in intenSiVe care PatientS
Both the SCCM [2] and the NVIC guidelines [11] recommend the use of morphine or fentanyl 
as intravenous opioid analgesics for postoperative pain relief [2]. Overall, opioids have mini-
mal haemodynamic effects in euvolemic patients [22]. Besides, morphine may provide car-
dioprotection and anti-inflammatory response in contrast to fentanyl in patients after cardiac 
surgery [23-25], and is therefore one of the most commonly used drug in pain management 
[26].
Morphine is metabolised via glucuronidation by phase II metabolism enzyme UDP-
glucuronosyl transferase-2B7 (UGT2B7). Regardless of the mode of administration, approxi-
mately 44–55% of a morphine dose is converted to M3G, which is the main metabolite, and is 
suggested to have antagonistic or hyperalgesic effects [27-28]. The metabolite morphine-6-
glucuronide (M6G), is formed in 9-10% of the morphine dose, and may have analgesic activity 
[29]. The morphine dose required to produce analgesia for pain relief is characterized by a 
large inter-individual variability. This variability may partly be explained by environmental 
factors, as age, gender or anxiety [30-32]. Some genetic polymorphisms have also been 
described and may partly explain the variability of morphine’s analgesic effects [33-34], 
although its clinical relevance is unknown.
Especially intensive care patients, who may suffer from a variety of diseases, which can 
range from patients undergoing elective (cardiothoracic) surgery to patients suffering from 
sepsis with multi-organ failure and circulation failure, the pharmacokinetic and pharmaco-
dynamic parameters of analgesics may be altered in these patients. Additionally, the use of 
sedatives in these patients may influence the effect of the analgesics. Eventually, this results 
in a complex treatment of each individual intensive care patient [16-17].
objectiVe of tHe tHeSiS
The overall goal was to improve pain management in patients after cardiac surgery and criti-
cally ill patients in the intensive care unit.
Therefore, the first main objective is to study the most optimal method for measuring pain 
in intensive care patients.
The second aim was to improve pain management at rest and during routine care proce-
dures in patients after cardiac surgery in the intensive care unit.
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At last, we studied the pharmacokinetics of morphine and metabolites in intensive care 
patients and the safety of paracetamol in intensive care patients after cardiac surgery.
outline of tHe tHeSiS
Pain assessment in intensive care patients
Improvement of effective pain management can only be achieved with accurate pain assess-
ment. In chapter 2 we evaluated three pain rating scales for pain at rest, e.g. the numeric 
rating scale (NRS), the behavioral pain scale (BPS) and visual analogue scale (VAS) in (non-)
ventilated intensive care patients, who were conscious or sedated. In chapter 3, the behav-
ioral pain scale (BPS) and the verbal rating scale (VRS-4) were compared for pain assessment 
at rest in conscious sedated patients.
Pain management for intensive care patients after cardiac surgery
In order to reduce the incidence for pain at rest, in chapter 4 the impact of the implementa-
tion of a pain management programme, which consisted of systematic pain assessment by 
trained personnel, was evaluated in intensive care patients for postoperative pain at rest 
after cardiac surgery. In order to improve pain management during unavoidable routine care 
procedures, in chapter 5 we evaluated the efficacy of two doses of a bolus morphine in 
intensive care patients who already receive continuous pain relief using morphine infusions 
and intermittent paracetamol according to a pain titration protocol. chapter 6 investigated 
the influence COMT Val158Met polymorphism on pain sensitivity in morphine-treated pa-
tients undergoing an unavoidable painful routine healthcare procedure after cardiac surgery. 
In a follow-up study in these patients, the development of chronic pain after sternotomy was 
evaluated in chapter 7.
morphine and paracetamol analgesia in intensive care patients
Morphine was studied in the population of postoperative cardiac patients and critically ill 
patients, who are characterized by high variability in dosing requirements between and 
within patients. In chapter 8 morphine glucuronidation and elimination clearances in inten-
sive care patients receiving continuous morphine infusions were studied, and compared to 
healthy volunteers. Finally, chapter 9 describes the safety of short-term use of paracetamol 
four grams daily in postoperative cardiac patients.
conclusions and perspectives
The results of the investigations described in this thesis are reviewed and discussed in chap-
ter 10. Additionally, the implications for clinical practice and recommendations for future 
research are provided.
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abStract
background and objectives Pain in critically ill patients in the intensive care unit (ICU) is 
common. However, pain assessment in critically ill patients is often complicated because 
these patients are unable to communicate effectively. Therefore, we designed a study (a) to 
determine the inter-rater reliability of the numeric rating scale (NRS) and the behavioral pain 
scale (BPS), (b) to compare pain scores of different observers and the patient, and (c) to com-
pare NRS, BPS, and the visual analogue scale (VAS) for measuring pain in patients in the ICU.
methods We performed a prospective observational study in 113 non-paralyzed critically ill 
patients. The attending nurses, two researchers, and the patient (when possible) obtained 
371 independent observation series of NRS, BPS, and VAS. Data analyses were performed on 
the sample size of patients (n=113).
results Inter-rater reliability of the NRS and BPS proved to be adequate (kappa = 0.71 and 
0.67, respectively). The level of agreement within one scale point between NRS rated by the 
patient and NRS scored by attending nurses was 73%. However, high patient scores (NRS 
≥4) were underestimated by nurses (patients 33% vs. nurses 18%). In responsive patients, a 
high correlation between NRS and VAS was found (rs = 0.84, P<0.001). In ventilated patients, 
a moderate positive correlation was found between the NRS and the BPS (rs = 0.55, P<0.001). 
However, whereas 6% of the observations were NRS of greater than or equal to 4, BPS scores 
were all very low (median 3, range 3 to 5).
conclusions The different scales show a high reliability, but observer-based evaluation often 
underestimates the pain, particularly in the case of high NRS values (≥4) rated by the patient. 
Therefore, whenever this is possible, ICU patients should rate their pain. In unresponsive 
patients, primarily the attending nurse involved in daily care should score the patient’s pain. 
In ventilated patients, the BPS should be used only in conjunction with the NRS nurse to 
measure pain levels in the absence of painful stimuli.
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introDuction
Pain is a frequently experienced problem in critically ill patients in the intensive care unit (ICU) 
[1]. Pain may increase morbidity and mortality and may decrease the comfort of patients and 
health related quality of life. The adequate use of analgesics and sedatives therefore may 
decrease morbidity and mortality [2]. Measurement of pain in ICU patients however, may be 
complicated by decreased consciousness, severity of illness, mechanical ventilation and the 
use of sedatives in these patients, particularly when high doses of sedatives are administered 
[3-4]. Although self-report is still the ‘gold standard’ in pain measurement according to the 
guidelines of the International Association for the Study of Pain [5], one segment of the ICU 
patients is unable to communicate effectively. In these cases, the gold standard (that is, the 
pain intensity reported by the patient) is not possible or potentially unreliable. This is also a 
common problem in, for example, neonates and children, who are not able to report pain in 
a reliable manner [6].
Therefore, pain assessment in the ICU remains a challenge for clinicians and researchers. 
There is no specific neurobiological parameter for the evaluation of pain, nor does an objec-
tive quantification of pain intensity or relief exist [7]. Various pain scales are available, but 
it remains unclear whether they can be applied reliably in the diverse patient population 
of the ICU, where patients may not only be mechanically ventilated but also are subject to 
repeated painful procedures. Therefore, it is of interest to define which score should be used 
for which patient (for example, ventilated, responsive or unresponsive) and by which health 
care worker, in case the patient cannot communicate. These results can be used to imple-
ment a systematic evaluation of pain in all ICU patients. While, to date, the use of scoring 
systems for pain severity and sedation depth and the implementation of protocols increase 
with a more patient-orientated regime for analgesia and sedation, a trend is observed away 
from a hypnosis-based approach and towards an analgesia-based approach. Although these 
changes may improve pain and sedation practice, further efforts are needed for widespread 
implementation of pain scoring systems and analgesia protocols [8-9]. Of the available pain 
scales, the numeric rating scale (NRS; range 0-10) and visual analogue scale (VAS; range 
0-100) have been validated for acute pain only, and not in mechanically ventilated patients 
in the ICU [10]. The behavioral pain scale (BPS) was developed specifically for measuring the 
severity of pain in sedated, mechanically ventilated, unresponsive patients [11], but this pain 
scale still is not generally accepted for routine use. Another question in pain management 
in the ICU is which health care worker (nurse, physician or consultant) should rate pain, in 
case the patient cannot communicate verbally. While the attending nurse is involved in close 
daily care of the patient, the physician seems to have a more distinct relation to the patient. 
Therefore, we designed a study (a) to determine the inter-rater reliability of the NRS and BPS, 
(b) to compare pain scores of different observers and the patient and (c) to compare NRS, 
VAS, and BPS for measuring pain in ventilated and non-ventilated patients in the ICU.
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materialS & metHoDS
Design
A prospective observational study was performed in a 30-bed surgical/medical ICU in a 
teaching hospital in Nieuwegein, The Netherlands. The Medical Ethical Committee of the St. 
Antonius Hospital approved the study protocol and waived the need for informed consent 
because the observational study design and pain measurements are part of the standard 
care.
Participants
All patients in the ICU who were at least 18 years old were included between 27 June and 4 
August, 2005. Patients who received neuromuscular blocking medications or muscle-para-
lysing drugs continuously, who were unconscious after resuscitation, who were quadriplegic, 
who suffered from a critical illness (poly)neuropathy, or who had an epidural catheter were 
excluded. Paralysis, whether caused by a pre-existing condition or by medication, makes the 
BPS unreliable.
Pain measurement instruments
To assess pain intensity, three pain scales (that is BPS, NRS, and VAS) were used.
The BPS is used after an observation of the patient for about one minute and was validated 
in critically ill, sedated, and mechanically ventilated patients [10-11]. The BPS is a pain scale 
for sedated and ventilated patients exclusively and is based on a sum of three subscales: fa-
cial expression, upper limb movements, and compliance with mechanical ventilation (Table 
1). Each subscale is scored from 1 (no response) to 4 (full response). Therefore, BPS scores 
range from 3 (no pain) to 12 (maximal pain) [10-11]. The BPS has a maximal acceptable pain 
score of 5 [12].
Table 1. The behavioral pain scale [11]
item Description Score
Facial expression Relaxed 1
Partially tightened 2
Fully tightened 3
Grimacing 4
Upper limbs No movement 1
Partially bent 2
Fully bent with finger flexion 3
Permanently retracted 4
Compliance with ventilation Tolerating movement 1
Coughing but tolerating ventilation for most of the time 2
Fighting ventilator 3
Unable to control ventilation 4
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The NRS is based on a scale from 0 to 10; 0 represents no pain and 10 represents worst 
possible pain [13-14]. The NRS has a maximal acceptable pain score of 3 [15].
The VAS is a 100 mm ruler with a movable cursor. At the left side is written ‘no pain’, at the 
right side is written ‘worst possible pain’. The patient marks the intensity of pain [16-17]. The 
VAS has a maximal acceptable pain score of 30 mm.
Depth of sedation
The Ramsay scale (RS) was used to assess the sedation level [18]. The RS on a scale from 1 to 
6, with higher levels indicating increased degrees of sedation, and considers the following 
levels: (1) patient anxious, agitated, restless, (2) patient cooperative, orientated and tranquil, 
(3) patient drowsy or asleep, responds easily to commands, (4) patient asleep, brisk response 
to a light glabellar tap, (5) patient asleep, sluggish response to a light glabellar tap and (6) 
patient asleep, no response to a light glabellar tap [19].
Standard pain medication in the icu
All patients received pain medication according to the local standard protocol, consisting 
of 1 gram of paracetamol rectally three times daily and morphine 10 mg subcutaneously 
four times daily or 30-50 mg morphine per day using a continuous intravenous infusion, if 
required.
Procedures
Before this study, levels of pain were not systematically scored and recorded. During this 
study, assessments took place in all patients in the ICU twice a day (at 8.30 a.m. and 3.00 
p.m.) during 1 month. Assessments were initiated by two researchers who were trainees in 
pharmacy and who had been working for 6 months under close supervision of two anaes-
thesiologists of the Department of Anaesthesiology and Intensive Care, and one ICU nurse. 
These researchers were not involved in the patient’s care but took notice of the clinical and 
medical situation of the patient, similar to physicians on ward rounds. All assessments were 
made during non-nociceptive procedures, in order to obtain basal pain scores. First, the 
researchers observed every patient about one minute. Assessments of the researchers were 
made simultaneously but independent of each other. Then, the researchers scored the BPS, 
NRS, and RS in order to prevent the outcome from being influenced by the patient’s or nurse’s 
score. The BPS was scored only in patients who were ventilated. Then, the attending nurse 
was asked to score the pain of the patient with the NRS. If the patient was responsive, the 
patient was asked to score the pain using the NRS and VAS. Gender, length, weight, year 
of birth, ICU indication, and relevant history were collected. Patients were classified in one 
of the two ICU indications, ‘cardiothoracic surgery’ or ‘non-cardiothoracic surgery’ with a 
skewed distribution for ‘cardiothoracic surgery’.
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In this study, the ‘NRS researcher’ and ‘BPS researcher’ are defined by NRS rating and BPS 
rating by the researcher. The ‘RS researcher’ is defined by the RS rating by the researcher. ‘NRS 
nurse’ is defined by the NRS rating by the nurse. ‘NRS patient’ and ‘VAS patient’ are defined by 
the NRS rating and VAS ratings by the patient (Table 2).
training pain measurement instruments
For adequate use of the BPS, NRS, VAS, and RS, the two researchers attended a 4-hour training 
session (conducted by a trained ICU nurse), during which the BPS and RS were explained with 
examples of patients who were in the ICU at the time of the training. When the inter-rater 
reliability was acceptable according to a quadratic weighted Cohen’s kappa of greater than 
0.6, the researchers were allowed to score patients for the study [20].
Data analysis
Data were analysed with the statistical software S-Plus® version 6.2 (Insightful Corporation, 
Seattle, Washington, USA). To correct for the different numbers of measurements per patient, 
one observation per patient was randomly selected. All statistical analyses were performed 
using this independent sample, while all measurements were plotted in the figures for better 
illustration.
Kappa coefficients with quadratic weights were used to reflect agreement for ordinal 
scales (NRS, BPS, and RS) between the independent researchers. Weighted kappa penalizes 
disagreement in terms of their seriousness [20]. Theoretically, the value of kappa can range 
from 0 (disagreement) to 1 (perfect agreement). A value larger than 0.6 was regarded as 
satisfactory [21]. The 95% confidence intervals for kappa coefficients were calculated.
Spearman non-parametric rank correlation coefficients (rs) were used to measure the 
degree of correlation for two ordinal variables. The null hypothesis that the correlation coef-
ficient is zero was tested. A P-value <0.05 was considered statistically significant.
Table 2. Pain and sedation scales performed by researcher, nurse and patients
bPS
(if ventilated)
nrS VaS rS
Researcher X X X
Nurse X
Patient (whenever possible ) X X
BPS = behavioral pain scale; NRS = numeric rating scale; VAS = visual analogue scale; RS = Ramsay Scale
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reSultS
Patients characteristics and data
A total of 138 intensive care patients entered the study, with a median of two observation 
series per patient (range 1 to 15). In total, 25 patients were excluded (15 patients because of 
incomplete collection of the data and 10 patients because of exclusion criteria), resulting in a 
total of 113 included patients. Table 3 shows the baseline characteristics of the patients. The 
body mass index was recorded for 87 of 113 patients (77%).
In total, 371 observations were scored by the researchers and 322 observations were 
scored by the nurses. In a total of 75 patients (180 observations), the patient could report 
his or her pain using the NRS. In 141 observations, the patient could also report his or her 
pain using the VAS. Of the 57 ventilated patients, 13 patients were communicative and could 
report their pain.
inter-rater reliability
Table 4 depicts the exact agreement, the agreement within one scale point and the quadratic 
weighted kappa for the NRS, BPS, and RS scale in different groups of patients for the two in-
dependent researchers. There was no difference between the ICU indications ‘cardiothoracic 
surgery’ (n=83) and ‘non-cardiothoracic surgery’ (n=30) in exact agreement (60% vs. 57%) 
and agreement within one scale point (94% vs. 93%).
nrS patient versus nrS nurse or nrS researcher
For the patients who were able to report their own pain levels (n=75), the level of agreement 
within one scale point between NRS patient and NRS nurse was 73% compared to 58% for the 
NRS researcher, corrected for multiple observations per patient. Similar results were found 
Table 3. Baseline patient characteristics
all patients
Number of patients 113
Age (years) 66 ± 15
Male gender, n (%) 78 (69%)
BMI (kg/m2)* 26.6 ± 4.7
Diagnostic categories, n (%)
Cardiothoracic surgery
Non-cardiothoracic surgery
83 (73%)
30 (27%)
Mechanical ventilation, n (%)
None
Pressure Support
Volume Controlled
56 (50%)
36 (32%)
21 (19%)
Median Ramsay score (range) 2 (1 -5)
Values expressed as mean ± SD or number (percentage).
* = 26 missing values
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for the exact agreement (42% vs. 19%, respectively). The correlation between NRS of patient 
and nurses (Figure 1) and between NRS of patient and researcher was moderate and low 
respectively (rs= 0.55, P<0.001 vs. rs=0.38, P =0.009). Whereas 33% of the patients scored NRS 
values of greater than or equal to 4, only 18% of the attending nurses scored NRS values in 
that range, particularly when the patient rated his or her pain as unacceptable, nurses tend 
to underestimate the pain level of the patient on the NRS.
nrS patient and VaS patient
In responsive patients, there was a strong positive correlation between the NRS patient and 
the VAS patient. (rs=0.84, P<0.001, n=75, Figure 2). The correlation between NRS patient and 
VAS patient was slightly lower in cardiothoracic patients than in non-cardiothoracic patients 
(rs= 0.79, P<0.001, n=25 patients vs. rs=0.95, P<0.001, n=11 patients).
nrS nurse and bPS researcher
While a moderate positive correlation was found between the NRS nurse and the BPS re-
searcher in ventilated patients (rs=0.55, P<0.001, n=57 patients, Figure 3), Figure 3 also shows 
that using the NRS, only 5% of the observations (n=151 observations of 57 patients) was 
NRS=0 (no pain), whereas on the BPS, 68% of the observations were BPS=3 (no pain). Besides, 
using the NRS, 6% of the observations were greater than or equal to 4, considered to be 
unacceptable pain. However, corresponding BPS scores were all low (median 3, range 3-5) 
and below the acceptable BPS of 5, which means that no unacceptable pain was observed 
using the BPS.
Table 4. Inter-rater reliability of the NRS, BPS, and RS score
agreement between exact 
agreement
agreement within 
1 scale point
Kappa (ci) n
all patients
NRS 59% 94% 0.71 (0.61-0.81) 113
BPS 80% 100% 0.67 (0.54-0.80) 57
RS 91% 100% 0.66 (0.36-0.97) 44
Non-ventilated patients
NRS 66% 95% 0.63 (0.45-0.82) 56
Volume Controlled ventilated patients
NRS 56% 94% 0.64 (0.48-0.81) 36
BPS 81% 100% 0.59 (0.36-0.82) 36
Pressure Support ventilated patients
NRS 48% 90% 0.80 (0.68-0.93) 21
BPS 81% 100% 0.76 (0.62-0.90) 21
cardiothoracic patients
NRS 60% 94% 0.65 (0.53-0.77) 83
non-cardiothoracic patients
NRS 57% 93% 0.80 (0.65-0.93) 30
RS = Ramsay scale; NRS = numeric rating scale; BPS = behavioral pain scale
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Figure 1. Correlation between numeric rating scale (NRS) scores of patient and nurses. Data of 75 responsive patients with 165 measurements 
are presented.
0 2 4 6 8 10
NRS score
0
2
4
6
8
10
VA
S 
sc
or
e
Figure 2. Correlation between numeric rating scale (NRS) score and visual analogue scale (VAS) score of the patient. Data of 75 responsive 
patients with 131 measurements are presented.
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There was no difference in the correlation between cardiothoracic patients and non-car-
diothoracic patients (rs=0.54, P<0.001, n=47 patients vs. rs= 0.53, P=0.047, n=10 patients) or 
between pressure-supported ventilated patients compared to volume-controlled ventilated 
patients (rs=0.64, P=0.004, n=21 patients vs. rs=0.49, P=0.004, n=36 patients).
nrS researcher and rS researcher
The correlation between the NRS researcher and the RS researcher was low (rs= 0.28, P=0.078, 
n=40). The correlation was weak in both cardiothoracic patients and non-cardiothoracic 
patients (rs=0.24, P =191, n=31 patients vs. rs=0.04, P =0.9, n=13 patients).
DiScuSSion
In our study, we found that the inter-rater reliability for the NRS and BPS was good, which 
proves that it is possible to train medical personnel to use these scales in a reliable way in ICU 
patients. However, although the different pain scales show a high reliability, an important 
finding of our study is that especially unacceptably high patient scores (NRS≥4) were un-
derestimated by both the nurses and the researchers as 33% of the NRS patient values were 
greater than or equal to 4 compared to 18% for the nurses. As it is known that the patients 
may underestimate pain by themselves (caused by factors like culture and the environment 
[22-23]), the risk of underestimation seems to be an important issue when scoring pain in 
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Figure 3. Correlation between numeric rating scale (NRS) score and behavioral pain scale (BPS) score. Data of 57 ventilated patients with 151 
measurements are presented.
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ICU patients. The underestimation of patients’ pain scores by the nurses is already supported 
in the literature. However, the finding that underestimation occurs in especially high patient 
scores was never reported. Therefore, it is of utmost importance to use restrictive sedation 
protocols aiming at cooperative sedation levels instead of unconscious levels [4], allowing 
for response to questions about pain evaluation and thereby reducing observed-based pain 
evaluations and allowing for self-report of pain.
The correlation between the NRS and the BPS in our study is in accordance with the study 
of Payen et al. [11], which showed that the BPS is reliable for measuring the severity of pain 
in sedated and ventilated patients. Also, Aissaoui et al. [10] concluded that the BPS is valid 
and reliable for measuring intervention pain in non-communicative ICU patients. In our study 
however, in 57 ventilated patients of which 13 were communicative, only 5% of the obser-
vations (n=151 observations of 57 patients) was NRS of 0 (no pain), whereas on the BPS, a 
remarkable 68% of the observations were BPS of 3 (no pain). In addition, although 6% of our 
observations were greater than or equal to 4 (unacceptable pain according to [24]), the BPS 
scores were all low with a median value of 3 (range 3-5), which is the lowest possible value 
of the BPS in a scale with a maximum value of 12. Also in the study of Payen et al. [11] a high 
non-response on the BPS was found in assessments completed at rest (BPS score of 3 in 88% 
to 97% of the observations) and 82% of the observations at rest and during interventions 
were clustered around BPS 3 to 6.
The high non-response on the BPS can be explained by the short time of observation. Dur-
ing one minute of observation, the patient may seem pain free (BPS of 3). However, using the 
NRS, a higher score may be rated, as the nurse tends to include more background information 
of the patient (for example, the pain levels from the last hours while caring for the patient). 
So the BPS reflects the objective visible behavior at one specific time point, whereas the NRS 
represents a global impression of pain, including several contextual factors during a longer 
time period. It seems, therefore, that the BPS should be used only in conjunction with the NRS 
nurse to measure pain levels the ICU.
Various studies concluded that, compared with the NRS, the VAS is not an adequate tool in 
patients with a decreased consciousness [25-26]. This appears to be related to the lack of abil-
ity for abstraction and comprehension and provides difficulties in patients who are injured 
to the upper limbs. In our study, the correlation between the NRS and VAS estimated by the 
patient is strong (rs=0.84, P<0.001, n=75), suggesting that the VAS is also an adequate tool 
for measuring pain in about two thirds of the patients in our ICU. However, the VAS could be 
used in only 75 patients of the 113 patients, in particular in patients with intact comprehen-
sion and abstraction, when recovering from critical illness and just before leaving the ICU 
following cardiac surgery. Therefore, it is unknown whether this finding can be extrapolated 
to other ICUs.
The correlation between the NRS score and RS score was low (rs= 0.28, P=0.078, n=40). So 
the degree of pain intensity does not seem to depend on the level of sedation. This is impor-
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tant because these two scores should be able to distinguish between the level of analgesia 
and the level of sedation. Whereas high RS levels (deep sedation) may be expected in more 
severely ill patients experiencing more pain, patients with low RS levels (light sedation), in 
contrast, have more ability to show painful behaviours, resulting in absence of a significant 
correlation.
This study had several limitations. In the present study, we collected pain scores of ICU 
patients at rest and without painful stimuli. In the ideal study design in which different pain 
scoring systems in the ICU are compared, the pain scores in the absence and presence of an 
unavoidable painful stimulus should be tested in order to be able to study the sensitivity to 
change for each pain scale. In further studies, therefore, basal pain scores should be obtained 
together with intervention pain scores in order to evaluate and judge pain scales for different 
purposes (for example, at rest and during painful interventions).
Furthermore, the patients included in this study are characterized by a high percentage 
(73%) of post-cardiothoracic surgery patients and a 50% rate of mechanical ventilation, which 
was partly due to pain measurements before leaving the ICU, so extrapolation of the result 
to other ICUs may be limited. In addition, in our ICU, sedation levels are aimed at cooperative 
levels comparable to those of Kress et al. and Brook et al. [27] whenever possible. Both these 
characteristics of our ICU may have resulted in the relatively high percentage of responsive 
patients (66%) who were able to report pain using NRS and VAS. This should still be con-
sidered when the results of our study are extrapolated to other ICUs. On the other hand, 
in our study, there were no significant differences when the results were divided between 
‘cardiothoracic surgery’ patients and ‘non-cardiothoracic surgery’ patients.
In conclusion, the different scales show a high reliability, but observer-based evaluation 
often underestimates the pain, particularly in the case of high NRS values (NRS≥4) rated 
by the patient. Therefore, whenever this is possible, ICU patients should rate their pain. In 
unresponsive patients, primarily the attending nurse involved in daily care should score the 
patient’s pain. The BPS should be used only in conjunction with the NRS nurse to measure 
pain levels in the absence of painful stimuli.
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abStract
background and objectives Assessing pain in mechanically ventilated critically ill patients 
is a great challenge. There is a need for an adequate pain measurement tool for use in con-
scious sedated patients because of their questionable communicative abilities. In this study, 
we evaluated the use of the behavioral pain scale (BPS) in conscious sedated patients in com-
parison to its use in deeply sedated patients, for whom the BPS was developed. Additionally, 
in conscious sedated patients the combination of the BPS and the patient-rated verbal rating 
scale (VRS-4) was evaluated.
methods We performed a prospective evaluation study in 80 non-paralyzed critically ill adult 
intensive care unit (ICU) patients. Over two months, nurses performed 175 observation series: 
126 in deeply sedated patients and 49 in conscious sedated patients. Each observation series 
consisted of BPS ratings (range 3-12) at four points: at rest, during a non-painful procedure, 
at retest rest, and during a routine painful procedure. Patients in conscious sedated state also 
self-reported their pain using the 4-point VRS-4.
results BPS scores during painful procedures were significantly higher than those at rest, 
both in deeply sedated patients (5.1 [4.8-5.5] vs. 3.4 [3.3-3.5], respectively) and conscious 
sedated patients (5.4 [4.9-5.9] vs. 3.8 [3.5-4.1], respectively) (mean [95% confidence interval]). 
For both groups, scores obtained during the non-painful procedure and at rest did not sig-
nificantly differ. There was a strong correlation between nurses’ BPS ratings and conscious 
sedated patients’ VRS-4 ratings during the painful procedure (rs=0.67, P<0.001). At rest and 
during non-painful procedures, 98% of the observations were rated as acceptable pain (VRS 
1 or 2) by both nurses and patients. During painful procedures, nurses rated the pain higher 
than patients did in 16% of the observations and lower in 12% of the observations.
conclusions The BPS is a valid tool for measuring pain in conscious sedated patients during 
painful procedures. Thus for non-communicative and mechanically ventilated patients it may 
be regarded as a bridge between the observational scale used by nurses and the VRS-4 used 
by patients who are able to self-report pain.
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introDuction
Many critically ill patients in the intensive care unit (ICU) suffer from pain [1-3], notably those 
on mechanical ventilation [4-5]. From 35% to 55% of nurses have been reported to under-
rate patients’ pain [6-7], and a current practices study revealed that the observed rates of 
assessment during procedural pain in mechanically ventilated patients remain below 40% [8]. 
Researchers have recognized that pain and inadequate pain relief are major causes of physi-
ological adversity and emotional stress [9-11]. Therefore, it would seem important to achieve 
effective management of analgesia, first by measuring pain in a valid and reliable manner.
Various pain scales are available, but there is insufficient evidence of their reliability in the 
diverse ICU population. The Society of Critical Care Medicine recommends self-reporting 
by communicative patients using the numeric rating scale (NRS, range 0-10) [7]. This scale 
requires a certain level of comprehension, so one may opt for an alternative, the 4-point 
verbal rating scale (VRS-4), which has shown good reliability and validity [12]. Postoperative 
patients even prefer the VRS-4 over the NRS because of its ease of use [12].
The observational behavioral pain scale (BPS, range 3-12), applied by nurses, has been 
validated in deeply sedated, mechanically ventilated patients [13-14]. It is composed of three 
subscales: facial expression, movement of the upper limbs, and compliance with mechanical 
ventilation [13]. The BPS reflects objective visible behavior at one specific time point, whereas 
the NRS represents a global impression of pain, including several contextual factors during a 
longer time period [15]. Gélinas et al. [16] recently developed the Critical Care Pain Observa-
tion Tool (range 0-8). Based on the BPS, the Critical Care Pain Observation Tool has not yet 
been tested among different critical care populations and requires additional validation [17].
Apart from communicative and deeply sedated patients, a third group can be identified, 
i.e. conscious sedated mechanically ventilated patients. Current ICU practice strives to restrict 
sedation to a conscious level whenever possible, in agreement with the landmark report [18] 
that showed that ventilated patients benefit from daily interruption of sedative infusions. 
Ventilation could be stopped earlier in these patients, resulting in shorter ICU stays, and they 
showed no adverse psychosocial outcomes [19].
Self-reporting using the NRS or VRS-4 may be complicated or unreliable in these patients 
due to their temporarily limited capacities of abstraction and concentration, and lack of 
comprehension [7,11]. Furthermore, the BPS has been validated only in deeply sedated and 
non-communicative patients.
For this growing group of conscious sedated patients, an observational pain scale such as 
the BPS, which can be used by the nurse, can add value to VRS-4 scores, because patients’ 
self-reporting may be complicated and/or unreliable. Therefore, we designed a study to 
compare use of the BPSnurse in conscious sedated patients and in deeply sedated patients, for 
whom the BPS was developed. Additionally, in conscious sedated patients, the combination 
of the BPSnurse and the patient-rated VRS-4 was evaluated.
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materialS anD metHoDS
Design
A prospective, observational study was performed in a 30-bed surgical/medical ICU in a teach-
ing hospital in Nieuwegein, the Netherlands. The Medical Ethical Committee of the St. Antonius 
Hospital approved the study protocol and waived the need for informed consent because the 
observational study design and pain measurements are considered as standard care.
Patients and classifications
During the two-month study period, all patients admitted to the ICU were evaluated for 
inclusion in the study once a day (between 8:00 a.m. and 12 noon). ICU patients who were 
18 years and older, sedated irrespective of sedation depth, and ventilated for at least 8 hours 
before assessment were eligible for inclusion. Patients who received neuromuscular blocking 
medications or muscle-paralyzing drugs, who were unconscious after resuscitation, quad-
riplegic, had a critical illness (poly) neuropathy, or had an epidural catheter, were excluded.
Included patients were classified as ‘sedated’ or ‘conscious sedated’ on the specific day. 
Sedated patients were defined as patients who were not able to communicate during all 
4 consecutive assessments (at rest, during non-painful procedures, at retest rest and dur-
ing painful procedures) on that particular day. Conscious sedated patients were defined as 
patients who were able to communicate during at least one part of the assessment. Patients 
could be included on multiple days, an approach also used in the first BPS validation study in 
non-responsive critically ill patients [13].
Eighty patients were included during the two-month study period. Fifty patients were clas-
sified as sedated on all study days, 17 as conscious sedated on all study days, and 13 as either 
sedated or conscious sedated on different days in the study period.
Pain measurement instruments
BPS. The BPS is an observational pain scale, preferably applied by the attending nurse. It has 
been validated for use in deeply sedated, mechanically ventilated patients [13,20]. Easy to use 
and well accepted by nurses, the BPS contains three subscales: facial expression, upper limb 
movements, and compliance with mechanical ventilation (Table 1). Each subscale is scored 
from 1 (no response) to 4 (full response). Therefore, BPS scores range from 3 (no pain) to 12 
(maximal pain) [13]. A BPS score of 6 or higher is considered to reflect unacceptable pain [2].
VRS-4. The VRS-4 is a 4-point verbal rating scale (range 1-4) used for patient self reporting. 
It was adapted from the verbal graphic scale [21], which includes four categories: 1) free of 
pain (NRS 0), 2) mild pain (NRS 1-3), 3) moderate pain (NRS 4-6), and 4) severe pain (NRS 7-10). 
This shorter version was used because conscious sedated patients may temporarily lack full 
comprehension of the more complex 11-point NRS. Unacceptable pain using the 11-point 
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NRS is defined as NRS>3 (moderate pain and severe pain) [6-7], thus unacceptable pain using 
the 4-point VRS was defined as a score of 3 or 4. In this study, the ‘BPSnurse’ is defined based on a 
BPS rating by the attending nurse. The ‘VRS-4patient’ is defined by the VRS-4 rating by the patient.
Study procedures and intervention
Pain was assessed during two routine nursing procedures. One was an arterial catheter dress-
ing change, identified as a non-painful procedure from a pilot study in our ICU. The second 
was turning, a procedure that patients have described as painful [22-23]. In addition, pain was 
assessed at rest, i.e. before the first of these procedures, and in between these procedures, at 
least 30 minutes after the first procedure.
At each of these four points, a nurse researcher (AV, critical care nurse and student in 
nursing sciences) and an attending nurse simultaneously observed the patient for about 
one minute, with the observers’ assessments made independently. The attending nurse 
then determined the Ramsay score (RS). Next, the nurse researcher and the attending nurse 
independently determined the BPSnurse score. Communicative patients were then asked to 
apply the VRS-4patient. This order was decided upon to prevent the nurses’ scores from being 
influenced by the patient’s score.
Demographic data such as gender, age, intensive care indication and the Sequential Organ 
Failure Assessment (SOFA) score [24] were collected.
training
The 72 nurses who participated in the study all attended a 4-hour training session, given by 
a BPS-trained ICU nurse. Attention was paid to the essentials of pain and the difficulties of 
scoring pain in ventilated and sedated patients. The use of the BPS was explained by means 
of pictures of ICU patients. All received a protocol explaining the study and the BPS.
Table 1. The behavioral pain scale [13]
item Description Score
Facial expression Relaxed 1
Partially tightened 2
Fully tightened 3
Grimacing 4
Upper limbs No movement 1
2Partially bent
Fully bent with finger flexion 3
Permanently retracted 4
Compliance with ventilation Tolerating movement 1
Coughing but tolerating ventilation for most of the time 2
Fighting ventilator 3
Unable to control ventilation 4
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Depth of sedation
Depth of sedation was assessed by the Ramsay scale (RS), which is a single-item, six-level 
scale (scores range from 1 to 6) [25]. The levels are: (1) patient anxious, agitated, restless, (2) 
patient cooperative, oriented and tranquil, (3) patient drowsy or asleep, responds easily to 
commands, (4) patient asleep, brisk response to a light glabellar tap, (5) patient asleep, slug-
gish response to a light glabellar tap, and (6) patient asleep, no response to a light glabellar 
tap [9]. The RS was rated in the morning (between 7:30 and 8:00 a.m.), whereas the pain 
assessments were completed between 8:00 a.m. and 12:00 noon). In 8 patients, the RS was 
different during sedation assessment and pain assessment. The RS score for the conscious 
sedated patients (median 6, range 3-6) was significantly lower (P<0.001) than that for the 
sedated patients (median 3, range 2-5).
Standard pain and sedative medication in the icu
All patients received pain medication by protocol, i.e., four times daily 1 gram of paracetamol 
rectally plus either four times daily 10 mg morphine subcutaneously if in moderate pain or 
30-50 mg morphine per day by continuous intravenous infusion when in severe pain. Pain 
severity was evaluated on a daily basis. For procedural pain, patients received either no mor-
phine, or a bolus of 5 to 10 mg morphine, depending on the attending nurse’s judgement. 
Patients were sedated preferably with propofol or midazolam, according to local standard 
practice.
Data analysis
Data were analyzed using the SPSS software (version 15.0, Chicago, ILL, USA). The statistical 
analysis was performed by calculation on all measurements of all patients, including one 
measurement per day per patient. This approach was used by Payen et al. [13] when they first 
validated the BPS in non-responsive critically ill patients, and can be justified because a criti-
cally ill patient’s condition may rapidly change over 24 hours, e.g. when taken off mechanical 
ventilation, with consequences in terms of organ failure, neurological or respiratory situation, 
sedation levels, pain levels, and communication abilities.
Kappa coefficients with quadratic weights were used to reflect agreement between the 
nurse researcher and the attending nurse regarding the BPS. Weighted kappa penalizes 
disagreement in proportion to its severity [26]. Theoretically, the value of kappa can range 
from 0 (no agreement) to 1.0 (perfect agreement). A value larger than 0.6 was regarded as 
satisfactory [27]. The 95% confidence intervals (95%CI) for kappa coefficients were calculated.
Internal consistency, a measure of how the items within a scale are interrelated, was ex-
pressed in Cronbach’s α. A high Cronbach’s α value reflects high internal consistency. Gener-
ally, a value larger than 0.7 is regarded as satisfactory [28].
The effect size is a standardized way to express the magnitude and meaning of an instru-
ment’s capacity to change, in this case the BPS. The effect sizes of the BPS total and BPS items 
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were calculated as the difference between the score at rest and the score during the painful 
procedure, divided by the standard deviation (SD) at rest [29]. An effect size of around 0.20 
is generally considered to be small, one of 0.50 indicates moderate differences, and those of 
0.80 or above indicate large differences [30].
Values are expressed as mean and standard deviation (SD) or 95% confidence interval 
[95%CI]. Spearman non-parametric rank correlation coefficients (rs) were used to measure 
the degree of correlation for two ordinal variables. The unpaired t-test and the Mann-Whitney 
U test served to compare differences in quantitative and non-parametric data, respectively. 
The test-retest procedure was analyzed by the paired Student’s t-test. A P-value of <0.05 was 
considered statistically significant.
reSultS
Patients and data
Table 2 shows the characteristics of the 80 enrolled patients, classified by state of sedation. 
The mean amount of propofol administered (± SD) was 130.4 mg/h ± 58.8 for conscious 
sedated patients vs. 175.6 mg/h ± 72.6 for sedated patients (P<0.05). The mean amount of 
midazolam administered in conscious sedated patients and sedated patients was 3.3 mg/h ± 
1.2 vs. 4.8 mg/h ± 2.5 (P=0.32). The mean ICU stay at time of pain assessment (± SD) was 4.5 
days ± 3.6 for conscious sedated patients vs. 5.4 days ± 8.1 for sedated patients (P=0.43). One 
hundred seventy-five observation series were completed: 126 in 63 sedated patients and 49 
in 30 conscious sedated patients. The latter also included 49 VRS-4patient scores for 30 patients.
Table 2. Baseline patient characteristics of all 80 patients participating in the study, with patients in sedated state at all study days (n=50), 
patients in conscious sedated state at all study days (n=17) and patients in either sedated or conscious sedated state on different days (n=13).
Patients in sedated state 
on all days
Patients in conscious sedated 
state on all days
Patients in both 
states on different 
days
Number of patients 50 17 13
Age (years) (SD) 66 ± 12 61 ± 15 60 ± 11
Males/ females, n 30/20 12/5 7/6
Median SOFA score (range) 5 (1-14) 5 (1-10) 6 (2-9)
Diagnostic categories, n
 Cardiac surgery
 Abdominal surgery
 TAAA
 Non-surgical
22
9
5
14
9
6
0
2
3
4
0
6
TAAA = thoracoabdominal aortic aneurysm; SOFA = Sequential Organ Failure Assessment.
Chapter 3
40
inter-rater reliability
Table 3 gives the quadratic weighted kappa and the exact agreement (EA) for the BPSnurse in 
sedated patients (126 observation series) and conscious sedated patients (49 observation 
series) between the nurse researcher and the attending nurse. Kappa values were excellent 
(0.80 to 0.83). There was no difference in exact agreement for sedated and conscious sedated 
patients (0.83 [95%CI 0.76-0.87] vs. 0.80 [95%CI 0.72-0.88]).
Table 3. Inter-rater reliability of the BPS total and separate BPS items as evaluated by nurses in sedated patients (126 observation series) and 
conscious sedated patients (49 observation series).
Kappa ea (%) no. of observation series
Sedated patients
BPS total 0.83 (0.79-0.87) 67 126
 BPS facial expression 0.80 (0.75-0.85) 82 126
 BPS upper limb movement 0.72 (0.64-0.79) 82 126
 BPS compliance ventilation 0.62 (0.52-0.72) 88 126
conscious sedated patients
BPS total 0.80 (0.72-0.88) 70 49
 BPS facial expression 0.78 (0.69-0.87) 81 49
 BPS upper limb movement 0.67 (0.52-0.82) 87 49
 BPS compliance ventilation 0.61 (0.45-0.70) 89 49
EA = exact agreement, BPS = behavioral pain scale
Pain scores in conscious sedated patients and sedated patients
BPSnurse 
BPSnurse scores were significantly higher during painful procedures than at rest in both se-
dated patients (5.1 [95%CI 4.8-5.5] vs. 3.4 [95%CI 3.3-3.5]) and conscious sedated patients 
(5.4 [95%CI 4.9-5.9] vs. 3.8 [95%CI 3.5-4.1]) (Figure 1). There was no difference in BPSnurse scores 
between the non-painful procedure and rest in sedated patients (3.4 [95%CI 3.3-3.6] vs. 3.3 
[95%CI 3.2-3.4]) and conscious sedated patients (3.7 [95%CI 3.5-3.9] vs. 3.6 [95%CI 3.3-3.8]). 
BPSnurse scores did not differ between sedated patients and conscious sedated patients at rest 
or during non-painful or painful procedures.
Table 4 shows that the effect size for responsiveness of BPS total scores was large in sedated 
patients (126 observation series) and conscious sedated patients (49 observation series) (2.5 
and 1.8, respectively). The effect size of the item ‘facial expression’ was largest in both sedated 
patients (3.6) and conscious sedated patients (2.4). It was also large for ‘compliance with 
ventilation’ (1.4 and 0.9), but moderate for ‘upper limbs’ in both groups (0.7 and 0.5) (Table 4). 
During painful procedures, internal consistency was moderate in both sedated patients and 
conscious sedated patients (Cronbach’s α 0.63 and 0.66, respectively).
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VRS-4patient
In conscious sedated patients, VRS-4patient scores were significantly higher during painful pro-
cedures than at rest (2.2 [95%CI 1.9-2.5] vs. 1.1 [95%CI 1.0-1.2]). Scores did not differ between 
the non-painful procedure and rest (1.0 [95%CI 1.0-1.0] vs. 1.0 [95%CI 1.0-1.0]).
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Figure 1. Change in behavioral pain scale (BPS)nurse and verbal rating scale (VRS)-4patient at rest, during non-painful procedures, at retest rest, and 
during painful procedures (mean [95% confidence interval]) in sedated patients (126 observation series) and conscious sedated patients (49 
observation series).
Table 4. BPS total scores and BPS items scores (mean ± SD) at rest and during painful procedure, with effect size in sedated patients (126 
observation series) and conscious sedated patients (49 observation series).
retest rest Painful procedure P effect size
Sedated patients
BPS total 3.4 ± 0.7 5.1 ± 1.0 <0.001 2.5
BPS facial expression 1.1 ± 0.3 2.1 ± 1.0 <0.001 3.6
BPS upper limb movement 1.2 ± 0.4 1.4 ± 0.7 <0.001 0.7
BPS compliance ventilation 1.1 ± 0.4 1.6 ± 0.7 <0.001 1.4
conscious sedated patients
BPS total 3.8 ± 0.9 5.4 ± 1.8 <0.001 1.8
BPS facial expression 1.1 ± 0.4 2.0 ± 1.0 <0.001 2.4
BPS upper limb movement 1.5 ± 0.6 1.8 ± 0.8 0.003 0.5
BPS compliance ventilation 1.2 ± 0.4 1.6 ± 0.5 <0.001 0.9
BPS = behavioral pain scale
Chapter 3
42
comparison between bPSnurse and VrS-4patient in conscious sedated patients
During the painful procedure, there was a strong positive correlation between BPSnurse and 
VRS-4patient (rs=0.67, P<0.001, 49 observation series) (Figure 2). The four boxes in Figure 2 each 
have been divided into four quadrants, separating acceptable pain and unacceptable pain 
scores (unacceptable pain VRS-4>2 and BPS>5).
During painful procedures, in 16% of the observations the patient rated pain as acceptable 
(VRS scores 1 or 2) whereas the nurse rated it as unacceptable (BPS>5). Conversely, in 12% of 
the observations, the patient rated pain as unacceptable (scores VRS>2) whereas the nurse 
rated it as acceptable (BPS 3-5). At rest, during the non-painful procedure, and at retest rest, 
98% of the observations were in the quadrant with acceptable pain scores. In these cases, 
both the patient and the nurse assigned acceptable pain scores.
DiScuSSion
The findings from this study are consistent with the notion that the BPS is reliable for pain 
assessment in conscious sedated patients. This is of interest in that so far, the BPS has been 
validated for deeply sedated patients only [13]. All ICU patients recovering from a deeply 
sedated state will pass through this conscious sedated state. Thereby, patients who experi-
ence agitation or delirium, in whom self reporting will be complicated, benefit from this pain 
assessment in the conscious sedated state.
BPSnurse scores during painful procedures were significantly higher than those at rest 
in both sedated patients and conscious sedated patients. Payen et al. [13] made a similar 
observation in deeply sedated patients, i.e., BPS scores were significantly higher for painful 
procedures such as turning or tracheal suctioning. Therefore, it would seem that the BPS can 
detect and discriminate pain and is a valid measure of pain in both sedated and conscious 
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Figure 2. Correlation between behavioral pain scale (BPS)nurse and verbal rating scale (VRS)-4patient (49 observation series) at rest, during non-
painful procedures, at retest rest, and during painful procedures. The dotted line divides acceptable pain scores from unacceptable pain scores 
(VRS-4 >2 and BPS >5). Each number reflects how many similar results were observed per paired evaluation.
43
BPS in conscious sedated patients
sedated patients. Furthermore, the internal consistency was comparable for observations in 
both groups, demonstrating similar homogeneity of the items. The fact that the effect size 
was large in both groups shows that the BPS is able to quantify change in clinical status and 
detect painful procedures. In both groups, the BPS subscale ‘facial expression’ was the most 
sensitive to change, as in a previous study [20]. The value of facial expression has been proven 
for both acute and chronic pain not only in adults [31-32], but also in infants and children 
[33].
Underestimation of patients’ pain by nurses is a well-known problem [5]. Surprisingly, us-
ing the BPS, nurses also tend to overestimate patients’ pain. On the other hand, conscious 
sedated patients’ pain scores are not always reliable. Therefore, use of the BPS in combination 
with the VRS-4 during painful procedures may lead to a more reliable rating of patients’ pain. 
A previous study from our group [34] also concluded that a combination of self-reporting and 
observational measures is recommended when credibility of self-reporting is doubted. Each 
method yields unique information. Self-reporting primarily reflects expressive pain behavior 
that is under control of higher mental processes. Observational measures capture behavior 
that is less subject to voluntary control and more automatic [34].
The level of agreement between the research nurse and the attending nurse was high for 
both sedated patients and conscious sedated patients (kappa 0.83 and 0.80, respectively). 
The fact that the kappa values in this study pertained to 72 nurses and generally remained 
good, shows that nurses can be trained to use the BPS in a reliable way in both sedated and 
conscious sedated patients.
In the ideal study design, nurses would be blinded to the nature of the procedure (painful 
or non-painful) that is being performed at the point of assessment. This could be achieved 
by videotaping the scenes and having the nurses rate the scenes afterwards. Care should be 
taken then to conceal the procedure. A limitation of video recordings is the likelihood that 
some aspects are missed because the general overview of the patients’ situation is necessar-
ily is not provided.
In this study, we used the VRS-4 instead of the 11-point NRS, because of the lack of capabil-
ity in conscious sedated patients. This approach was inspired by a study from Briggs and 
Closs [12], who showed that postoperative patients prefer the VRS. It would be of interest to 
test whether our assumption that conscious sedated patients are indeed incapable of using 
an 11-point scale is valid.
In this study, most patients were in a sedated state, although it is desirable for patients to 
be in a conscious sedated state. This suggests that the health staff should give more attention 
to the sedation state of the patients in our ICU.
Nevertheless, as the BPS may both overrate and underrate patients’ pain, and the patient’s 
self-report is not always reliable, a combination of the nurse-rated BPS and the patient-rated 
VRS-4 is perhaps ideal for estimating patients’ pain. Within this context, patients’ sedation 
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levels must be frequently assessed as well, and conscious patients’ own self-reported pain 
scores must be considered the ‘gold standard’.
In conclusion, the BPSnurse is valid for use in conscious sedated patients during painful proce-
dures. Thus, the BPS thus can be regarded as a bridge between the observational scale for 
non-communicative and mechanically ventilated patients and the VRS-4 used by patients 
who are able to self-report pain.
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abStract
background and objectives Although clinical guidelines recommend systematic evaluation 
of pain in intensive care patients, we know little about the effects from such systematic pain 
evaluation. This study aims to quantify the effect of a pain management programme in the 
intensive care unit (ICU).
methods In this prospective two-phase study, pain levels scored by ICU patients after cardiac 
surgery through sternotomy were compared before and after the implementation of a pain 
management programme. The pain management programme consisted of a three-fold strat-
egy; all staff was trained in assessing pain and in providing adequate analgesia, a new patient 
data management system obliged nurses to ask patients for their pain score three times a day 
and the preferred analgesic treatment was optimized. The numeric rating scale (NRS 0-10) 
was used by the 190 patients. A NRS≥4 was considered unacceptable. A generalized linear 
mixed-effects model was used for analysing repeated measurements data.
results The occurrence of unacceptable pain (NRS≥4) was significantly lower in the interven-
tion group (OR 2.54 [95%CI 1.22 - 5.65; P=0.01 for the control group). Patients in the interven-
tion group received significantly more morphine (29.3 mg [IQR 10.0-36.0] vs. 22.6 mg [IQR 
0-42.7] a day, P<0.01), with higher morphine amounts administered to patients with higher 
NRS scores (P=0.01). In the control group no such relation was observed (P=0.66). There was 
no difference in length of stay in the ICU or in ventilation time.
conclusions The intervention programme successfully reduced the occurrence of unaccept-
able pain. Further improvement of pain management should focus on the prevention of pain.
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introDuction
Pain is a frequently experienced phenomenon in patients in the intensive care unit (ICU) 
[1-2]. Of these patients, 63-77% reported pain during their stay in the ICU [3-4]. Negative 
effects of inadequate analgesia, such as a stress response with increased myocardial oxygen 
consumption and tachycardia [5-7], an increased risk of respiratory insufficiency [8-10] con-
tributing to a prolonged duration of mechanical ventilation and in consequence prolonged 
ICU length of stay [11], warrant a good pain management system for every ICU. Moreover, 
good pain management reflects a standard quality in daily patient care and is considered an 
important health care benchmark. A reduction of postoperative pain scores and increased 
use of analgesics have been shown after the implementation of a pain management system 
for patients in the post anaesthesia care unit (PACU) and in the wards after various types of 
surgery [12-13].
Also in the ICU, clinical practice guidelines recommend systematic evaluation of pain in 
patients for optimal pain management [14], but how to introduce this evaluation and in 
which form is not specified. Literature search revealed only little information concerning the 
effects of the introduction of a pain management system and pain education programme in 
the ICU [11,15]. This is in particular of relevance since it is known that even in the context of 
observational studies where caregivers knew their pain evaluations were being monitored, 
pain assessment was not performed according to acceptable standards [16]. Similar results 
were shown by Watt-Watson and colleagues [17], who showed that only 33-47% of the pre-
scribed dose of analgesics was actually administered despite the fact that the patients after 
coronary artery bypass grafting (CABG) experienced considerable pain. Most patients would 
not voluntarily ask the nurse for analgesics.
In this study, we describe an ICU pain management system consisting of 3 steps: a pain 
education programme for the health staff, the introduction of systematic pain measurement 
and registration using an automated patient data management system (PDMS), and an opti-
mization of the analgesia protocol. The current study was conducted to evaluate the effect of 
this new ICU pain management system on pain levels in patients after cardiac surgery in the 
ICU, the use of analgesics, and possible influences on ventilation time or ICU length of stay.
materialS anD metHoDS
Study design
The two-phase prospective controlled study was performed in the ICU of the St. Antonius 
Hospital, Nieuwegein, The Netherlands. The Medical Ethical Committee of the St. Antonius 
Hospital approved the study protocol and waived the need for informed consent. The trial 
was registered under number NCT00773045.
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Patients
All patients after cardiac surgery through sternotomy i.e. CABG, valve surgery, aortic root, 
ascending aorta and aortic arch surgery, admitted to the ICU in the period from June to 
August 2005 and in the same period in 2006 were included. Patients who were under 18 
years old, who received muscle paralysing agents continuously, or patients with debilitating 
neuromuscular illnesses such as critical illness polyneuropathy or severe encephalopathy 
and patients unable to speak Dutch or English were excluded from the study. Demographic 
patient data and both prescribed and administered analgesics were obtained from the medi-
cal records (see below for details).
Pain measurements
The numeric rating scale (NRS) was chosen as scoring system [6,14]. As pain scores reported 
by the patients themselves are the gold standard for measuring pain, in this study only pain 
scores reported by the patients themselves are evaluated [18-19]. The NRS has been validated 
for acute pain and is commonly accepted for pain assessment, particularly for postoperative 
patients [20]. The NRS has also been proven to be useful in ICU patients [19]. The NRS is an 
11-point scale from 0 to 10, where 0 represents ‘no pain’ and 10 represents ‘worst pain imagin-
able’. A NRS≥4 was considered unacceptable, while a NRS≥6 was considered extreme pain 
[6]. Pain scores were recorded during a maximum of 3 postoperative days in the ICU, as most 
patients were expected to have left the ICU by then after uncomplicated cardiac surgery.
control phase
During the control phase, pain was not systematically evaluated and registered by the nursing 
staff in the ICU. Therefore, twice a day from Monday till Friday, two trained independent re-
searchers [19] paid visits to all patients and their attending nurses and then asked all patients 
to score their pain. This evaluation of pain occurred when patients were at rest between 9.00 
and 10.00 a.m. and between 2.00 and 3.00 p.m.
Directly following cardiac surgery at ICU admittance, the anaesthesiologist prescribed 1 
gram of paracetamol 3-4 times daily (rectal or oral administration) and either subcutaneous 
morphine “when required” 4 times daily or morphine by continuous intravenous infusion. 
The intensive care doctors could adjust this prescribed morphine dose if clinically judged 
necessary. All analgesic medication was prescribed manually on the medical order sheet at 
the patient’s bedside.
Pain management programme
Following the control phase a pain management programme was introduced consisting of 
3 steps; the entire health staff was trained in assessing pain, an automated PDMS (Metavi-
sion suite, version 5.43.15, SP07, iMDsoft Ltd, Massachusetts, USA, 2005) was introduced to 
record pain scores, and the analgesics protocol was optimized. The steps of the pain training 
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programme and the differences between the control and the intervention phase are sum-
marized in Table 1.
Training sessions for nurses, intensive care doctors and anaesthesiologists were given twice 
in 2006. The sessions based on the available literature discussed various possible pain scoring 
systems, the difficulties of scoring pain in ventilated and sedated patients, the importance of 
adequate analgesia, and the effect of pain on morbidity and ICU length of stay. Furthermore, 
the sessions confronted both groups with the high percentage of unacceptable pain levels 
found during the control phase. The sessions especially for nurses concentrated further on 
the importance of self-report by patients, the need to ask patients actively about their pain 
levels using the NRS, and the fact that in the control phase analgesics had been administered 
relatively infrequent although adequately prescribed. The sessions for the doctors (intensive 
care doctors, anaesthesiologists and their trainees) emphasized on the fact that in the control 
phase accurately prescribed analgesics, had not been administered adequately. They were 
encouraged to activate a standard analgesic protocol in the PDMS which consisted of intra-
venous morphine as a continuous infusion instead subcutaneously or “when required”, in 
combination with the administration of paracetamol directly upon ICU arrival.
The training sessions for the nurses took place in groups of maximum 10 persons. Approxi-
mately 80 of the 100 regularly working nurses took part in the training, which was repeated 
Table 1. Steps of the pain management programme during the control and intervention phase
control phase intervention phase
Step 1: Pain education programme
Structure none -  2 training sessions per group of 10 nurses or 
doctors
- e-mail
- weekly info bulletins
Contents -  presentation of actual pain scores in ICU during 
control phase
- relevance of analgesia
- different pain measurement instruments
- clinical signs of pain
Step 2: Pain registration
When not regularly at least 3 times a day
Where no predefined space in medical record PDMS, predefined space
How no defined scoring system similar as vital signs
NRS (0-10)
Step 3: analgesia protocol
Paracetamol
 Route rectal or oral intravenous, rectal or oral
 First dose on first routine administration time after ICU 
admittance
immediately after surgery
Morphine
 Route preferably subcutaneously preferably intravenously
 Start administration no specific timing immediately after surgery
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after a few months. Apart from the training sessions, all information was repeated in weekly 
and monthly information bulletins and emailed to all nurses and doctors.
intervention phase
During the intervention phase the attending nurses asked patients their pain levels upon 
preset times by alarms of the PDMS three times a day (7 days a week) at 8:00 a.m., 4:00 p.m. 
and midnight. They were allowed to record pain scores next to the appointed times. Nurses 
were instructed to refer directly to the attending intensive care doctor for the administration 
of more analgesics in case of unacceptably high pain levels (NRS≥4).
At ICU admittance, the anaesthesiologist activated a standard pain protocol in the PDMS, 
prescribing a starting dose of morphine left to his discretion, and paracetamol. Intensive care 
doctors were free to adjust the prescribed analgesics if necessary during the stay in the ICU. 
Paracetamol could be administered intravenously in addition to the rectal and oral route. 
Morphine through continuous intravenous infusion was preferred over morphine subcutane-
ously and dosing “when required”. Administration of analgesics was started directly upon 
admittance to the ICU.
endpoints
Primary endpoint was the occurrence of unacceptable pain (NRS≥4) reported by the patients 
themselves before and after the introduction of the pain management programme. Second-
ary endpoints were the administered postoperative doses of morphine and paracetamol 
during the ICU stay, the ICU length of stay, and duration of mechanical ventilation.
Statistical analysis
Data were analysed using SPSS software (version 14.0, Chicago, ILL, USA). The Mann-Whitney 
test was used for quantitative data. In order to correct for the different numbers of measure-
ments per patient between the control and the intervention group, a linear mixed-effects 
model was used (statistical software R, version 2.6.1). A generalized linear mixed-effects 
model was used for binomial variables. A P-value of <0.05 was considered to be statistically 
significant. Data are presented as mean with interquartile range (IQR) or range, unless stated 
otherwise.
reSultS
Patient characteristics and data
Table 2 shows patient characteristics of the control group (n=60) and the intervention group 
(n=130). There were no significant differences between the groups.
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Because in the intervention group, the automatic requests by the PDMS for pain evalu-
ations were thrice daily in all patients admitted to the ICU including during the weekends, 
more patients and more pain scores per patient were available during the intervention phase 
compared to the control phase (130 vs. 60 patients, and 716 vs. 127 scores, respectively). All 
self-reported pain scores from the intervention phase (during and after regular office hours) 
were used for analysis because there were no differences between patients admitted to the 
ICU during or after regular office hours (Monday till Friday from 8:00 to 17:00 vs. Monday 
till Friday 17:00-8:00 and during weekends, respectively), e.g. age (mean 65 years [range 27-
86] vs. mean 67 years [range 37-83], respectively; P=0.25) and gender (male 71% vs. 67%, 
respectively; P=0.67). In the intervention group, 113 patients of the 130 patients (87%) were 
able to report their pain, resulting in 185 self-reported pain scores over the first three days. 
In the control group, 48 patients from the 60 patients (80%) were able to report their pain 
themselves resulting in 64 pain scores within three days.
nrS pain scores
Only pain scores that were scored by patients themselves were evaluated. Unacceptable pain 
events (NRS≥4) occurred in 23% (42 of 185 pain scores) of all measurements in the interven-
tion group and in 41% (26 of 64 pain scores) in the control group during the first 3 days in 
the ICU (Figure 1). Not all patients were able to report a pain score on the day of surgery and 
some patients left the ICU early on postoperative day 1 or day 2. This explains the differences 
in number of pain scores between days.
Unacceptable pain scores were significantly reduced in the intervention group with an 
odds ratio of 2.54 [95%CI 1.22 - 5.65], P=0.01) for unacceptable pain in the control group. 
This odds ratio was calculated with a generalized mixed-effects model for repeated measure-
ments correcting for the differences of number of pain scores per patient between groups.
The percentage of patients who developed at least one unacceptable pain event (NRS≥4) 
or at least one extreme pain event (NRS≥6) was comparable between the groups (interven-
tion vs. control group: 46% vs. 49%; P=0.74 and 17% vs. 19%, P=0.72).
Table 2. Patient characteristics
control group
n = 60
intervention group
n = 130
P
Age (years) 68 [35-92] 66 [27-86] NS
Male gender, n (%) 40 (67%) 88 (68%) NS
Type of cardiac surgery (n) (%)
 CABG or valve surgery
 CABG & valve surgery
 Aorta surgery (& valve surgery)
 Other
37 (62%)
14 (23%)
7 (12%)
2 (3%)
86 (66%)
26 (20%)
12 (9%)
7 (5%)
NS
EuroSCORE (median) 5 [0-16] 5 [0-16] NS
Data is expressed in mean [range] or number (percentage). NS = not significant
EuroSCORE: European System for Cardiac Operative Risk Evaluation score [21]
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use of paracetamol and morphine
ICU patients in the intervention group received signifi cantly more morphine than in the con-
trol group (mean 29.3 mg vs. 22.6 mg per day, P<0.01, Table 3). Linear mixed eff ects model for 
repeated measures detected a signifi cant positive relation between the amount of morphine 
administered and the NRS scores in the intervention group (0.015 [95%CI 0.0035-0.027], P = 
0.01), showing that more morphine was administered to patients with higher pain scores. In 
the control group no such relation was observed (-0.0075 [95%CI -0.042-0.02], P=0.66). There 
was no diff erence in paracetamol administration between groups (median 2.8 gram vs. 2.7 
gram per day; P=0.61, Table 3).
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Figure 1. Patient self-report pain levels on postoperative days 0, 1 and 2 in the ICU after cardiac surgery
Table 3. Morphine and paracetamol administration, length of ICU stay and duration of mechanical ventilation
control group
(n = 60)
intervention group
(n = 130)
P
Paracetamol, gram per day * 2.7 (2.0 - 4.0)  2.8 (2.1 - 3.3) 0.61 †
Morphine, mg per day * 22.6 (10.0 - 36.0) 29.3 (11.8 - 44.1) <0.01 †
 Morphine iv 12.2 (0 - 24.1) 22.9 (0 - 42.7) <0.001†
 Morphine sc 10.4 (0 - 19.5) 6.4 (0 - 10.0) 0.03 †
ICU stay, hr 42 (23 - 46) 38 (23 - 51) 0.54 ‡
Mechanical ventilation, hr 10 (7 - 16) 11 (7 - 16) 0.82 ‡
Data are expressed as mean (interquartile range). iv = intravenous, sc = subcutaneous
* 2 missing values; † general mixed-eff ect model; ‡ Mann-Whitney U test
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length of stay and duration of mechanical ventilation
The ICU length of stay was not significantly different between the intervention group (median 
38 hours [IQR 23-51]) and the control group (median 42 hours [IQR 23-46]; P=0.54). Neither 
was there a difference in the duration of mechanical ventilation between groups (interven-
tion, median 11 hours [IQR 7-16] vs. control, median 10 hours [IQR 7-16]; P= 0.82) (Table 3).
DiScuSSion
While optimal pain management is considered as one of the main features in benchmarking 
and grading the quality of care, only a very limited number of studies has evaluated the 
effect of systematic pain assessment and pain training in the ICU. It has been shown before 
in a heterogeneous population of ICU patients by Chanques et al. [11], that systematic pain 
assessment may result in a decrease of unacceptable pain levels from 63% to 42% in the ICU. 
In our study, we focussed in particular on patients in the ICU after cardiac surgery in order to 
optimize pain treatment in a more homogenous group of ICU patients and observed a clini-
cally relevant reduction of 56% in unacceptable pain scores. Diby et al. [15] also described 
the implementation of a postoperative pain treatment programme for patients in the ICU 
after cardiac surgery. After the implementation, pain intensity at rest decreased significantly, 
morphine was more adequately administered and patients’ sleep quality was improved. Our 
study not only underlines their finding that a pain management programme reduces pain in 
patients in the ICU after cardiac surgery, but moreover shows that the same applies for an ICU 
population with co morbidities such as history of pulmonary oedema and renal failure, which 
were excluded in the study by Diby et al. [15].
The currently described three-step pain management programme, that consisted of a 
health staff pain education program, systematic pain measurement and registration, and an 
optimization of the analgesia protocol, successfully reduced the occurrence of unacceptable 
pain (NRS≥4) in patients after cardiac surgery with an odds ratio for unacceptable pain of 
2.54 in the control group. Although this seems a major reduction in unacceptable pain levels, 
we even think that various influences may have contributed to an underestimation of the 
decrease of these pain scores. As this study was derived from a practical wish to improve 
the quality of care, several limitations to the methodology and consequently the interpreta-
tion of results have to be considered. The pain scores in the control group were asked when 
patients were at rest, not undergoing interventions, which may lead to relatively low pain 
levels at that particular moment. The pain scores in the intervention group however were 
taken at preset times initiated by PDMS, regardless of an intervention at that time. This may 
have resulted in higher pain scores in the intervention group, thereby underestimating the 
actual effect of the pain management programme.
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Additionally, during the intervention phase, nurses were trained to be more alert of high 
NRS levels compared to the control phase and they were allowed to rate pain at any other time 
in addition to the appointed times. This may have resulted in recording especially high pain 
levels more frequently in the intervention group. On the other hand, a bias may have been 
introduced by letting nurses, being the patients’ caregiver, ask for the patients’ actual pain 
scores that provide a reflection of the quality of care being provided by them. The patients in 
the intervention group reported their pain scores to nurses in a care dependent relation, as 
opposed to the fact that the patients reported their actual pain scores to the independent re-
searchers in the control group. We think however, that differences in reporting pain between 
the groups are not relevant for the conclusions of this study for three reasons; first in the 
control phase the ICU nurses were also present when the researchers asked the patient their 
actual pain scores. So, any restriction that patients may have felt in reporting their pain score 
in the presence of their caregiver would be present in both situations. Secondly, the patients 
were neither aware of nor trained in the pain management programme and they were asked 
exactly the same question in both phases, albeit by different persons. Thirdly, in order to 
avoid a difference in interpretation between the two phases, we only used pain scores given 
by the patients themselves.
The comparison of the pain levels between groups was complicated by the difference in 
the number of scores per patient and the total number of patients per group. This was a 
result of the difference in registration of pain scores. We managed to overcome this difficulty 
via a generalized mixed-effects model for repeated measurements. Another way to achieve 
the pain scores during the control phase would potentially have influenced the results as it 
seems logical that the registration of pain itself would have led to an intervention at the time, 
which would have made it impossible to compare the groups before and after the introduc-
tion of the pain management programme.
The intervention phase showed reduced pain levels, higher doses of intravenous morphine 
and lower doses of subcutaneous morphine. Although it seems obvious that higher doses of 
morphine resulted in lower pain levels, our study also shows that the increased morphine 
doses were administered in cases of higher NRS values (P=0.01). This indicates that the right 
patient, i.e. the patient in need for analgesia, received more morphine, which was in contrast 
with the control group in which there was no such relation. As little is known of the bioavail-
ability of subcutaneously administered morphine in the individual ICU patient with possible 
impaired perfusion and an altered volume of distribution, the programme intended and suc-
ceeded in a 38% reduction of the total amount of morphine administered subcutaneously.
In this study no reduction in ventilator days or ICU length of stay could be demonstrated 
in contrast with another study [22], where such an effect after the implementation of drug 
administration algorithms directed by levels of analgesia occurred. On the other hand, a 
prolongation of ventilator days as a possible negative influence of the increase in morphine 
administration did not occur either. The fact that we observed no difference in duration 
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of mechanical ventilation may also have been influenced by both the use of short-acting 
medication, e.g. propofol, a short-acting sedative, for sedation in both phases, and by the 
fact that most patients after cardiac surgery followed a fast-track regimen with anticipated 
short ventilation times.
Following the implementation of the pain management system, still 23% of all measure-
ments had an unacceptable outcome (NRS≥4). These results are comparable to the previously 
referred study in a diverse group of ICU patients [11] and approximately 3 times lower than in 
other reports [3-4]. Furthermore, 46% of the patients experienced at least one painful event 
during their stay in the ICU. Even though the results of our pain management programme 
were promising and of clinical importance, this still leaves us with a number of reports of 
unacceptable pain, which cannot be resolved by pain measurements and the suggested kind 
of programme, but needs to be addressed by new pain programmes which focus especially 
on prevention of for example intervention related pain, which has been suggested before 
[15].
Thus , we conclude that the pain management system containing 3 steps, i.e. a pain education 
programme, systematic pain measurement and registration with a PDMS and an optimized 
analgesia protocol significantly reduces the overall occurrence of unacceptable pain, and 
leads to the administration of more morphine in the patients in need for analgesia. Moreover, 
concerning patient safety, the increase of morphine administration does not increase ven-
tilation time or ICU length of stay. Therefore, we conclude that the effort invested in such a 
programme is very much worthwhile and should be implemented in all ICUs. Nonetheless, as 
46% of the patients in the intervention group still experienced at least one unacceptable pain 
event during their ICU stay, we suggest that the next step in optimising pain management 
will focus on more individually tailored analgesia and the prevention of pain and interven-
tion related pain.
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abStract
background and objectives As pain in the intensive care unit (ICU) is still common despite 
important progress in pain management, we studied the efficacy of an intravenous bolus of 
morphine 2.5 versus 7.5 mg for procedural pain relief in patients after cardiothoracic surgery 
in the ICU.
methods In a prospective double-blind randomised study, 117 ICU-patients after cardiotho-
racic surgery were included. All patients were treated according to a pain titration protocol 
for pain at rest, consisting of continuous morphine-infusions and paracetamol, which is 
applied during the entire ICU stay. On the first postoperative day, patients were randomised 
to intravenous morphine 2.5 (n=59) or 7.5 mg (n=58) at thirty minutes before a painful inter-
vention (turning of the patient and/ or chest drain removal). Pain scores using the numeric 
rating scale (NRS, range 0-10) were rated at rest (baseline), and around the painful procedure.
results At rest (baseline), overall incidence of unacceptable pain was low (NRS≥4; 14% vs. 
17%, P=0.81) for patients allocated to morphine 2.5 mg and 7.5 mg respectively. For proce-
dural related pain, there was no difference in incidence of unacceptable pain (NRS≥4; 28% 
vs. 22%, P=0.53) and mean pain scores (2.6 [95%CI 2.0-3.2] vs. 2.7 [95%CI 2.0-3.4]) between 
patients receiving morphine 2.5 and 7.5 mg, respectively.
conclusions In intensive care patients after cardiothoracic surgery with low pain levels for 
pain at rest, there was no difference in efficacy between a bolus of intravenous morphine 2.5 
mg or morphine 7.5 mg for pain relief during a painful intervention.
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introDuction
Despite important clinical progress in pain management [1], patients after cardiothoracic 
surgery in the intensive care unit (ICU) may suffer from postoperative pain [2-3]. Procedural 
related pain is the most common form of health care induced pain [4], of which turning of the 
patient and chest drain removal have been identified as the most painful procedures [5-6]. 
More specifically, patients recall repeated painful procedures as strong negative memories of 
the time in intensive care unit [7]. Additionally, it has been demonstrated that postoperative 
pain is a predictor for the development of chronic thoracic pain [8]. When receiving adequate 
pain relief, ICU patients are reported to be more comfortable, thereby also improving pa-
tients’ outcome like mortality or morbidity [9].
For pain at rest, recent studies [2,10-11] showed that a pain training programme, in which 
pain scores were systematically recorded by trained personnel, results in a successful reduc-
tion in the occurrence of unacceptable pain at rest. In the study conducted in our ICU [11], 
46% of the patients treated after the introduction of the pain training programme, expe-
rienced at least one unacceptable pain event at rest during their stay. In order to reduce 
this incidence, a pain titration protocol for pain management at rest is implemented in our 
ICU, because individualized titration of analgesia is associated with shorter ICU- and hospital 
length of stay a lower mortality [12].
Apart from pain at rest, ICU patients may suffer from routine health care painful proce-
dures. However, according to available evidence, procedural pain is difficult to treat, in which 
one part of the patients will experience unacceptable pain despite treatment [13-15]. No 
studies are available in which a bolus of analgesics is studied for procedural pain relief in ICU 
patients who are already treated with individualized titration of analgesia for pain at rest. 
Therefore, we designed a randomised controlled study to compare the efficacy of a bolus of 
intravenous morphine 2.5 versus 7.5 mg for procedural pain relief in postoperative patients 
after cardiothoracic surgery in the ICU, who were already treated according to a pain titration 
protocol for pain at rest.
materialS & metHoDS
Design
A prospective, double-blind, randomised clinical trial was performed in a 30-bed surgical/
medical intensive care unit (ICU) in a teaching hospital, Nieuwegein, The Netherlands. The 
study was approved by the local Ethics Committee of the St. Antonius Hospital, Nieuwegein, 
The Netherlands. Written informed consent was obtained from the patients before the 
cardiothoracic surgical procedure. The study was registered at ClinicalTrials.gov (identifier 
NCT00558090).
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Patients
During a 10-month period, patients admitted to the ICU after cardiothoracic surgery though 
sternotomy, between 18-85 years old and weighting between 45-140 kg were included. Ex-
clusion criteria were planned postoperative admission to the postoperative anaesthesia care 
unit (PACU) instead of ICU (depending on their co-morbidities), pregnancy or breast-feeding, 
a language barrier, coma or brain death, patients with a known morphine or paracetamol 
allergy and patients who refused informed consent. Participant flow is summarized in the 
CONSORT diagram (Figure 1). Of 528 patients who were scheduled for cardiothoracic surgery 
Excluded (n = 16)
To PACU* af ter surgery (n = 3)
Non sternotomy (n = 1)
Died before intervention (n = 1)
No intervention due to illness (n = 2)
No morphine due to (drowsiness) (n=9)
Assessed for eligibility
(n = 528)
Excluded (n = 393)
Age > 85 (n = 7)
Weight < 40 kg (n = 1)
Language barrier (n = 3)
Known allergy to morphine (n = 2)
To PACU* af ter surgery (n = 225)
Non-sternotomy (n = 84)
Refused study entry (n = 29)
Not present during inclusion round (n = 42)
Included in study
(n = 135)
Randomized
(n = 119)
Allocated to morphine 2.5 mg
(n = 61)
Allocated to morphine 7.5 mg
(n = 58)
Analyzed (n = 59)
Excluded f rom analysis (n=2)
Analyzed (n=58)
Excluded f rom analysis (n = 0)
* PACU = Post Anesthesia Care Unit
Figure 1. CONSORT diagram
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and assessed for eligibility, 393 were excluded and 135 patients were enrolled in the study. 
The 42 patients who were excluded because they were not present on the ward during inclu-
sion rounds due to medical examination, did not differ from included study patients in terms 
of demographic characteristics, i.e. mean age (68 years ± 15 vs. 69 years ± 11, P=0.51), mean 
BMI (26 kg/m2 ± 3 vs. 27 kg/m2 ± 4, P=0.14), and mean baseline pain scores (NRS 1.4 ± 1.5 vs. 
1.5 ± 1.7, P=0.93) or incidence of unacceptable pain scores at baseline (NRS≥4; 10% vs. 13%, 
P=0.78).
Of the 135 patients enrolled in the study, 16 patients were excluded before randomisation 
of the study medication (Figure 1). Random allocation resulted in 61 patients assigned to 2.5 
mg morphine and 58 patients assigned to the 7.5 mg morphine group. In the patients receiv-
ing 2.5 mg morphine, one patient was excluded from analysis, because the pain score during 
the painful procedure was not recorded. One patient was excluded because the intervention 
was not executed according study protocol.
intra-operative anaesthetic technique during cardiothoracic surgery
In all patients, midazolam or diazepam, fentanyl and propofol was used for induction of an-
aesthesia. All patients were paralyzed with pancuronium. Anaesthesia was maintained with 
propofol, sevoflurane, nitrous oxide and either fentanyl or remifentanil as preferred by the 
attending anaesthesiologist.
Pain measurements instruments
The NRS was scored by the patient which is considered the gold standard for pain measure-
ment [16]. The NRS was explained to participating patients before cardiothoracic surgery. The 
NRS is based on a scale from 0 to 10; 0 represents no pain, and 10 represents worst possible 
pain [17-18]. The NRS has a maximal acceptable pain score of 3 [19]. Severe pain was defined 
as a NRS≥7 [20]. The minimum clinically significant difference in pain reduction has been 
determined to be 1.3 to 1.5 [21-22]. In case the patient was not able to report his or her pain, 
the NRS was scored by the nurse, which has been proven to be a reliable measure [23]. There 
was no difference between mean NRS scores by the patient and mean NRS scored by the 
nurse before administration of the study dose morphine (1.7 [95%CI 1.3-2.0] vs. 1.3 [95%CI 
0.7-1.9]; P=0.38) and during intervention (2.7 [95%CI 2.2-3.2] vs. 2.3 [95%CI 1.5-3.0].
Standard pain titration protocol for treatment of pain at rest
For basic pain relief, a standard pain titration protocol (Figure 2), consisting of intravenous 
morphine infusions and intermittent paracetamol, was used in all patients, which is current 
practice in this ICU since 2007. When patients had an NRS score of ≥4, the attending nurse 
together with the responsible physician administered additional analgesic medication.
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Contact physician if:
* NRS ≥4 and CO2 ≥7 kPa
* Morphine continuous infusion ≥ 3 mg /hour
* 2x NRS ≥ 5
START pain protocol 
directly on admission
* Start paracetamol 1 gram, 4 times daily
* Start morphine continuous infusion (2mg / hour)
Contra-indication for 
paracetamol 
morphine/ propofol?
1. Decrease/ stop propofol
2. Decrease morphine if: 
- Propofol continuous infusion is stopped > 2-3 hours and
- The patient has no pain (NRS<4), or 
- In case of insufficient breathing 
Alternative medication for pain and sedation  contact
physician
Stable patient? *
Mechanically ventilated patient: 
- bolus of 5 mg morphine intravenously and
- increase morphine continuous infusion with 0.5 mg / hour 
Non-mechanically ventilated patient:
- bolus 2.5 mg morphine intravenously and
- increase morphine continuous infusion with 0.5 mg / hour 
Re-evaluate NRS after 30 minutes.
Don’t change morphine dosage
NRS 0 or 1?
Decrease morphine continuous infusion with 0.5 mg / hour every 
3-4 hours 
NRS ≥4?
Morphine intravenously 
2.5-5 mg, 4 x daily, if necessary 
or
Morphine subcutaneously
7.5-10 mg, 4 x daily, if necessary
* Evaluate NRS and RASS every 6 hours
DISCHARGE ICU
* Morphine continuous infusion stop, administrate 7.5-10 mg of morphine subcutaneously 
* Continue paracetamol 1 gram, 4 x daily
* Check prescriptions of morphine and paracetamol in ICU discharge letter 
* Hemodynamicly stable, acceptable leakage through thoracic drains, adequate time after muscle 
relaxation, adequate core temperature
NRS = numeric rating scale
RASS = Richmond Agitation Sedation Scale
ICU = Intensive Care Unit
Continuous 
infusion of 
morphine?
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
NRS 2 or 3?
Figure 2. Pain titration protocol for pain at rest
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Study procedures
According a standard pain titration protocol for pain at rest, patients were treated with con-
tinuous morphine infusions. The painful intervention took place during routine healthcare 
procedures on the first postoperative day after cardiothoracic surgery (day 1), between 7.30 
a.m. and 9.30 a.m.. Patients received either morphine 2.5 or 7.5 mg intravenously, 30 minutes 
prior to an unavoidable painful routine intervention, i.e. turning of the patient and/ or chest 
drain removal, which were both described as painful by patients [5,24]. Pain levels using the 
NRS were assessed at rest (baseline, before administration of a bolus morphine 2.5 or 7.5 
mg), and 5 minutes before, during and 5 minutes after the painful intervention. If necessary, 
rescue medication (fentanyl) could be administered.
Sample size calculation
With an incidence of unacceptable pain (NRS≥4) of 60% [13] during a painful intervention, the 
sample size needed for a 25% reduction in incidence of unacceptable pain, is 120 patients. 
The sample size was calculated with a power of 0.80 and an alpha of 0.05, two sided. Turning 
of the patient and drain removal have been identified as the most painful routine procedures 
performed for adults [5-6], in which pain intensity between chest drain removal and turning 
of the patient was comparable (NRS 6.5 ± 3.9 vs. NRS 4.1 ± 3.4) [6]. In our study, there was no 
difference in pain intensity between turning of the patient and chest drain removal as well 
(NRS 2.2 ± 2.0 vs. 3.1 ± 2.7 respectively; P=0.07).
Study medication
Morphine 2.5 and 7.5 mg syringes were prepared using morphine HCl 10 mg = 1 ml solution 
for injection (Pharmachemie, Haarlem, The Netherlands), which was diluted with sodium 
chloride 0.9% for a final concentration of morphine 2.5 mg = 10 ml and morphine 7.5 mg = 10 
ml respectively. The preparation, packaging and labelling was performed by the Department 
of Clinical Pharmacy. Syringes were blinded for patients, nurses, physicians and researchers.
randomisation to morphine 2.5 or 7.5 mg before the painful intervention
Randomisation to one of the two groups was performed using a random allocation schedule 
generated in blocks of 6 using SPSS. Randomization was performed in blocks of 6 patients 
to ensure that the morphine 2.5 mg group and 7.5 mg group would be of approximately 
equally size through the course of the study. The studied dose of 7.5 mg was chosen because 
it corresponds - in combination with the baseline morphine dosage according to the pain 
titration protocol - to the morphine dosage of 0.15 mg/kg, which was shown to be effective 
for pain relief in patients with severe pain [20]. The studied dose of 2.5 mg results from our 
hypothesis that a pain titration pain protocol combined with a low dose or placebo is suf-
ficient to prevent or treat procedural pain.
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endpoints
Primary endpoint of the study was the percentage of patients with an unacceptable pain score 
(NRS≥4) at baseline and during painful intervention, in both the group receiving morphine 
2.5 mg or 7.5 mg. Secondary endpoints were mean NRS scores during intervention, extreme 
pain (NRS≥7) during painful intervention, and clinically relevant decrease or increase in the 
NRS during intervention compared with the NRS before intervention.
Data-analysis
The SPSS statistical package (version 15.0.1 for Windows; SPSS, Chicago, IL) was used for the 
statistical analyses. Analysis was conducted in patients allocated to receive morphine 2.5 mg 
and 7.5 mg, although at baseline (at rest), patients still had to receive the study medication. 
Descriptive statistics are reported as means with SDs, medians with ranges, and proportions. 
Means were compared using a t-test for normally distributed data or the non-parametric 
Mann Whitney two-sample rank sum test for data not fitting the assumptions of parametric 
testing. Proportions were compared by using chi-square tests or Fisher’s exact test when ap-
propriate. A P-value of less than 0.05 was considered statistically significant.
reSultS
baseline patient characteristics
Baseline demographic and clinical characteristics of patients are described in Table 1. Patients 
allocated to 7.5 mg morphine were significantly older (72 years ± 9 vs. 66 years ± 12, P<0.002), 
had a higher median euroSCORE (8 [range 0-13] vs. 6 [range 2-12], P=0.03), and were less 
often exposed to the combination of turning and drain removal (22 patients vs. 36 patients, 
P=0.03).
nrS scores at baseline (before administration of a bolus morphine 2.5 or 7.5 
mg)
At rest (baseline), overall incidence of unacceptable pain (NRS≥4) was low (16%), and compa-
rable between patients planned for randomization to morphine 2.5 mg and 7.5 mg (14% vs. 
17%, P=0.81) (Table 2, Figure 3). Mean baseline NRS scores at rest were not different between 
patients receiving 2.5 mg and 7.5 mg morphine (1.5 [95%CI 1.2-2.0] vs. 1.7 [95%CI 1.1-2.2]; 
P=0.62). Patients planned for randomization to morphine 7.5 mg received significantly less 
morphine (13.1 ± 5.9 mg vs. 15.9 ± 5.5 mg, P=0.03) compared to the patients planned for 
randomization to morphine 2.5 mg.
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Table 1. Baseline characteristics of patients receiving morphine according to the pain titration protocol for pain at rest and a bolus of morphine 
2.5 or 7.5 mg thirty minutes before a painful intervention.
Pain titration protocol + 
morphine 2.5 mg (n = 59)
Pain titration protocol + 
morphine 7.5 mg (n = 58)
P
Male gender, n (%) 46 (78%) 41 (71%) 0.40
Age (years) 66 [63-69] 72 [70-74] 0.002
Body Mass Index (kg/m2) 27 [26-28] 27 [26-29] 0.68
History of sternotomy, n (%) 5 (8%) 10 (17) 0.17
History of Diabetes Mellitus, n (%) 10 (17%) 9 (16%) 1.00
History of pain a, n (%) 11 (18%) 16 (28%) 0.28
Preoperative Pain score NRS ≥ 4 n (%) 3 (5%) 9 (16%) 0.12
Preoperative chronic use, n (%)
 Benzodiazepines # 7 (12.3%) 10 (18%) 0.30
 Analgesics b # 7 (10.3%) 12 (21%) 0.22
Median euroSCORE (range) 6 (2-12) 8 (0-13) 0.03
Intraoperative dose fentanyl
 Total dose (mg) 1.7 [1.5-1.9] 1.6 [1.5-1.7] 0.35
 Dose (mcg/kg) 21.1 [19.0-23.2] 20.0 [18.6-21.4] 0.45
Intraoperative dose remifentanil
 Total dose (mg) 1.1 [0.7-1.4] 1.2 [0.9-1.5] 0.49
 Dose (mcg/kg) 13.2 [9.1-17.3] 15.2 [11.6-18.9] 0.46
Surgery in the morning/ afternoon 44/15 34/24 0.08
Median RASS score before intervention (range) 0 (-4-2) 0 (-5-1) 0.41
Intervention
 Turning/ Turning & Drain removal, n 23/36 35/23 0.03
 Mechanical ventilation, n (%) 9 (15%) 11 (19%) 0.63
 NRS scored by patient / nurse, n 48/11 49/9 0.81
  Duration between bolus morphine 2.5/7.5 mg  
and procedural intervention (min)
32 [28-35] 30 [28-32] 0.42
Data are mean [95%CI], median (range), number (percentage) or number/number. a Includes chronic back pain, rheumatoid arthritis, 
polyneuropathy, Herniated Nucleus Pulposus (HNP). b Includes paracetamol, NSAID’s and opioids. euroSCORE = European System for Cardiac 
Operative Risk Evaluation score [25]; RASS = Richmond Agitation and Sedation Scale [31]; NRS = numeric rating scale
Table 2. Baseline NRS scores at rest and baseline morphine consumption in patients planned for randomization to morphine 2.5 mg (n=59) vs. 
7.5 mg (n=58)
Pain titration protocol +  
morphine 2.5 mg (n = 59)
Pain titration protocol + 
morphine 7.5 mg (n=58)
P
baseline (at rest)
 NRS ≥ 4, n (%) 8 (14%) 10 (17%) 0.81
 NRS ≥ 7, n (%) 0 (10%) 3 (5%) 0.12
 Mean NRS [95% CI] 1.5 [1.2-2.0] 1.7 [1.1-2.2] 0.62
 Median NRS [IQR] 1 [0-3] 1 [0-3] 0.95
Baseline cumulative dose morphine on day of 
intervention (mg)
15.9 ± 5.5 13.1 ± 5.9 0.03
Baseline cumulative dose morphine on day of 
intervention (mg/kg)
0.19 ± 0.08 0.15 ± 0.08 0.03
Dose bolus morphine 2.5 / 7.5 mg (mg/kg) 0.03 ± 0.005 0.09 ± 0.016 <0.001
Data are expressed as number (percentage), mean (95%CI) or median (interquartile range [IQR])
NRS = numeric rating scale
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Pain scores before, during and after the painful intervention in patients 
randomised to receive morphine 2.5 mg versus 7.5 mg
During intervention, overall incidence of unacceptable pain (NRS≥4) was low (25%), and com-
parable between patients allocated to morphine 2.5 and 7.5 mg (28% and 22% respectively) 
(Table 3, Figure 3). In both the 2.5 morphine and 7.5 morphine groups, mean NRS scores 
were low (2.6 [95%CI 2.0-3.2] vs. 2.7 [95%CI 2.0-3.4]). 8% and 14% of the patients experienced 
severe pain (NRS≥7) during the intervention in the morphine 2.5 and 7.5 mg group, respec-
tively. There were no significant differences in mean NRS scores 5 minutes before, during and 
5 minutes after the painful intervention between patients receiving morphine 2.5 mg and 
patients receiving morphine 7.5 mg (Table 3, Figure 3).
No difference was found between the groups morphine 2.5 and 7.5 mg in clinically relevant 
(ΔNRS≥1.3) decrease (0% vs. 3%; P=0.24) or increase (42% vs. 38% P=0.71) in NRS scores. 
There was also no difference in mean change in NRS scores between both groups (1.5 [95%CI 
1.1-1.9] vs. 1.4 [95%CI 0.1-2.6] respectively, P=0.64) (Table 4). Additionally, in patients with 
unacceptable pain at rest (baseline), the mean change in NRS score was similar between 
patients allocated to morphine 2.5 and 7.5 mg (-1.1 [95%CI -2.9-0.7] vs. 0.4 [95%CI -2.1-2.9], 
P=0.27). None of the patients received fentanyl rescue medication.
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Figure 3. Mean NRS scores (95%CI) and the percentage of patients with unacceptable pain (NRS≥4) at rest (baseline) and before, during and 
after intervention in patients randomised to receive 2.5 mg (n=59) or 7.5 mg morphine (n=58).
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DiScuSSion
In this study, we evaluated the efficacy of morphine 2.5 versus 7.5 mg for the prevention 
and treatment of a non-avoidable painful intervention in ICU patients after cardiothoracic 
surgery, who were already treated according to a pain titration protocol for pain at rest. In 
patients with low pain levels for pain at rest, there was no difference in efficacy between a 
Table 3. NRS scores before, during and after the painful intervention (turning and/or drain removal) in patients randomised to receive 
morphine 2.5 mg (n = 59) vs. 7.5 mg (n = 58).
Pain titration protocol + 
morphine 2.5 mg
(n = 59)
Pain titration protocol + 
morphine 7.5 mg
(n=58)
P
before painful intervention (5 minutes before intervention)
 NRS ≥ 4, n (%) 2 (5%) 6 (10%) 0.16
 NRS ≥ 7, n (%) 0 (0%) 1 (2%) 0.50
 Mean NRS [95% CI] 1.1 [0.7-1.4] 1.3 [0.9-1.8] 0.35
 Median NRS [IQR] 1 [0-2] 1 [0-2] 0.66
During painful intervention
 NRS ≥ 4, n (%) 17 (28%) 13 (22%) 0.53
 NRS ≥ 7, n (%) 5 (8%) 8 (14%) 0.39
 Mean NRS [95% CI] 2.6 [2.0-3.2] 2.7 [ 2.0-3.4] 0.86
 Median NRS [IQR] 2 [1-4] 2 [1-3] 0.81
after painful intervention (5 minutes after intervention)
 NRS ≥ 4, n (%) 3 (7%) 6 (10%) 0.32
 NRS ≥ 7, n (%) 0 (0%) 2 (3%) 0.24
 Mean NRS [95% CI] 1.3 [0.9-1.7] 1.2 [0.7-1.7] 0.70
 Median NRS [IQR] 1 [0-2] 0 [0-2] 0.21
NRS=numeric rating scale
Table 4. Change in mean NRS scores in patients randomised to receive morphine 2.5 mg (n = 59) vs. 7.5 mg (n = 58).
Pain titration protocol 
+ morphine 2.5 mg
(n = 59)
Pain titration protocol 
+ morphine 7.5 mg
(n=58)
P
mean Δ nrS [95%ci]
Between ‘baseline intervention’ and ‘during intervention’ 1.1 [0.5-1.7] 1.0 [0.4-1.6] 0.92
Between ‘baseline intervention’ and ‘before intervention’ -0.4 [-0.7- 0.1] -0.3 [-0.6 -0.0] 0.59
Between ‘before intervention’ and ‘during intervention’ 1.5 [1.0-2.1] 1.4 [0.8-1.9] 0.64
Between ‘during intervention’ and ‘after intervention’ -1.3 [0.8-0.1.8] -1.5 [1.0-2.0] 0.58
clinically relevant decrease nrS, n (%)*
Between ‘before intervention’ and ‘during intervention’ 0 (0) 2 (3) 0.24
Between ‘during intervention’ and ‘after intervention’ 20 (33) 23 (40) 0.57
clinically relevant increase nrS, n (%)*
Between ‘before intervention’ and ‘during intervention’ 25 (42) 22 (38) 0.71
Clinically relevant decrease/ increase = Δ NRS> 1.3
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bolus of intravenous morphine 2.5 mg or morphine 7.5 mg for pain relief during a painful 
intervention.
During the painful intervention, we found a substantially lower incidence of unaccept-
able NRS scores (25%), compared to previous reports. In these studies, incidences of 32% to 
62% were reported during endotracheal suctioning and movement in patients with various 
morbidities [13-15]. In addition, mean NRS scores during the painful intervention were low 
(Table 3) compared to other studies, in which mean NRS scores of 5 and 7 were recorded 
during turning and drain removal, respectively [5-6]. In these studies, pain was managed with 
standard doses of analgesics for pain relief at rest or during procedural interventions only 
[26-28], in contrast to our study using a pain titration protocol. As such, the pain titration 
protocol which is applied during the entire ICU stay may not affect pain scores at rest alone, 
but may also lead to a decrease of pain intensity during painful procedures. This is partly 
explained by the study of Aubrun et al. [20], who concluded that patients with an initial 
visual analogue scale (VAS) ≥6 need more often rescue medication after morphine titration 
compared to patients with VAS<6 in the treatment of postoperative pain.
The dose of morphine 7.5 mg in our study was in accordance with the described literature 
for the prevention of procedural pain. Aubrun et al. [20] reported that a threshold of 0.15 mg/
kg morphine is needed for pain relief in patients with severe pain (NRS≥7) during postopera-
tive pain titration. A lower dose of 0.10 mg/kg was less effective compared to 0.15 mg/kg for 
pain reduction in emergency department patients with acute pain. A higher dose of 0.25 mg/
kg morphine was reported to lead to respiratory depression compared to 0.15 mg/kg [29]. 
Our dose of morphine 7.5 mg combined with the standard titration protocol is therefore the 
most optimal dose as it is in accordance with the maximum dose of 0.15 mg/kg. In contrast, 
the dose of morphine 2.5 mg results from our hypothesis that a pain titration protocol for 
managing pain at rest combined with only a low dose morphine is sufficient to prevent or 
treat procedural pain. However, we cannot exclude that morphine 2.5 mg is comparable 
to placebo. In that case, the pain titration protocol is more important for procedural pain 
management than a bolus of morphine.
Concerning pain at rest, previous reports showed that systematic pain measurement 
reduced incidences of unacceptable pain (NRS≥4) at rest to approximately 40% [2,10-11]. In 
our study, we were able to reduce the incidence of unacceptable pain at rest to 16%, as result 
of morphine titration adapted to individual pain. In the group patients allocated to morphine 
7.5 mg, similar NRS scores could be achieved by a lower baseline morphine consumption 
compared to the patients allocated to morphine 2.5 mg. The difference in morphine con-
sumption can be explained by the difference in baseline characteristics, as patients allocated 
to morphine 7.5 mg were significantly older and had a higher euroSCORE. It is well known 
that older patients need less analgesics for pain relief than younger patients [30]. Patients 
with a high euroSCORE are probably more vulnerable for the effects of medication, due to 
impaired condition of elimination organs, e.g. kidney and liver. This condition may result in 
75
Morphine for procedural pain relief
a slower elimination of morphine, thereby leading to lower morphine consumption in these 
patients. Thus, the pain titration protocol leads to an individual dosing regimen of analgesics, 
thereby resulting a low incidence of unacceptable pain at rest (16%).
Some remarks must be included concerning the limitations of our study. First, patients 
receiving 7.5 mg were more often exposed to the intervention ‘drain removal’, which may 
be more painful than the intervention ‘turning’ and thus may have reduced the difference in 
effect of pain relief between the patients receiving 2.5 mg and 7.5 mg. However, there was no 
significant difference in pain intensity between turning and drain removal. Secondly, the low 
procedural pain levels may theoretically have contributed to the reported lack of difference 
in pain levels between the morphine 2.5 and 7.5 mg group. I.e. as a result of the low overall 
pain scores which the patients reported within the context of the pain titration protocol, 
further decrease of pain intensity is more difficult to detect. In the ideal study design, we 
compared morphine 7.5 mg with placebo in combination with the pain titration protocol. 
However, for ethical considerations we preferred to treat these patients with a low dose of 
morphine. In this context, morphine may be dosed on kg bodyweight instead of a fixed dose. 
Finally, it cannot be excluded that the low overall pain scores in a context of studying the 
clinical trial itself. During a clinical trial with relation to pain management, all health care 
workers in the ICU will be “affected” in their approach to pain treatment.
In conclusion, in intensive care patients after cardiothoracic surgery with low pain levels for 
pain at rest, there was no difference in efficacy between a bolus of intravenous morphine 2.5 
mg or morphine 7.5 mg for pain relief during a painful intervention.
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abStract
background and objectives The catechol-O-methyltransferase (COMT) Val158Met poly-
morphism affected healthy volunteers’ pain sensitivity upon experimental pain stimuli. The 
relevance of these findings in morphine-treated postoperative cardiac patients undergoing 
painful health care procedures is unknown. Therefore, we aimed to investigate whether the 
COMT Val158Met polymorphism influences pain sensitivity in morphine-treated patients 
undergoing an unavoidable routine painful procedure after cardiac surgery.
methods 117 non-paralysed postoperative cardiac patients in the intensive care (ICU) were 
genotyped for the COMT Val158Met polymorphism. All patients were treated with continuous 
morphine infusions for pain at rest, and received a bolus of morphine (2.5 or 7.5 mg) before 
a painful procedure (turning and/or chest drain removal) on the first postoperative day. NRS 
scores were evaluated at four time points, i.e. at baseline (at rest), and before, during, and 
after the painful procedure.
results Overall mean NRS scores were significantly higher in patients carrying the Met-
variant allele. During the painful procedure, the mean NRS score was significantly higher for 
Met/Met patients compared to Val/Met and Val/Val patients (mean NRS 3.4 ± 2.8, 2.7 ± 2.4 
and 1.7 ± 1.7, respectively; P=0.04). In Met/Met patients, the increase in NRS scores during 
the painful procedure compared with baseline NRS score was clinically relevant (ΔNRS≥1.3) 
and statistically significant and appeared independent of sex and the morphine bolus dose.
conclusions Our results show that the COMT Val158Met polymorphism contributes to vari-
ability in pain sensitivity in morphine treated-patients after cardiac surgery in the ICU, as 
Met-allele carriers were more sensitive to overall pain and procedure-related pain.
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introDuction
Postoperative pain is a frequent problem in cardiac surgery [1]. It is characterized by a large 
inter-individual variability, even when the patient is at rest [2]. On the other hand, the nu-
merous unavoidable painful health care procedures in the intensive care unit (ICU) produce 
pain levels that may differ largely between patients. Turning of the patient and chest drain 
removal have been identified as the most painful procedures [3-4]. This inter-patient vari-
ability in pain sensitivity may partly be explained by environmental factors such as age, sex 
or anxiety [5-7]. Furthermore, some candidate genes have been associated with differential 
pain sensitivity [2,8].
The cathechol-O-methyltransferase (COMT) enzyme may contribute to the variability in 
pain sensitivity because it has a role in pain processing. COMT metabolizes dopamine, epi-
nephrine and norepinephrine, and is a key modulator of dopaminergic and adrenergic neuro-
transmission [9]. COMT contains a common functional coding polymorphism corresponding 
to a valine-to-methionine substitution at codon 158 (Val158Met). This substitution has been 
associated with a three- to four fold decrease in COMT activity [10]. Zubieta et al. [11] have 
suggested that lower COMT activity leads to an enhanced activation of the dopaminergic 
neurotransmission, with lower endogenous levels of enkephalins and thus exaggerated pain 
sensitivity as a result [11]. More specifically, in an experimental study these authors showed 
that healthy volunteers with the Met/Met genotype reported higher pain ratings than did 
those with the Val/Val genotype. In addition, subjects with the Met/Met genotype showed 
weaker activation of the endogenous opioid system on experimental pain stimuli than did 
subjects with the Val/Val genotype. These results were confirmed in two other experimental 
studies with healthy volunteers [12-13], and in one study evaluating morphine consumption 
in patients with chronic cancer pain [9]. There are however no reports on the relevance of 
this polymorphism on acute postoperative pain, i.e. after cardiac surgery, experienced either 
at rest or upon an unavoidable painful healthcare procedure, such as chest drain removal 
or turning of the patient, when patients were treated with intravenous morphine infusions.
In a recent clinical trial in postoperative cardiac patients of our group [14], pain levels were 
studied around an unavoidable routine painful procedure, i.e. turning of the patients and/
or chest drain removal. Despite continuous morphine infusions and a bolus dose of mor-
phine before the procedure, 25% of the patients experienced unacceptable pain rated on 
the numeric rating scale (NRS≥4, range 0-10 [15]) [14]. In the present study we tested the 
hypothesis that the COMT Val158Met polymorphism may explain these high pain levels upon 
the unavoidable painful procedure in these postoperative cardiac patients. Therefore, the 
aim of this study was to investigate the influence of the COMT Val158Met polymorphism on 
pain sensitivity during an unavoidable painful routine healthcare procedure in morphine-
treated adult patients after cardiac surgery in the ICU.
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metHoDS
Design
A prospective observational study was performed in a 30-bed surgical/medical ICU in a teach-
ing hospital, St Antonius Hospital, Nieuwegein, The Netherlands. The study was part of a ran-
domised controlled trial (registered at ClinicalTrials.gov, identifier NCT00558090) evaluating 
postoperative cardiac patients’ pain levels around an unavoidable painful procedure in the 
ICU. The clinical trial was approved by the St. Antonius Hospital Ethics Committee and written 
informed consent was obtained from all patients before the cardiac surgical procedure.
Patients
During a 10-month period, we considered eligibility of all patients aged from 18 to 85 years 
admitted to the ICU after cardiac surgery though sternotomy, as described in a previous 
report [14]. Within the randomised controlled trial for the prevention and treatment of proce-
dural pain, 135 patients were considered, 129 of whom were enrolled in the study according 
to the eligibility criteria. Nine of those 129 patients were excluded from analysis because 
they underwent a second sternotomy in the first 48 postoperative hours. Two patients were 
excluded because the painful procedure was not executed. One other patient was excluded 
because genotyping failed. Hence, 117 patients were included in the analysis.
Pain measurements instrument
The patients themselves, in principle, rated their pain levels on the numeric rating scale (NRS), 
as this is considered as the gold standard for pain measurement [16]. The NRS is based on a 
scale from 0 to 10; 0 represents no pain, and 10 represents worst possible pain [17-18]. A NRS 
score of 4 and higher is considered as unacceptable pain [15]. Pain increase or decrease is 
considered as clinically significant when the NRS change is at least 1.3 to 1.5 [19]. The NRS was 
used to assess postoperative pain at rest and during procedural pain. Scoring was explained 
to all participating patients before cardiac surgery. If a patient was not able to self-report, the 
NRS was scored by the nurse, which has been proven to be a reliable measure [20].
Standard pain titration protocol for treatment of pain at rest
For basic pain relief, a standard pain titration protocol, consisting of intravenous morphine 
infusions and intermittent paracetamol administration, was used in all patients, which is 
current practice in our ICU since 2007. Postoperatively patients rated their pain using the 
NRS at three standardised times, which is routine nursing care. At NRS scores of ≥4, the at-
tending nurse, along with the responsible physician, prescribed and administered additional 
analgesic medication [21].
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Procedures
On day 0, patients underwent (non)-elective cardiac surgery through sternotomy. Before 
surgery, one blood sample (10 ml) for COMT genotype determination was collected. After 
surgery, patients were admitted to the ICU, and were treated with continuous morphine infu-
sions according to the standard pain titration protocol to manage pain at rest [14].
On the first postoperative day, thirty minutes prior to the unavoidable routine care pain-
ful procedure, i.e. turning of the patient and/or chest drain removal between 7.30 a.m. and 
9.30 a.m., patients received an intravenous bolus dose of morphine of either 2.5 or 7.5 mg 
[14]. Pain levels were assessed using the NRS at four time points, i.e. at baseline (immediately 
before administration of the morphine bolus dose), and 5 minutes before, during, and 5 
minutes after the procedure. Patients’ characteristics and perioperative data were collected.
genotype analysis
Genomic DNA was isolated from 200 µl ethylenediaminetetraacetic acid-treated whole 
blood using a MagnaPure LC (Roche Diagnostics GmbH, Mannheim, Germany). The COMT 
rs4680G>A polymorphism (Val158Met) was determined through allelic discrimination analy-
sis using TaqMan® (Applied Biosystems, CA, USA) genotyping assays (C__25746809_50) on 
the ABI PRISM 7500® Fast real-time PCR Systems (Applied Biosystems, CA, USA). The PCR cycle 
consisted of an initial step of 1 min at 60°C, followed by a denaturation step at 95°C for 30 sec 
and 40 cycles with 95°C for 3 sec and 60°C for 30 sec. The final post-PCR read was made in 1 
min at 60°C. The volume for each reaction was 12 μl, consisting of 5 μl TaqMan® GTXpress™ 
Master Mix, 0.125 μl of TaqMan® SNP genotyping assay (80x), containing the primers (64 μM) 
and the probes (16 μM), and 20 ng genomic DNA.
Statistical analysis
Statistical analyses were made with the SPSS statistical package (version 18.0 for Windows; 
SPSS, Chicago, IL). Continuous data are expressed as mean ± SD or median (range) where 
appropriate. To estimate the effect of genotype on the outcome variables (NRS scores), NRS 
scores were compared between genotypes by a linear mixed-model analysis based on the 
maximum likelihood ratio with the patient genotype status as fixed factors and the time 
point of pain assessment as repeated measurement. No structure was imposed on variances 
and covariances between and within times of the repeated measurements. To adjust for 
potential confounding, linear mixed-model analysis was also performed by adding sex and 
the dose of morphine as covariates.
One-way ANOVA was performed to compare means between the three genotype groups 
(Val/Val, Val/Met and Met/Met genotype) at a single time point under the null hypothesis that 
the means of the compared groups were equal. Potentially confounding effects of patient’s 
sex status and the morphine dose (2.5 vs. 7.5 mg) were assessed with multiple linear regres-
sion analyses. For these models, the homozygous genotype for the most frequent allele was 
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set as the reference. Student’s paired t-tests served to test the significance of the change in 
NRS scores during the painful procedure (third time point) when compared to baseline (i.e. 
before morphine bolus dose; first time point), either for the entire population or for sub-
groups stratified by COMT genotype. Categorical data are expressed as percentage of total in 
each category and the associations were tested by Pearson’s Chi Square test. A P-value of ≤ 
0.05 was considered as statistically significant.
reSultS
Patient characteristics
Thirty-two women and eighty-five men were included in the study, all Caucasian except two 
patients, who were of Asian and African American origin. Thirty patients were homozygous 
for the wild-type allele (Val/Val) with regard to the COMT Val158Met polymorphism; 66 
were heterozygous (Val/Met); and 21 were homozygous for the variant allele (Met/Met). 
This yielded a 46.2% frequency of the Met-allele, in line with previous data [13], while the 
genotype distribution did not deviate from the Hardy-Weinberg equilibrium (χ²=2.1, P=0.14). 
Patient characteristics are presented in Table 1; there were no differences between the three 
genotype groups with respect to sex, age, type of surgery, intraoperative use of analgesics, 
Table 1. Patients’ characteristics
Val/Val Val/met met/met P
Number of patients 30 66 21
Age (yrs) 71 ± 11 69 ± 11 66 ± 12 0.45
Sex (male/ female), n 22/8 49/17 14/7 0.79
BMI (kg/m2) 27.7 ± 4.3 27.5 ± 4.2 26.6 ± 3.9 0.59
Type of cardiac surgery, n (%) 0.41
 CABG 7 (23%) 16 (24%) 2 (10%)
 Valve 5 (17%) 16 (24%) 7 (33%)
 CABG and Valve surgery 14 (47%) 23 (35%) 6 (29%)
 Aorta surgery 4 (13%) 11 (17%) 6 (29%)
Mean duration of anaesthesia (hours) 4.2 ± 1.2 4.2 ±1.0 3.7 ± 1.1 0.24
Mean intraoperative dose of fentanyl (mg) 1.6 ± 0.5 1.6 ±0.5 1.7 ±0.6 0.68
Mean intraoperative dose of remifentanil (mg) 1.0 ± 1.0 1.2 ±1.3 1.3 ±1.3 0.71
Cumulative postoperative dose morphine (mg)
 before morphine bolus
12.6 ± 6.8 13.6 ± 6.7 14.7 ± 6.6 0.55
Dose morphine bolus 2.5 or 7.5 mg * 14/13 30/33 15/6 0.16
Unavoidable routine care procedure
Turning/ turning & drain removal 11/19 36/30 8/13 0.18
Mean ICU stay (days) 2.1 ± 1.6 2.3 ± 2.2 2.4 ± 1.5 0.83
All values are expressed as mean ± SD or as number (percentage). COMT = catechol-O-methyltransferase; BMI = body mass index; 
CABG=coronary artery bypass graft; ICU=intensive care unit
* 6 missing values.
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or cumulative morphine consumption before the painful procedure. Finally, proportions of 
patients randomised to receive either a 2.5 or 7.5 mg bolus dose of morphine did not differ 
between the three genotype groups (χ²=3.6, P=0.16, Table 1).
nrS scores around the painful procedure
Figure 1 illustrates the NRS pain scores at the four time points for the three genotype groups. 
In a linear mixed-model considering all four time points, analysis of repeated measurement 
demonstrated that the overall mean NRS scores estimated from the model were significantly 
different across COMT genotype clusters, being on average 1.2 ± 0.2, 1.6 ± 0.1 and 1.9 ± 0.2 for 
Val/Val, Val/Met and Met/Met patients, respectively (P ANOVA=0.03) (Figure 1).
Pair-wise analyses revealed that the mean difference in NRS score significantly differed 
between patients with the Met/Met genotype and patients with the Val/Val genotype (ΔNRS 
= 0.7 ± 0.3; P=0.01). This difference was not significant between Val/Met patients versus 
Met/Met patients (ΔNRS = -0.3 ± 0.2; P=0.19) and versus Val/Val patients (ΔNRS = 0.4 ± 0.2, 
P=0.07) (Figure 1). When sex was introduced as a covariate in the linear mixed-model analysis, 
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Figure 1. Mean NRS scores around the painful procedure.
Pain was rated at four individual times using the numeric rating scale (NRS). A bolus morphine was administered after time point ‘at baseline’. 
Linear mixed model analysis revealed a significantly higher overall NRS score in patients with the Met/Met genotype compared to patients with 
the Val/Met patients and Val/Val patients.
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adjusted mean NRS scores were 1.1 ± 0.23, 1.5 ± 0.15 and 1.8 ± 0.20 for Val/Val, Val/Met and 
Met/Met patients, respectively (P ANOVA=0.03), indicating that the effect of COMT genotype 
was independent of sex.
Table 2 reports mean NRS scores for the four time points separately. Only the mean NRS 
scores during the painful procedure were significantly different between the genotype 
groups (P=0.04). The highest pain score was recorded for patients with the Met/Met genotype 
(mean NRS 3.4 ± 2.8), followed by heterozygous patients with the Val/Met genotype (mean 
NRS 2.7 ± 2.4) and patients with the Val/Val genotype (mean NRS 1.7 ± 1.7). At this time point, 
the difference in mean NRS scores between Val/Val and Met/Met patients was thus 1.7, which 
is considered clinically relevant (ΔNRS≥1.3-1.5). In an additional analysis, we adjusted for 
potential confounding by sex. In a multiple linear regression model, the difference in mean 
NRS score between the genotype groups at any of the four time points remained significant 
(P=0.01).
At last, unacceptable pain scores (NRS≥4) during the painful procedure were considered. 
In total, 26% of the 117 patients experienced unacceptable pain (NRS≥4) during the painful 
procedure. Proportions of patients reporting such high scores did not differ between the 
three genotype groups (P = 0.14).
increase in nrS scores upon the painful procedure compared with baseline
For all patients, the NRS increase (ΔNRS), corresponding to the NRS score recorded during the 
painful procedure minus the baseline NRS score recorded before the bolus administration 
of morphine, was a mean of 1.1 ± 2.3, indicating a statistically significant increase (P<0.001), 
albeit not a clinically significant increase (ΔNRS<1.3).
Regarding the subgroups, the Met/Met homozygote group showed a statistically signifi-
cant and clinically relevant increase in the NRS score during the painful procedure compared 
with baseline, with a mean ΔNRS of 1.6 ± 2.5 (P=0.001). The mean ΔNRS for the Val/Met group 
was 1.1 ± 2.2 (P<0.001), which is not considered clinically relevant; that for the Val/Val homo-
zygote group 0.2 ± 1.8 (P=0.63), thus neither statistically significant nor clinically relevant. In 
a multiple linear regression model to adjust for potential confounding by sex, the ΔNRS score 
was significantly related with the COMT allelic status (P=0.03) and this relationship was not 
table 2. nrS scores at individual time points
baseline
(pain at rest)
before painful 
procedure
During painful 
procedure
after painful 
procedure
NRS score
 Val/Val 1.5 ± 1.8 0.9 ± 1.4 1.7 ± 1.7 1.0 ± 1.2
 Val/Met 1.6 ± 1.8 1.5 ±1.7 2.7 ± 2.4 1.2 ± 1.5
 Met/Met 1.8 ± 2.0 1.4 ±1.8 3.4 ± 2.8 1.7 ± 2.1
P – value 0.86 0.34 0.04 0.20
All values are expressed as mean ± SD
COMT = catechol-O-methyltransferase; NRS = numeric rating scale
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modified when sex was introduced as an independent variable. Similar results were observed 
after stratification according to the bolus dose of morphine (i.e. 2.5 or 7.5 mg), indicating that 
the change in NRS scores was independent of the bolus morphine dose (data not shown). 
Altogether, 29 patients (24%) who reported acceptable pain (NRS<3) at baseline, reported 
unacceptable pain (NRS≥4) during the painful procedure; proportions of these patients did 
not differ between the genotype groups (P = 0.20).
DiScuSSion
We evaluated the influence of the COMT Val158Met polymorphism in postoperative cardiac 
patients treated with continuous morphine infusions to manage pain at rest and with an 
additional bolus dose of morphine before an unavoidable postoperative painful procedure 
(chest drain removal and/or turning of the patient) in the ICU. The main finding was that 
patients carrying the Met-variant allele experienced both significantly increased overall pain 
and significantly increased pain during the painful procedure, compared to patients with the 
Val/Val genotype. More specifically, patients with the Met/Met genotype showed a statisti-
cally significant and clinically relevant increase in pain scores during the painful procedure, 
unlike patients with the Val/Val genotype. To our knowledge, this is the first study evaluat-
ing the impact of the COMT Val158Met polymorphism on pain sensitivity within a clinical 
research design in morphine-treated postoperative patients undergoing an unavoidable 
painful stimulus. So far, only healthy volunteer studies have evaluated this polymorphism 
in relation to pain sensitivity applying experimental pain stimuli, with similar results as in 
the present study (Table 3). Loggia et al. [22] demonstrated that individuals with the Met/
Met genotype exhibit stronger pain signals in numerous cortical and subcortical structures 
after repeated noxious stimulation when compared to other genotype groups. This is also 
consistent with other studies evaluating the impact of the COMT Val158Met polymorphism 
on pain sensitivity. Zubieta et al. [11] demonstrated that Met/Met subjects were character-
ized by higher sensory and affective pain ratings; two other studies [12-13] found that Met/
Met individuals were more susceptible to pain after repeated thermal stimuli. Jensen et al 
[13] showed that, after remifentanil bolus injection and repeated heat pain stimuli, Met/Met 
subjects reported higher pain scores than did Val/Val subjects, while heterozygous subjects 
reported intermediate scores. Thus, the results of our clinical study confirm the results of the 
experimental pain studies in healthy volunteers, where pain sensitivity of patients carrying 
the Met-allele experience was higher than that of patients with the Val/Val genotype. As such, 
we showed that this genotype-related difference in pain sensitivity is clinically relevant in 
morphine-treated patients after cardiac surgery undergoing an unavoidable – instead of 
experimental – pain stimulus in the ICU.
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Although, we found a clinically relevant increase in NRS score in patients with the Met/Met 
genotype, proportions of patients whose pain increased from an acceptable level (NRS<4) 
at baseline to an unacceptable level (NRS≥4) during the painful procedure did not differ 
between the genotype groups. We realize that in our study the mean NRS scores generally 
were low (NRS<4), and that especially the increase to unacceptable pain during the painful 
procedure should be prevented. However, the knowledge that patients with the Met/Met 
genotype are at higher risk for a clinically relevant increase in pain during a painful interven-
tion may be of value for procedural-related pain management.
The results of our study suggest that patients carrying the Met-allele may benefit from 
a more individualized therapy in case of a second surgery. Higher morphine doses may be 
anticipated, although only a small increase in efficacy may be expected at an increased inci-
Table 3. Overview of studies which investigated the COMT Val158Met polymorphism in relation to pain sensitivity
Study design Study population intervention main outcome reference
Experimental 29 Healthy 
volunteers
Binding potential of the mu-receptor 
and muscle pain was measured twice: 
during intensity controlled sustained 
pain induced by infusion of 5% 
hypertonic saline into the masseter 
muscle and during the infusion of non-
painful 0.9% isotonic saline.
Subjects with the Met/Met 
genotype of the COMT Val158Met 
polymorphism showed diminished 
regional μ-opioid system responses 
to pain compared with Met/Val and 
Val/Val subjects. These effects were 
accompanied by higher sensory and 
affective ratings of pain.
[11]
Experimental 202 Female 
healthy volunteers
Threshold and tolerance to thermal, 
ischemic, and mechanical stimuli, as 
well as temporal summation to heat 
pain, were determined.
The Val158Met polymorphism was 
associated with sensitivity to painful 
heat stimuli, which suggest that the 
Val158Met polymorphism plays a 
primary role in variation in temporal 
summation of pain.
[12]
Experimental 43 Healthy 
volunteers
Five blocks of thermal heat pain 
were induced to the hand. After each 
stimulus subjects rated pain on a VAS. 
Before the second and the fourth 
stimulus, respectively an intravenous 
injection of remifentanil (0.08 mg/kg) 
and placebo was administered.
Met/Met subjects reported 
significantly more pain compared to 
Val/Val subjects in case of repeated 
pain stimuli, although not during an 
initial response of the descending 
pain system. The opioid intervention 
induced analgesia without a 
separating effect for genotype.
[13]
Experimental 54 healthy 
volunteers
Subjects received two heat pain 
stimuli on the right forearm during 
functional Magnetic Resonance 
Imaging (fMRI). After each stimulus, 
subjects rated their pain intensity 
using the Gracely Sensory scale (GSS).
Met/Met subjects showed stronger 
pain-related fMRI signals than Val/Val 
subjects in several brain structures, 
only for high intensity pain stimuli 
after repeated administration
[22]
Clinical 
research 
design
207 morphine-
treated patients 
for chronic cancer 
pain
Between the genotype groups, 
morphine doses, serum concentrations 
of morphine and morphine 
metabolites were compared.
After a mean treatment period of 
3.5 months, patients with the Val/Val 
genotype needed more morphine 
when compared to the Val/Met and 
the Met/Met genotype groups. Pain 
scores were not reported.
[9]
VAS = visual analogue scale, range 0-10
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dence of adverse events. In this respect, non-opioid analgesics may be preferable, as they act 
independent of endogenous enkephalin levels and the μ-receptor density. However, agents 
such as nonsteroidal anti-inflammatory drugs (NSAIDs) may be disadvantageous in post-
operative cardiac patients as they carry the risk of cardiovascular side effects. Thus, further 
research should focus on these and other aspects of individualized pain management.
In our study, patients received continuous morphine infusions for pain at rest, and a bolus 
dose of morphine before a painful procedure. Morphine requirement did not differ between 
the genotype groups during ICU stay and during the painful procedure. Interestingly, at first 
sight our results deviate from the observation made by Rakvåg et al. [9] that Met/Met homo-
zygous cancer patients required less morphine compared to patients with the Val/Val variant. 
The authors suggest this may be explained by an increase in μ-opioid receptor density in 
Met/Met patients, which causes morphine to be more effective. However, those patients 
were treated for prolonged cancer pain for approximately 3.5 months [9], in contrast with our 
patients who were treated for postoperative acute pain (maximum for 48 hours). It is possible 
that an increase in μ-opioid receptor density may occur after a more prolonged period of 
opioid treatment. Moreover, the study of Rakvåg et al. [9] concerned a heterogeneous group 
of patients, with differences in disease severity and progression, and thus several nociceptive 
stimuli, whereas in our study all patients underwent the same painful procedure.
Considering the bolus morphine (2.5 vs. 7.5 mg), we observed no significant effect of the 
genotype on the analgesic response of morphine. These results are supported by the study 
of Jensen et al. [13] (Table 3), in which a single dose of remifentanil before a heat stimulus 
induced analgesia, without a separating effect for genotype. They also found that Met/Met 
subjects reported significantly more pain than did Val/Val subjects in case of repeated pain 
stimuli, except after the initial pain stimulus. As our patients underwent cardiac surgery the 
day before the painful procedure, it is likely that the pain system was already triggered at 
the time of the painful procedure. Therefore, we suggest that Met/Met patients receiving the 
same dose as Val/Val patients are more sensitive to pain as a result of repeated painful stimuli, 
which is independent of a morphine bolus dose.
Two limitations of our pilot study should be addressed. Firstly, our study was in fact un-
derpowered because this analysis was conducted within a randomised controlled trial, and 
was thus not designed primarily as a pharmacogenetic study. However, even with these low 
numbers of patients, we found a significant effect of genotype on both overall pain levels and 
pain during the painful procedure. Secondly, pain sensitivity is influenced by many factors, 
including probably genetic contributions of more than one gene. Therefore, this study can-
not determine the relative importance of the COMT Val158Met polymorphism compared to 
other genes involved in pain.
In conclusion, the results of the present clinical study suggest that the COMT Val158Met 
polymorphism is correlated to pain sensitivity in morphine treated-patients undergoing a 
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painful healthcare procedure after cardiac surgery, showing that Met-allele carriers are more 
sensitive to overall pain and procedural pain.
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abStract
background and objectives Chronic thoracic pain after cardiac surgery is a serious condition 
affecting many patients. The aim of the study was to identify predictors for chronic thoracic 
pain after sternotomy in cardiac surgery patients by analysing patient and perioperative 
characteristics.
methods A follow-up study was performed in 120 patients who participated in a clinical trial 
on pain levels in the early postoperative period after cardiac surgery. The presence of chronic 
thoracic pain was evaluated by a questionnaire one year after surgery. Patients with and 
without chronic thoracic pain were compared. Associations were studied using multivariable 
logistic regression analysis.
results Questionnaires of 90 patients were analysed. Chronic thoracic pain was reported by 
18 patients (20%). In the multivariable regression model, remifentanil during cardiac surgery, 
age below 69 years and a body mass index above 28 kg/m² were independent predictors for 
chronic thoracic pain (Odds ratios 8.9 [95%CI 1.6-49.0], 7.0 [95%CI 1.6-31.7], 9.1 [95%CI 2.1-
39.1], respectively). No differences were observed in patient and perioperative characteristics 
between patients receiving remifentanil (58%, n=52) compared to patients not receiving 
remifentanil (42%, n=38).The association between remifentanil and chronic thoracic pain 
appeared dose-dependent, both for total dose and for dose corrected for kg Lean Body Mass 
and duration of surgery (P for trend <0.01 and <0.005, respectively).
conclusions In this follow-up study in cardiac surgery patients, intraoperative remifentanil 
was predictive for chronic thoracic pain in a dose-dependent manner. Randomized studies 
designed to evaluate the influence of intraoperative remifentanil on chronic thoracic pain are 
needed to confirm these results.
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introDuction
Chronic thoracic pain after cardiac surgery via sternotomy is a serious condition affecting 
many patients. Recent studies report incidences varying from 11 to 56% [1-6], depending 
on the definition and the study population [7]. Patients suffering from chronic thoracic pain 
experience a significantly lower physical and mental health status compared with patients 
without chronic thoracic pain [1-2,8-9]. In order to prevent chronic pain, studies are needed 
to identify factors that may predict an increased likelihood [7].
Previous studies recognized younger age [2-3,8,10], increased body mass index (BMI) [8] 
and female gender [6] as predictors for chronic thoracic pain. Furthermore, in different studies 
severe immediate postoperative pain [6,10], non-elective surgery [6] or a resternotomy in the 
early postoperative period [6] have been suggested. The variety in the identified predictors 
may result from the different definitions for chronic pain and heterogeneity of the patient 
populations, as well as the retrospective design of most studies. The majority of the studies 
lacked detailed information from the perioperative period, such as pain levels before surgery 
or the choice and dose of anaesthetics and analgesics used during cardiac surgery. In this 
respect, it has been shown that the anaesthetics used during surgery may have long-term 
effects regarding chronic pain, as Salengros et al. [11] showed for remifentanil in patients 
who underwent a thoracotomy.
We performed a follow-up study of patients who participated in a clinical trial on pain 
levels in the early postoperative period in the intensive care unit (ICU) after cardiac surgery. 
The present study aimed to identify predictors for chronic thoracic pain one year after car-
diac surgery via sternotomy by analysing detailed patient and pre-, intra- and postoperative 
characteristics.
metHoDS
Design and patients
A follow-up study was conducted in 120 patients who participated in a prospective, double 
blind randomised clinical trial on procedural analgesia in the ICU after cardiac surgery 
(ClinicalTrials.gov identifier: NCT00558090). The inclusion criteria for this clinical trial were 
patient informed consent, admittance to the ICU after cardiac surgery via sternotomy, age 
between 18 and 85 years and body weight between 45 and 140 kg. Exclusion criteria were 
pregnancy or breast-feeding, an inability to communicate in either Dutch or English, coma 
or brain death and a known morphine or paracetamol allergy. For the clinical trial, informed 
consent was given by 135 patients. Four patients were excluded directly after surgery be-
cause they were not admitted to the ICU but to the post anaesthesia care unit (n=3) or did 
not undergo a sternotomy (n=1). Eleven patients died within one year after surgery, resulting 
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in 120 patients eligible for the follow-up study. The follow-up study was approved by the 
Ethics Committee (VCMO, Nieuwegein, The Netherlands) as an amendment to the clinical 
trial. Additional written informed consent was obtained from the patients. Participant flow is 
summarized in a flow chart (Figure 1).
Preoperative evaluations
Preoperatively, patient characteristics were collected and patients were questioned about 
their pain history, the use of analgesics and preoperative pain score. For the latter the nu-
meric rating scale (NRS) (range 0-10, with “0” representing “no pain” and “10” representing 
“the worst pain imaginable”) was used [12-13].
intraoperative anaesthesia and analgesia
For induction of anaesthesia, midazolam and propofol bolus injections were administered 
together with fentanyl. Patients were paralyzed with pancuronium. Anaesthesia was primar-
ily maintained with propofol, with optional use of nitrous oxide. According to local practice, 
sevoflurane 0.25 – 1.00 minimum alveolar concentration was added for cardio-protection 
until the start of the extra corporeal circulation. For intraoperative analgesia, intermittent 
fentanyl doses were used, while remifentanil continuous infusion was initiated directly after 
the induction of anaesthesia at the discretion of the attending anaesthesiologist. Total dose 
of remifentanil and remifentanil dose corrected for kg Lean Body Mass (LBM) and duration of 
surgery in minutes were calculated. LBM was defined for male (1.1 * weight (kg) - 128 (weight/
height (cm)) and female 1.07 * weight (kg) - 148 (weight/ height (cm)) [14]. Perioperative data 
were registered in the clinical trial registration form. In total, eighteen anaesthesiologists and 
ten surgeons were involved during surgery. The specific combination of a surgeon and an 
anaesthesiologist was unique for 43 patients and did not occur more than five times.
Questionnaires sent
(n=120 )
Questionnaires answered
(n=9)1
Questionnaires analysed
(n=90)
Excluded (n= 29)
Inability to cooperate in follow-up (n=3 )
Questionnaire returned empty (n=2)
Questionnaire not returned (n=24)
Excluded (n=1)
No information on doses of  peroperative
anaesthetics and analgesics
Figure 1. Participant flow
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Postoperative pain measurement and analgesia in the icu
According to standard care in our ICU, a patient data management system (PDMS) obliged 
nurses to ask patients for their pain score three times a day (8.00 a.m., 4.00 p.m. and midnight) 
[15]. A pain titration protocol was used in all patients as part of standard care, consisting of 
intermittent paracetamol 4 grams daily and a continuous intravenous infusion of morphine, 
which was started directly upon admittance to the ICU. According to the pain titration pro-
tocol, in case of a NRS score of more than 3, an extra bolus of morphine and/or an increase in 
continuous morphine infusion was applied. Pain scores were registered in the patient data 
management system (PDMS).
follow-up study one year after cardiac surgery
A questionnaire enquiring after the presence of chronic thoracic pain was sent to the patients 
one year (13 months ± 0.6) after cardiac surgery. This previously used questionnaire [6] was 
based on the McGill Pain Questionnaire [16]. Chronic thoracic pain was defined as sternal 
and/or thoracic pain (NRS>0), which the patient identified as related to surgery, which was 
different from angina and which was present in the 2 weeks preceding the interview [6].
Data-analysis
All statistical analyses were performed using IBM SPSS Statistics (version 19.0 for Windows; 
SPSS, Chicago, IL). Descriptive statistics of demographic and clinical variables were expressed 
as frequencies with percentages (%), median with interquartile range [IQR] or mean with stan-
dard deviation (SD) where appropriate. Categorical data were analyzed by χ2 or Fisher’s exact 
tests and continuous data by Student’s t-tests or Mann-Whitney U-tests. In case of significant 
differences in frequencies between patients with and without chronic pain in continuous or 
ordinal variables, receiver operating characteristic (ROC) curves were constructed to identify 
cut-off points with most discriminative value. By using these cut-off points (dichotomiza-
tion) and adding all other associated clinical variables (P<0.10), a backward stepwise logistic 
regression analysis was performed to identify variables with most predictive value. Addition-
ally, as a sensitivity analysis, the regression analysis was repeated without dichotomization. 
Imputation has been applied for 5 data-entries (0.3% of all data entries). A two-tailed P-value 
<0.05 was considered significant for all tests.
reSultS
Patients and data
Of the 120 sent questionnaires, 96 (80%) were returned. Two were returned empty and three 
questionnaires were accompanied by a note that these patients were unable to fill in the 
questionnaire. This resulted in 91 answered questionnaires. Responders of the question-
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naire were more often men compared to non-responders (76% (69/91) versus 55% (16/29), 
respectively, P=0.03). Otherwise no differences were observed between responders and non-
responders, i.e. mean age (69 years ± 11 vs. 70 years ± 12, P=0.69), median European System 
for Cardiac Operative Risk Evaluation score (euroSCORE [17]) (7 [range 0-13] vs. 6 [range 2-13], 
P=0.39) and mean BMI (27 kg/m2 ± 4 vs. 28 kg/m2 ± 5, P=0.41, respectively). One patient was 
excluded during the analysis because details of intraoperative anaesthetics and analgesics 
could not be retrieved. Patient characteristics of the 90 included patients are summarized in 
Table 1.
univariate analysis of patient and pre-, intra- and postoperative characteristics
One year after cardiac surgery, 20% of the patients (n=18) reported chronic thoracic pain (NRS 
>0). Table 2 compares patient and perioperative characteristics of patients with and without 
chronic thoracic pain. Patients with chronic thoracic pain were significantly younger (mean 
age 63 years ± 12 vs. 70 years ± 10), had a higher mean BMI (30.2 kg/m2 ± 4.6 vs. 26.6 kg/m2 ± 
3.3), a lower median euroSCORE (4.5 [IQR 3-7] vs. 7 [IQR 5-9]), and used more preoperative an-
algesics (27.8% vs. 11.1%) compared to patients without chronic thoracic pain. Furthermore, 
mean preoperative NRS scores were higher in patients with chronic pain compared to pa-
tients without chronic thoracic pain (1.9 ± 3.1 vs. 0.5 ± 1.3). During anaesthesia, patients with 
chronic thoracic pain received significantly more often remifentanil compared to patients 
without chronic thoracic pain (83.3% vs. 51.4%). The dose of fentanyl during anaesthesia 
was not different between patients with and without chronic thoracic pain (1.7 mg ± 0.6 vs. 
1.7 mg ± 0.4, P = 0.44). Postoperative pain scores in the ICU were not significantly different 
between patients with chronic thoracic pain and without chronic thoracic pain (Table 2).
Cut-off points identified via ROC curve analysis were 69 years for age, 28 kg/m² for BMI and 
an euroSCORE of 6. These three variables, together with preoperative pain (NRS>0), chronic 
use of analgesics before surgery and anaesthesia that included remifentanil, were selected 
for multivariate logistic regression analysis with stepwise backward elimination.
Table 1. Patient characteristics
all patients
Number of patients 90
Male/female, n 69/21
Age, years (range) 68.9 (32-85)
BMI, kg/m² (±SD) 27.3 ±3.8
Type of cardiac surgery, n (%)
 CABG 22 (24.4%)
 CABG and valve surgery 30 (33.3%)
 Valve surgery 19 (21.1%)
 Aortic surgery 19 (21.1%)
Diabetes, n (%) 16 (17.8%)
EuroSCORE, median [IQR] 7 [4-9]
SD =standard deviation, IQR = Interquartile Range. EuroSCORE = European System for Cardiac Operative Risk Evaluation score [18]
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multivariate analysis of patient and pre-, intra- and postoperative 
characteristics
In the multivariate logistic regression analysis, anaesthesia that included remifentanil, age 
younger than 69 years and a BMI above 28 kg/m² all appeared independent predictors for 
chronic thoracic pain with corresponding odds ratios as shown in Table 3. The goodness-of-fit 
of the final model was excellent (P-value by Hosmer and Lemeshow test 0.94). Preoperative 
pain, chronic use of analgesics before surgery and EuroSCORE were not statistically significant 
associated with chronic pain in the multivariate analysis. In analysis without dichotomization 
of continuous variables, remifentanil was confirmed as independent predictor of chronic 
thoracic pain (OR 1.7; [95%CI 1.1-2.8]).
Table 2. Patient and perioperative characteristics of patients with and without chronic thoracic pain one year after surgery
no chronic pain
n=72
chronic pain
n=18
P-value
Patient characteristics
Male gender, n (%) 53 (74%) 16 (89%) 0.19
Age, years (±SD) 70.2 (±9.6) 63.4 (±12.4) 0.02
BMI, kg/m² (±SD) 26.6 (±3.3) 30.2 (±4.6) <0.0001
EuroSCORE, median [IQR] 7 [5-9] 4.5 [3-7] 0.01
Preoperative NRS, mean (±SD) 0.5 (±1.3) 1.9 (±3.1) 0.01
History of chronic pain, n (%) a 16 (22%) 4 (22%) 0.98
Previous sternotomy, n (%) 8 (11%) 1 (6%) 0.49
Use of analgesics before surgery (%) b 8 (11%) 5 (28%) 0.08
intraoperative characteristics
Type of surgery, n (%) 0.93
 CABG 18 (25%) 4 (22%)
 CABG and valve surgery 23 (32%) 7 (39%)
 Valve surgery 15(21%) 4 (22%)
 Aortic surgery 16 (22%) 3 (17%)
 Non-elective surgery, n (%) 7 (9.7%) 0 (0%) 0.17
Anaesthesia that included nitrous oxide, n (%) 46 (64%) 13 (72%) 0.32
Anaesthesia that included remifentanil (%) 37 (51%) 15 (83%) 0.02
Fentanyl during anaesthesia, mg, (mean) (±SD) 1.7 (±0.4) 1.7 (±0.6) 0.44
Duration of surgery, minutes, mean (±SD) 242 (±79) 255 (±59) 0.53
Postoperative characteristics
Mechanical ventilation, hours, mean (±SD) 13.6 (±19.6) 14.2 (±16.2) 0.93
Length of stay in the ICU, days, mean (±SD) 2 (2) 2 (2) 0.48
Resternotomy during admittance, n (%) 7 (10%) 3 (17%) 0.41
NRS at 16:00 on day of surgery, mean (±SD) * 0.9 (±0.9) 1.2 (±2.0) 0.37
NRS at 23:59 on day of surgery, mean (±SD) # 1.4 (±1.3) 1.8 (±1.9) 0.51
NRS at 8:00 on first POD, mean (±SD) 1.6 (±1.8) 2.1 (±2.0) 0.28
SD=standard deviation, IQR=interquartile range, BMI=body mass index, EuroSCORE = European System for Cardiac Operative Risk Evaluation 
score [18], NRS=numeric rating scale, CABG=Coronary artery bypass grafting, ICU=intensive care unit; POD = postoperative day. a Includes 
chronic back pain, rheumatoid arthritis, polyneuropathy, hernia. b Includes paracetamol, non steroidal anti inflammatory drugs (NSAID’s) and 
opioids. * 15 missing values. # 3 missing values
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Based on these findings, the association between remifentanil and chronic thoracic pain was 
examined in more detail. In total, 52 patients (58%) received remifentanil during cardiac sur-
gery. Table 4 shows that there were no differences in patient characteristics or perioperative 
characteristics between patients who received remifentanil and patients who did not receive 
remifentanil.
Table 3. Multivariate analysis for independent predictive factors of chronic thoracic pain one year after sternotomy
odds ratio 95% ci P-value
Anaesthesia that included remifentanil 8.93 1.6 - 49.0 0.01
Age <69 years 7.03 1.6 - 31.7 0.01
BMI ≥28 kg/m² 9.05 2.1 - 39.1 0.003
Backward stepwise binary logistic regression, variables entered: age, BMI, EuroSCORE, preoperative NRS score, use of analgesics in history and 
anaesthesia that included remifentanil
BMI = body mass index, NRS=numeric rating scale, EuroSCORE=European System for Cardiac Operative Risk Evaluation score [17]
Table 4. Characteristics of patients with and without anaesthesia with remifentanil during cardiac surgery
remifentanil
n=52 (58%)
no remifentanil
n=38 (42%)
P-value
Patient characteristics
Male gender, n (%) 40 (77%) 29 (76%) 0.95
Age, years (±SD) 69 ± 10 68 ± 11 0.79
BMI, kg/m² (±SD) 28 ±4 27 ±4 0.60
EuroSCORE, median [IQR] 6 [4-8] 7 [4-9] 0.24
Preoperative NRS, mean (±SD) 0.8 ±1.9 0.8 ± 2.0 0.59
intraoperative characteristics
Type of cardiac surgery, n (%) 0.03
CABG 17 (33%) 5 (13%)
CABG and valve surgery 18 (35%) 12 (32%)
Valve surgery 11 (21%) 8 (21%)
Aortic surgery 6 (12%) 13 (34%)
Length of surgery, minutes, mean (±SD) 244 ±68 246 ±84 0.85
Anaesthesia that included nitrous oxide, n (%) 34/52 (65%) 25/37 (68%) 0.83
Fentanyl during anaesthesia, mean (±SD)
 in mg 1.7 ± 0.44 1.7 ± 0.65 0.69
 in mcg/kg LBM/ minute 0.13 ± 0.05 0.12 ± 0.04 0.94
Propofol during anaesthesia, gram, mean (±SD) 1.1 ± 0.6 1.0 ± 0.5 0.86
Postoperative characteristics
Mechanical ventilation, hours, mean (±SD) 11.7 ± 7.7 16.5 ± 27.6 0.87
Length of stay in the ICU, days, mean (±SD) 1.7 ± 1.5 2.0 ± 2.0 0.90
Resternotomy during admittance, n (%) 5 (10%) 5 (13%) 0.60
Mean NRS at 16:00 hours on the day of surgery, (±SD)* 1.2 ±1.4 0.7 ± 0.8 0.11
Mean NRS at 23:59 hours on the day of surgery, (±SD)# 1.5 ±1.5 1.5 ±1.3 0.55
Mean NRS at 8:00 hours on the first postoperative day, ±SD 1.8 ± 2.0 1.5 ± 1.7 0.61
EuroSCORE=European System for Cardiac Operative Risk Evaluation score [17]
* 15 missing values; # 3 missing values
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Table 5 shows the association between remifentanil dose administered during anaesthesia 
for cardiac surgery and Odds ratio for chronic thoracic pain one year after surgery. Both with 
increasing total amounts of remifentanil (mg) and with increasing remifentanil dose corrected 
for kg Lean Body Mass (LBM) and duration of surgery, the Odds ratio for chronic thoracic pain 
increased with a significant P-value for trend (P for trend <0.01 and <0.005, respectively). This 
table shows the division of patients into 3 groups; the first group contains patients who did 
not receive remifentanil (n=38), while the patients who received remifentanil during anaes-
thesia (n=52) were equally divided over the second and third group. This resulted in cut-off 
points between the second and third group of 1.7 mg for total dose of remifentanil and 0.12 
mcg of remifentanil/kg LBM/minute of surgery. The correlation (r2) between remifentanil 
total dose and dose flow rate related to lean body mass was 0.82.
DiScuSSion
Besides younger age and increased BMI, remifentanil during cardiac anaesthesia appears 
an independent predictor for chronic thoracic pain one year after sternotomy. To our best 
knowledge, so far, chronic thoracic pain has not been associated with remifentanil in patients 
after cardiac surgery, although a relation between chronic post-thoracotomy pain and remi-
fentanil has been described [11]. Despite the fact that the current study was not designed to 
investigate the role of remifentanil in chronic pain after surgery, we found the relation be-
tween remifentanil and the Odds ratio for chronic thoracic pain to be dose-dependent. There 
were no other differences in patient and perioperative characteristics between patients who 
received remifentanil and those who did not. Furthermore, remifentanil was administrated 
in a substantial percentage of patients (58%) and was either started as a continuous infusion 
directly after the induction of anaesthesia, or not started at all. Therefore, the present study 
provided a unique possibility to compare patients with and without remifentanil during 
Table 5. Association between intraoperative total dose of remifentanil and the remifentanil dose corrected for lean body mass (LBM) and 
duration of surgery, and Odds ratio for chronic thoracic pain one year after surgery.
no chronic 
pain
n=72
chronic pain
n=18
odds ratio 95% ci P -value P -value for 
trend
total dose of remifentanil in mg, n (%)
0 35 (49%) 3 (17%) 1.00 0.04 0.01
> 0 and <1.7 19 (26%) 6 (33%) 3.68 0.8 - 16.4
≥ 1.7 18 (25%) 9 (50%) 5.83 1.4 - 24.3
remifentanil in mcg /kg lbm/ minute, n (%)
0 35 (49%) 3 (17%) 1.00 0.02 0.005
> 0 and <0.12 19 (26%) 5 (28%) 3.07 0.7 - 14.3
≥ 0.12 18 (25%) 10 (55%) 6.48 1.6 - 26.5
LBM= lean body mass
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surgery, possibly leading to the identification of a risk factor for chronic pain that can actually 
be avoided.
Chronic post-surgical pain related to remifentanil during anaesthesia has so far only been 
described by Salengros et al. [11] in patients after thoracotomy. Remifentanil high dose 
(0.14-0.26 µg/kg/min) during elective thoracotomy combined with postoperative epidural 
analgesia was not only associated with a larger area of allodynia around the wound in the 
first 72 postoperative hours, but also with a significant higher incidence of chronic pain com-
pared with a three times lower dose of remifentanil and epidural analgesia during surgery. In 
patients after major abdominal surgery, a higher dose of remifentanil (0.3 ± 0.2 µg/kg/min) 
has been associated with acute opioid tolerance and opioid-induced hyperalgesia compared 
with a lower dose of remifentanil (0.1 ± 0.0 µg/kg/min), suggested by higher pain scores in 
the first postoperative hour and exaggerated postoperative opioid consumption in the first 
24 postoperative hours [19]. Similar to other studies upon cardiac surgery [20-22], we were 
not able to evaluate pain scores in the first postoperative hour due to prolonged sedation 
after cardiac surgery. Therefore, we cannot not report on the actual presence of acute opioid 
tolerance in our patients. Higher doses of remifentanil during cardiac surgery were, however, 
shown to be associated with hyperalgesia for the first seven postoperative days compared 
with a 1.5 times lower dose of remifentanil when applied via target controlled infusion [22]. 
Unfortunately, in the aforementioned study populations the development of chronic pain 
was not evaluated. It can be anticipated that hyperalgesia is linked to peripheral and central 
pain sensitization and thereby correlates with the development of postoperative chronic 
pain [23]. This suggests that hyperalgesia due to remifentanil in the early postoperative 
period may explain the higher incidence of chronic pain.
In addition to the finding of a dose-dependent association between remifentanil and de-
velopment of chronic thoracic pain, the present study also confirmed an increased BMI (>28 
kg/m2) and a younger age (<69 years) as risk factors [2-3,8,10]. As surgery may be more diffi-
cult in the obese patient, with both a larger surface of tissue damaged and a longer retraction 
time [8], this may explain the association between an increased BMI and chronic thoracic 
pain. For the observed association between younger age and the presence of chronic tho-
racic pain after surgery, Bruce and colleagues [8] have suggested that younger patients have 
a lower pain threshold and are less likely to accept, and more likely to report pain. Another 
explanation is that younger patients are more active and more likely to be hampered by pain 
in their activities, whereas older patients may be more likely to accept their limitations.
We consider some limitations of our study. First, the studied patients participated in a clini-
cal trial on pain levels in the early postoperative period after cardiac surgery. This may have 
led to a selection bias because patients may have had either a specific reason not to partici-
pate or on the contrary, may have been eager to participate in a study with the expectation 
of additional attention for pain and analgesia. On the other hand, the fact that the patients 
participated in this clinical trial, which resulted in a carefully prospectively monitored group 
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of patients with amongst others, detailed information on patient and perioperative charac-
teristics, could be considered as a strength of the present study. Second, despite the high 
response rate of 75% of the questionnaires, another selection bias cannot be excluded, as 
we are not informed about the patients who did not respond. Moreover, the association be-
tween remifentanil and chronic pain was not suspected until the analysis of the study. Third, 
continuous infusion of remifentanil during cardiac anaesthesia could be initiated after induc-
tion of anaesthesia at the discretion of the attending anaesthesiologist. Surgeons, surgical 
techniques and anaesthesiologists were not randomized or standardized for the study, even 
though the large number of surgeons (n=10) and anaesthesiologists (n=18) without fixed 
combinations between the two, could be considered a strength as well. These limitations 
make it impossible to draw any more conclusions than the reported association between 
remifentanil and chronic thoracic pain after cardiac surgery. Unmeasured confounding can 
therefore not be ruled out, even though there were no significant differences in patient or 
other characteristics between the patients who received remifentanil and those who did not. 
As such, the results of this study, with higher amounts of remifentanil being significantly 
associated with higher Odds ratios for chronic pain, warrant further blinded, randomized and 
prospective studies as this may prevent the development of chronic thoracic pain or at least 
part of this serious condition. In further research, a follow-up at 3-6 months after cardiac 
surgery should be considered, thereby identifying chronic pain in an earlier period, which 
would increase the response rate.
In conclusion, chronic thoracic pain after sternotomy was associated with the use of remi-
fentanil during cardiac surgery, younger patients and an increased BMI. Higher doses of 
remifentanil were positively associated with significantly higher Odds ratios for chronic pain. 
As this is the second study that reports an association between remifentanil and chronic pain, 
further research is needed through randomized controlled trials with and without remifent-
anil during cardiac surgery is called for to investigate the relation between remifentanil and 
the development of chronic thoracic pain.
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abStract
background and objectives While morphine is the preferred analgesic for moderate to 
severe pain in the intensive care unit, its pharmacokinetics have not been adequately quanti-
fied in these patients. The aim of this study was to evaluate the glucuronidation and elimina-
tion clearance of morphine in intensive care patients in conjunction with healthy volunteers, 
on the basis of morphine and morphine-3-glucuronidation (M3G) concentrations.
methods A population pharmacokinetic model with covariate analysis was developed with 
the non-linear mixed-effects modelling (NONMEM) VI. The analysis included 3012 morphine 
and M3G concentrations from 135 intensive care patients (117 cardiothoracic surgery pa-
tients and 18 critically ill patients), who received continuous morphine-infusions adapted 
to individual pain levels, and 622 morphine and M3G concentrations from a previously 
published study of 20 healthy volunteers, who received an intravenous bolus of morphine 
followed by a 1-hour infusion.
results For morphine a three-compartment model best described the data, while for M3G 
a one-compartment model was used. In intensive care patients, glucuronidation clearance 
of morphine to M3G and elimination clearance of M3G were significantly decreased with 
17% and 81% respectively, compared to healthy volunteers. Moreover, serum creatinine 
concentration was identified as a covariate for both elimination clearance of M3G within the 
group of intensive care patients and for non-M3G clearance of morphine in both intensive 
care patients and healthy volunteers.
conclusion In intensive care patients, glucuronidation of morphine to M3G and elimination 
of M3G appeared significantly decreased compared to healthy volunteers. As a result, sub-
stantially elevated M3G concentrations may be anticipated in intensive care patients, which 
is even more pronounced in case of increased serum creatinine concentrations.
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introDuction
Morphine is the preferred analgesic for moderate and severe (postoperative) pain in the in-
tensive care unit (ICU) [1-2]. However, the clinical use of morphine is characterized by a large 
inter-individual variability in analgesic effect, which may be related to patient characteristics, 
such as age [3], sex [4], ethnic origin [5], anxiety [6] and genetic polymorphisms [7]. More 
specifically, this variability may also be caused by differences in morphine pharmacokinet-
ics as a result of variability in health status, hepatic metabolic capacity and renal clearance, 
particularly when intensive care patients are concerned [8]
Morphine is mainly metabolized in the liver via glucuronidation by phase II metabolism 
enzyme UDP-glucuronosyltransferase (UGT)2B7 [9] to morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G). Both metabolites and unchanged morphine are excreted by 
the kidneys [10]. The main metabolite M3G is suggested to have antagonistic or hyperalgesic 
effects, which may potentially result in reduced morphine efficacy [11]. While M6G concentra-
tions are usually low, its clinical analgesic potency appeared recently lower than previously 
found in animals [11-13] and therefore M6G concentrations now seem of limited interest. As 
a consequence, insight in the pharmacokinetics of morphine and its main metabolite M3G 
seems of relevance in guiding dosing regimes in specific patient groups such as intensive 
care patients who may receive prolonged infusions of morphine.
To date, there are no reports on the pharmacokinetics of morphine and M3G in intensive 
care patients, even though morphine is extensively investigated in terms of efficacy and side 
effects in a variety of patient groups [10,14-18]. In intensive care patients, glucuronidation 
of morphine through UGT2B7 to M3G and/or renal excretion of morphine and M3G may be 
impaired as a result of major surgery such as cardiac surgery with cardiopulmonary bypass, 
or critical illness related to septic shock, or multiple organ failure. Furthermore, some of these 
patients may suffer from acute renal failure. Therefore, in this study a population pharmaco-
kinetic model of morphine and its main metabolite M3G was developed in order to study the 
glucuronidation of morphine to M3G and elimination of M3G and morphine in intensive care 
patients in conjunction with healthy volunteers.
metHoDS
Study design
This analysis was based on observations obtained in intensive care patients participating in a 
clinical trial in which pain management for procedural related pain was evaluated (registered 
at ClinicalTrials.gov (identifier NCT00558090)). In this study, both intensive care patients after 
cardiac surgery through sternotomy [19] and critically ill patients with an expected duration 
of mechanical ventilation of more than 48 hours were included. The study was performed in 
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a 30-bed surgical/medical ICU in a teaching hospital, Nieuwegein, The Netherlands and was 
approved by the Ethics Committee of the St. Antonius Hospital. Written informed consent 
from cardiac surgery patients was obtained the day before the cardiac surgery. Written 
informed consent from critically ill patients was obtained by their next of kin on the first day 
of admission to the intensive care. Whenever possible, (written) informed consent was also 
obtained from the critically ill patient himself during or after the study.
Patients
Intensive care patients after cardiac surgery through sternotomy and critically ill patients 
with an expected duration of mechanical ventilation of more than 48 hours, were included. 
Additional inclusion criteria were age between 18-85 years and weight between 45-140 kg. 
Exclusion criteria were patients with a known morphine or paracetamol allergy, planned 
admission to the postoperative anaesthesia care unit (PACU), pregnancy or breast-feeding, 
serious neurological deficits (e.g. coma or brain death), a language barrier, and patients who 
refused informed consent [19].
Twenty healthy volunteers were enrolled earlier as part two other studies and detailed 
information can be found in the references [20-21].
morphine dosing schemes
Upon admission to the ICU, in all intensive care patients a morphine continuous infusion (2 
mg/hour) was started, with subsequent doses adapted to individual pain levels resulting in 
morphine doses ranging from 0.5 to 2.5 mg/hour [19]. In addition, before a painful procedure 
(turning of the patient and/or chest drain removal), patients received a bolus dose of mor-
phine (2.5 or 7.5 mg) on the first postoperative day (cardiac surgery patients) or on the first 
or second day after admission in the ICU (critically ill patients) [19]. Also for other procedures, 
additional bolus doses of morphine could be administered at the discretion of the attending 
intensivist which were registered on the case report form.
In the previously published study in healthy volunteers, 20 young men and women (10 of 
each sex) received intravenous morphine bolus 0.10 mg/kg dose followed by an infusion of 
0.03 mg/kg/h for 1 hour [20-21].
blood sampling
In the intensive care patients, 2 ml arterial blood was drawn for determination of serum 
concentrations of morphine and M3G four times daily (3.00 a.m., 7.00 a.m., 3.00 p.m. and 9.00 
p.m.), during their ICU stay. Additionally, a blood sample was collected at 5 minutes before 
and 5 minutes after the painful procedure (turning of the patient and/ or chest drain removal) 
which corresponded to 30 and 40 minutes after the bolus dose of morphine of 2.5 or 7.5 mg, 
respectively, on the first day of ICU admittance.
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In the previously published healthy volunteer study [20-21], blood samples were collected 
at fixed times (t=5, 10, 20, 30, 40, 50, 60, 65, 70, 80, 100, 130, 180, 300, and 420 minutes after 
the morphine bolus dose).
analytical method
Blood samples were rapidly centrifuged and serum was stored at -20ºC until analysis. Mor-
phine and M3G serum concentrations were determined using a high-performance liquid 
chromatography tandem mass spectrometry (LC-MS-MS) method (see appendix I). The Lower 
Limit of Quantification was 1 μg/L for morphine and 2 μg/L for M3G. For morphine, within-
day coefficients of variation were 5.5% at 5 μg/L and 3.5% at 250 μg/L. For M3G within-day 
coefficients of variation were 10.4% at 10 μg/L and 3.5% at 500 μg/L. The molecular weights 
of morphine and M3G are 285 and 461 Da, respectively.
Data analysis
The non-linear mixed-effects modelling software NONMEM® VI (Globomax LLC, Hanover, MD, 
USA) was used, with S-plus® version 6.2 (Insightful Software, Seattle, WA, USA) for visualiza-
tion of the data.
Model building was performed in four different steps: (i) selection of the structural model 
(one, two or three compartment model); (ii) choice of a statistical sub-model; (iii) covariate 
analysis; and (iv) model evaluation. Discrimination between different models was made by 
comparison of the objective function (-2 log likelihood). A value of P<0.05, representing a 
decrease of 3.84 in the objective function, was considered statistically significant. In addition, 
goodness-of-fit plots (both observed vs. individual- and population-predicted concentra-
tions, and time as well as population predictions vs. weighted residuals) were evaluated, with 
specific emphasis on observed vs. population-predicted concentrations. Furthermore, visual 
improvement of the individual plots, the confidence interval of the parameter estimates and 
the correlation matrix were used to evaluate the model.
Pharmacokinetic model
The concentrations of morphine and M3G were expressed as microgram (μg) morphine 
units per L, logarithmically transformed and fitted simultaneously (NONMEM VI, ADVAN5). 
For morphine, a three-compartment model was preferred over a two-compartment model, 
since it was able to describe the datasets more accurately. For the metabolite M3G, a one-
compartment model was used (Figure 1). Due to the large number of observations in steady 
state and the relative sparse sampling after bolus injection in intensive care patients, mini-
mization difficulties occurred when all parameters of the four compartment model (Figure 1) 
were independently estimated, with particularly instable results for volume of distribution 
of central compartment of morphine (V1). As a result, V1 in the intensive care patients was 
modelled as a multiplication factor of V1 in the ‘healthy volunteers’ while according to previ-
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ous analyses of the healthy volunteers in this study [20-21], V1 in the ‘healthy volunteers’ was 
fixed to 3.67 litre (0.052 litre/kg*70.6 kg bodyweight). As an alternative approach, V1 in the 
intensive care patients was fixed to 14.2 litre, as reported by Mazoit et al. [13] in postopera-
tive patients. This alternative approach was rejected because diagnostics deteriorated, even 
though the estimates for the parameters of the model other than V1 were stable. Based on 
previous studies in adults, the metabolite volume of distribution of M3G was fixed at 23 litre 
[22].
The inter-individual value (post hoc value) of the parameters of the ith subject was mod-
elled by;
θi= θmean ·e
ηi (Eq.1)
where θmean is the population mean and ηi is a random variable with mean zero and vari-
ance ω2, assuming lognormal distribution in the population. The intra-individual variability, 
resulting from assay errors, model misspecifications, and other unexplained sources, was best 
described with a proportional error model. This means for the jth observed log-transformed 
morphine and M3G concentration of the ith individual, the relation (Yij) is described by equa-
tion 2:
Yij=logcpred,ij+εij (Eq. 2)
V1 
(M)
Q2V3 
(M)
V4 
(M3G)
Q1
CL1
V2 
(M)
CL2
CL0
Figure 1. Schematic representation of the model
M = morphine; M3G = Morphine-3-glucuronide; Cl0 = non-M3G clearance; Cl1= glucuronidation clearance of morphine to M3G; Cl2 = 
elimination clearance of M3G;; Q1 and Q2 = intercompartmental clearance of morphine; V1 = volume of distribution of central compartment of 
morphine; V2 and V3= volume of distribution of peripheral compartment of morphine; V4 = volume of distribution of M3G
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where cpred is the predicted morphine and M3G concentration and εij is a random variable 
with a mean of zero and variance of σ
2
.
covariate analysis
Covariates were plotted independently against the individual post hoc parameter estimates 
and the weighted residuals to visualize potential relationships. The following covariates were 
tested; study group (cardiac surgery patients, critically ill patients and healthy volunteers), 
age, sex, bodyweight, body mass index (BMI), type of cardiac surgery, and serum creatinine 
concentration. For the covariate study group, besides exploring differences between the 
three study groups, also differences between two groups were evaluated (intensive care 
patients vs. healthy volunteers). Continuous covariates (age, bodyweight, BMI and serum cre-
atinine concentration) were tested linear centred θi= θ1+ (COV - COVmedian)x θ2 or exponential 
θi= θ1 x (
COV
COVmedian
)θ2  in which θi represents the individual parameter estimate, COV denotes 
the covariate and COVmedian the median value of the covariate for the population. Categorical 
covariates (study group as three or two groups, sex, type of surgery) were tested fractional by 
estimation of an additional parameter on a structural parameter for each subgroup.
Covariates were separately incorporated into the model and considered statistically signifi-
cant if the objective function decreased 3.84 points or more (P<0.05). When more than one 
significant covariate was found, the covariate-adjusted model with the largest decrease in 
objection function was chosen as a basis to sequentially explore the influence of additional 
covariates with the use of the same criteria. Beside the objective function, other criteria as 
presented under data analysis were considered. This procedure was in particular applied to 
covariates that could be related such as study group, age and serum creatinine concentra-
tion. Finally, after forward inclusion, a backward exclusion procedure was applied to justify 
the covariate, and was considered statistically significant if the objective function decreased 
with 6.63 points or more (P<0.01), while also the criteria as discussed under data analysis 
were considered.
internal validation
For internal validation of the model, the normalized prediction distribution errors (NPDE) 
method was used [23-24], because there was a wide range in the administered morphine 
doses within the intensive care patients, and between the intensive care patients and the 
healthy volunteers. Besides, blood sampling schemes differed largely between intensive 
care patients and healthy volunteers. The NPDE method was implemented using the NPDE 
add-on software package, which was run in R. In this study, each observation was simulated 
2000 times. The results of NPDE method are visualized in different graphs: (i) a histogram 
showing the distribution of the NPDEs, which are expected to follow a normal distribution; (ii) 
a scatterplot NPDE vs. time; and (iii) a scatterplot NPDE vs. predicted concentrations.
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Simulations
With the developed pharmacokinetic model, simulations were performed to establish what 
serum concentrations of morphine and M3G would be achieved in healthy volunteers, in 
intensive care patients with a normal renal function (creatinine serum concentration 80 
μmol/L) and in intensive care patients with renal failure (creatinine serum concentration 250 
μmol/L), after receiving a continuous infusion of 2 mg/hour for 24 hours.
reSultS
Patients
The analysis was based on 1506 morphine and 1506 M3G serum concentrations obtained 
from 135 intensive care patients, i.e. 117 cardiac surgery patients and 18 critically ill patients. 
From the 20 healthy volunteers, 311 serum concentrations of morphine and 311 serum 
concentrations of M3G were available [20-21]. Patients’ characteristics and healthy volunteer 
characteristics are summarized in Table 1.
Table 1. Background characteristics
cardiac surgery 
patients
(n=117)
critically ill 
patients
(n=18)
Healthy volunteers
(n=20)
Male gender, n (%) 87 (74%) 12 (67%) 10 (50%)
Age (yr) 69 [32-85] 67 [50-79] 26 [20-36]
BMI (kg/m2) 27 [18-43] 28 [21-35] 22 [18-27] *
Type of cardiac surgery, n (%)
CABG 23 (20%) - -
Valve surgery 26 (22%) - -
CABG & valve surgery 43 (37%) - -
Aortic surgery 25 (21%) - -
Diagnostic group, n (%)
Sepsis - 14 (78%) -
Cardiac failure - 3 (17%) -
Respiratory failure miscellaneous - 1 (5%) -
Median euroSCORE 7 [0-13] - -
Median SOFA-score on the first day of admission - 9 [6-16] -
Median serum creatinine concentration (μmol/L) 80 [54-464] 132 [51-433] 80 [-]
Median length of ICU stay (days) 2 [1-13] 10 [3-52] -
Morphine infusion duration (hour) 21 [5-132] 123 [14-337] 1 [-]
Number of available samples
Morphine 982 524 311
Morphine-3-glucuronide 982 524 311
Data are expressed in number (percentage) or mean [range] unless when stated as median [range]. BMI=body mass index; CABG= coronary 
artery bypass graft; euroSCORE= European System for Cardiac Operative Risk Evaluation score [25] * = 1 missing value
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Structural model
The pharmacokinetic model used is depicted in Figure 1. The morphine data were best de-
scribed with a three-compartment model, parameterized in terms of volume of the central 
compartment (V1), two peripheral compartments (V2 and V3), intercompartmental clearances 
(and Q1 and Q2), glucuronidation clearance of morphine to M3G (CL1) and non-M3G clearance 
(CL0). The volume of distribution (V1) for the intensive care patients was modelled as multi-
plication factor of the V1 of the healthy volunteers, and was estimated 32.2. The formation 
of M3G was best described with a one-compartment model, parameterized in terms of the 
volume of distribution of M3G (V4) and elimination clearance (CL2). For the residual or intra-
individual variability, a proportional error model was used, with different errors for the study 
groups ‘healthy volunteers’ and ‘intensive care patients’.
covariate model
In the covariate analysis, study group (healthy volunteers vs. intensive care patients) proved 
the most significant covariate when implemented on CL2 (elimination clearance of M3G). Ad-
dition of this covariate as a study group multiplication factor on CL2 resulted in a decrease of 
objective function value by 754 points (P<0.001), and diagnostic plots of the model largely 
improved in comparison with the simple model. CL2 proved 5.37 times higher in healthy 
volunteers compared to intensive care patients with a median creatinine concentration of 
80 μmol/L (Table 2), which equals a reduction of 81% in intensive care patients. Further dif-
ferentiation in three study groups (healthy volunteers, cardiac surgery patients and critically 
ill patients) did not improve the results.
Within the group ‘intensive care patients’, serum creatinine concentration was an additional 
covariate for CL2, resulting in a decrease in objective function value by 523 points (P<0.001). 
The influence of serum creatinine concentration on clearance was best described using an 
exponential scaling factor (k2) and was estimated -0.71 (Table 2). Implementation of the 
creatinine concentration to CL2 resulted in improved diagnostics, especially for the intensive 
care patients (diagnostic plot ‘population predicted vs. observed concentrations’).
As a third covariate, serum creatinine concentration proved the most predictive covariate 
for CL0 (non-M3G clearance) in all patients, which resulted in a decrease in objective func-
tion value of 89 points (P<0.001). The influence of serum creatinine concentration on CL0 
was best described using an exponential scaling factor (k1) and was estimated -1.34 (Table 
2). Implementation of creatinine concentration as covariate to CL0 resulted in improved 
diagnostics, especially the diagnostic plot ‘population predicted vs. observed concentrations’ 
for the healthy volunteers.
Finally, addition of the covariate study group (healthy volunteers vs. intensive care 
patients) on CL1 (glucuronidation clearance of morphine to M3G) further improved the 
model, with the objective function value decreasing by 4 points (P<0.05). Diagnostic plots 
improved, especially the diagnostic plot ‘population predicted vs. observed concentrations’ 
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for the healthy volunteers. CL1 proved 1.20 times higher in healthy volunteers compared to 
intensive care patients (Table 2), which equals a reduction of 17% in intensive care patients. 
Further differentiation within the group of intensive care patients (cardiac surgery patients 
and critically ill patients) did not improve the results any further. No other covariates could 
be identified. Table 2 lists all parameter estimates with their confidence intervals obtained 
of the final model. Final diagnostics plots for morphine and M3G are shown in Figure 2 and 
Figure 3, respectively.
Table 2: Population pharmacokinetic parameters estimates of the final model
equation Value cV (%)
fixed effects
Cl0 (L/min) = CL0pop*(CRE/80)
k1
  CL0pop 0.694 9.86
  k1 -1.34 -24.7
CL1 (L/min)
 ICU-patients CL1popICU 0.537 8.83
 Healthy volunteers CL1popICU*mf
  mf 1.20 10.5
Cl2 (L/min)
 ICU-patients = CL2popICU*(CRE/80)
k2
  CL2popICU 0.0325 14.2
  k2 -0.71 -30.4
 Healthy volunteers = CL2popICU*mf
  mf 5.37 15.7
V1 (L)
 Healthy patients V1pophealthy 3.67 FIX -
 ICU patients V1pophealthy*mf
  mf 32.2 37.9
V2 (L) 90.9 5.81
V3 (L) 502 13.5
V4 (L) 23 FIX -
Q1 (L/min) 1.33 5.21
Q2 (L/min) 0.184 10.1
interindividual variability
ω2 (Cl0) 0.684 20.5
ω2 (Cl1) 0.091 16.9
residual error
σ2 (ICU patients) 0.285 11.6
σ2 (healthy volunteers) 0.049 13.4
CV = coefficient of variation; Cl0 = non-M3G clearance of morphine; Cl1 = glucuronidation clearance of morphine to M3G; Cl2 = elimination 
clearance of M3G; Q1 and Q2 = intercompartmental clearance; V1 = volume of distribution of central compartment of morphine; V2 and V3 
= volume of distribution of peripheral compartments of morphine; V4 = volume of distribution of M3G; pop = study population in general 
(both ICU patients and healthy volunteers); popICU = population of intensive care patients pophealthy = population of healthy volunteers; 
CRE = median serum creatinine concentration; k1 = exponential scaling factor for Cl0 (non M3G clearance) k2= exponential scaling factor for 
Cl2 (elimination clearance of M3G) in intensive care patients; mf = multiplication factor; ω
2 = interindividual variance; σ2 = proportional 
intraindividual variance.
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Figure 2. Observed vs. individual-predicted concentrations (left plots) and observed vs. population-predicted concentrations (right plots) of 
morphine in intensive care patients (a, b), and healthy volunteers (c, d).
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internal validation
Figure 4 shows the results of the NPDE for morphine and M3G. The histogram follows a nor-
mal distribution expected by the solid line. Although there was a slight overestimation of the 
interindividual variability, no trend was observed in the NPDE versus time or versus predicted 
concentrations.
Simulations
The simulations based on the final pharmacokinetic model presented in Figure 5a and 5b, 
show morphine and M3G serum concentrations in a typical healthy volunteer, a typical 
intensive care patient with normal renal function (creatinine concentration 80 μmol/L), and a 
typical intensive care patient with an impaired renal function (creatinine concentration 250 
μmol/L) upon a 24 hour morphine infusion of 2 mg/h. Figure 5a shows that similar morphine 
concentrations can be expected in intensive care patients compared to healthy volunteers, 
except in case of impaired renal function. Figure 5b shows that in intensive care patients 
increased M3G concentrations can be expected in comparison to healthy volunteers. When 
renal function is impaired in intensive care patients, even higher M3G concentrations are 
anticipated.
DiScuSSion
In order to quantify the glucuronidation and elimination clearance of morphine in intensive 
care patients in comparison to healthy volunteers, a pharmacokinetic model of morphine 
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Figure 4. Results of the internal validation with the normalized prediction distribution error (NPDE) method.
The histograms show the NPDE distribution for morphine (upper panel) and morphine-3-glucuronide (lower panel), with solid lines indicating 
normal distribution (left plots). The distribution of the NPDE versus time, and NPDE versus the log of the concentration are shown (middle 
and right plots). The dotted lines represent the 90% distribution of the NPDE.
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and morphine-3-glucuronide (M3G) was developed. In this model, 135 intensive care patients 
and 20 healthy volunteers were included. In the pharmacokinetic analysis, it was found that 
intensive care patients had a significantly decreased glucuronidation clearance of morphine 
to M3G (17%) and elimination clearance of M3G (81%) compared to healthy volunteers. 
Furthermore, serum creatinine concentrations proved a covariate for elimination clearance 
of M3G in intensive care patients, and for the non-M3G clearance in all patients. Simulations 
of these results illustrate that substantial accumulation of in particular M3G can be expected 
in intensive care patients upon 24 hour infusion, which is even more pronounced upon 
impaired renal function.
While in our study, glucuronidation clearance of morphine to M3G in healthy volunteers 
of 0.644 L/min (38.6 L/h) was found comparable to the results of Hasselstrom et al. [26], we 
identified a decrease of 17% in this glucuronidation clearance parameter in intensive care 
patients. In this respect, no differences between cardiac surgery patients and critically ill 
patients were observed. Nowadays, no data are available on glucuronidation clearance of 
morphine to M3G in intensive care patients. Studies so far focused on patients with cirrhosis, 
in whom glucuronidation clearance of morphine was shown to be decreased, probably due 
to reduction in hepatic clearance [27]. We hypothesize that in intensive care patients, the 
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Figure 5. Simulated concentrations of morphine (A) and M3G expressed as morphine equivalents (B) in healthy volunteers, intensive care 
patients with normal renal function (creatinine concentration 80 μmol/L) and intensive care patients with impaired renal function (creatinine 
concentration 250 μmol/L), upon on a dosing regimen of a continuous infusion of morphine 2 mg/hour for 24 hours.
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amount and/or activity of the metabolism enzyme UDP-glucuronosyltransferase (UGT)2B7 
may be (temporarily) decreased. Although no specific information is available on the UGT2B7 
enzyme in this specific study population, there is some evidence that the activity of other 
liver enzymes, such as cytochrome P-450 enzymes, is decreased in case of critically illness 
[28] or after surgery [29]. The consequences of this finding are illustrated in the simulations 
depicted in Figure 5A in which morphine concentrations in intensive care patients compared 
to healthy volunteers are only slightly increased, provided normal renal function is assumed. 
As such, the decrease of 17% in the glucuronidation clearance of morphine in intensive care 
patients by itself does not lead to morphine accumulation upon prolonged infusion.
This study identified a very large reduction (81%) in elimination clearance of M3G (CL2) in 
intensive care patients compared to healthy volunteers. While elimination clearance of M3G 
in healthy volunteers of 0.175 L/min (10.5 L/h) is similar to those reported in literature [26], 
the reduction of 81% in this parameter in intensive care patients was independent of renal 
function. Thus, in intensive care patients with normal renal function substantially higher M3G 
levels may be expected upon 24 hour continuous infusion, with even higher M3G levels upon 
renal failure (Figure 5B). So far, the relevance of high M3G levels in intensive care patients is 
unknown. Although controversial, M3G is thought to antagonize the analgesic effect, and to 
play a role in the development of tolerance and hyperalgesia [10]. Most studies arise from 
animal studies, in which M3G has been demonstrated to antagonize morphine and M6G an-
algesia [30-32]. Two healthy volunteer studies [22,33] were however not able to confirm these 
results, although this may be explained by the short study period of 2 hours. In contrast, in 
the study of Mazoit et al. [13], it was shown that M3G does have an antinociceptive effect. The 
authors discuss that this effect is moderate, and because of the very long transfer half-time 
from injection site to effect compartment, a significant effect of M3G is not though to occur 
before the 9th – 18th hour after initiation of analgesic treatment. In our study, the cardiac 
surgery patients had a mean infusion duration of 21 hours, while the critically ill patients 
received intravenous morphine infusions for a mean duration of 123 hours. In this respect, 
animal studies have found that M3G and high dose morphine produced altered pain behav-
ior, such as hyperalgesia, allodynia and motor excitation [10]. In humans, these symptoms 
have mostly been observed in cancer patients treated with high dose morphine. In several 
of these case reports very high levels of morphine and M3G, as well as accumulation of M3G 
relative to morphine or M6G has been demonstrated [10]. Thus, the very large decrease in 
elimination clearance of M3G in intensive care patients resulting in substantially elevated 
M3G concentrations, may be clinically relevant, in particular upon prolonged administration 
of morphine infusion.
In our study, serum creatinine concentration proved a covariate for elimination clearance 
for M3G (CL2) within the group of intensive care patients, and in addition to the decrease of 
81% in this parameter in intensive care patients in comparison to healthy volunteers. Also 
for non-M3G clearance (CL0), serum creatinine concentration was a significant covariate in all 
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patients, which may be explained by the fact that for this parameter study group could not 
be identified as a significant covariate. While the influence of serum creatinine concentration 
on these clearance parameters was best described using a negative exponential function, it is 
well known from literature in a diverse patient population that clearance of morphine and its 
metabolites deteriorates as result of renal failure [34-38]. In these studies, clearance of M3G 
and M6G were significantly correlated with creatinine clearance [34-35]. Additionally, a recent 
pharmacokinetic-pharmacodynamic study of Mazoit et al. [13] showed that M3G clearance 
was markedly decreased in postoperative patients after several types of surgery, receiving 
intravenous and intramuscular morphine during 48 hours. Thus, as illustrated in Figure 5, 
in intensive care patients with impaired renal function, morphine will cumulate compared 
to intensive care patients without renal failure and healthy volunteers. Also for M3G, higher 
concentrations than those anticipated in intensive care patients without renal failure will be 
reached, while these concentrations were already largely increased in intensive care patients 
without renal dysfunction compared to healthy volunteers (Figure 5B). Overall, these results 
suggest that significant accumulation of M3G may occur in intensive care patients, with or 
without renal failure. Considering the potential anti-nociceptive and hyperalgesic activity of 
M3G, this finding may be clinically relevant, and should be taken into account in this special 
patient group, particularly upon prolonged use of morphine infusions.
We consider some limitations of our study. In this analysis, we were not able to differentiate 
between the two subgroups of intensive care patients in our study population, i.e. cardiac 
surgery patients versus critically ill patients. We realize that there are many physiological 
differences between these two subgroups that may result in different pharmacokinetic 
parameters. An explanation for the lack of difference between these two groups may be the 
imbalance in patient numbers (117 vs. 18 patients). On the other hand it can be hypoth-
esized that differences in pharmacokinetic parameters between these two groups are mainly 
located in volumes of distribution, which are expected to be larger in critically ill patients. 
Obviously, there were insufficient data to properly estimate central volume of distribution 
due to the relative lack of data directly after bolus injection in the intensive care patients. 
As such, future research in intensive care patients should focus on obtaining more samples 
after bolus injection to study the influence of the intensive care subgroups on volume of 
distribution. This would also allow the resulting model to be used for simulations of concen-
trations after bolus injection, which was not performed in this study (Figure 5) as the result 
of this relative lack of data. In our opinion, it may hypothesized that clearance values are not 
that different between these two intensive care patient subgroups given the fact that many 
samples were obtained to estimate these parameters. Another issue may be the correlation 
between covariates within the study groups. Intensive care patients were older and had on 
average higher serum creatinine concentrations. By systematically testing of the influence 
of all these covariates in different functions on the basis of predefined statistical criteria, we 
were however able to identify which parameter was the most predictive which has ultimately 
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resulted in the model presented in this study. Finally, we were not able to differentiate among 
non-M3G clearance (CL0), which theoretically consists of unchanged morphine clearance, 
M6G clearance and potentially clearance through other pathways. Therefore, in the ideal 
study design, concentrations of M6G and/or excretion of morphine and metabolites in urine 
should be included in the analysis in order to distinguish between these routes. This may also 
lead to different covariates for sub-parameters of Cl0 as in our analysis serum creatinine could 
be identified for this parameter only. It seems reasonable that serum creatinine will account 
for the part of this parameter that is responsible for excretion of unchanged morphine but 
not for glucuronidation to M6G for instance. Nonetheless, the results of our final model seem 
valid as the percentage of the intravenous morphine dose that was converted through Cl1 to 
M3G and through CL0 was 46% and 54% respectively, which is in line with previous reports. 
In those reports, it was reported that 44-55% of the morphine dose was converted to M3G 
regardless of the morphine dose [10].
In conclusion, in intensive care patients, glucuronidation of morphine to M3G and elimina-
tion clearance of M3G appeared significantly decreased compared to healthy volunteers. 
As a result, in particular elevated M3G concentrations may be anticipated in intensive care 
patients, which is even more pronounced upon increased serum creatinine concentrations.
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Appendix I: Determination of morphine and morphine-3-glucuronide in serum by LC-MS-MS
For the construction of the calibration line, human pool serum was spiked with adequate volumes of morphine and morphine-3-
glucuronide (M3G)(Cerilliant, Texas, USA) in methanol/water to give a concentration of 0-2500 µg/L. 50 µl of the standards was stored 
in Eppendorf vials (VWR, Amsterdam, The Netherlands) at -20 degrees Celcius until analysis. 200 µl samples, standards, blanco’s and 
quality controls were transferred in a Eppendorf 1,5 ml vial. The protein was precipitated with 700 µl acetonitril which contained an 
adequate amount of 2H3-Morphin (2H3-M) (Cerilliant, Texas, USA) and 
2H3-Morphin-3-glucuronide (2H3-M3G) (Cerilliant, Texas, USA) 
as internal standard and 100 µl 1mM zinc sulphate. The vials were vortexed for 2 minutes and centrifuged for 5 minutes at 13000 
rpm. 200 μl of the supernatant was transferred in a glass tube and dried under a gentle stream of nitrogen at 50 degrees Celcius. 
The residues were reconstituted in 100 µl of 0.1 % (v/v) formic acid in water. 20 µl was injected by an Ultimate 3000 autosampler 
(Dionex, Amsterdam, The Netherlands) and pumped by a HPG680 pump (Dionex, Amsterdam, The Netherlands) on a 3 µm, 120Å, 
50 x 2.1 mm YMC-pack ODS-AQ column (YMC Inacom, Overberg, The Netherlands) with an ODS precolumn (Phenomenex, Utrecht, 
The Netherlands) at 30 degrees Celcius. This HPLC part of the equipment was controlled by Chromeleon (Dionex, Amsterdam, The 
Netherlands). The eluent was monitored by a Quattro micro API tandem mass spectrometer (Waters, Etten-Leur, The Netherlands). 
Peak areas of reaction ions from morphine and M3G and the internal standards 2H3-M, and 
2H3-M3G were obtained in the multiple 
reaction mode and integrated by data software Masslynx 4.1 (Waters, Etten-Leur, The Netherlands). m/z was 165.0 (285.9>165.0) for 
morphine and 286.0 (461.9>286.0) for M3G. For the internal standards m/z was 165.0 (288.9>165.0) for 2H3-M and m/z (464.9>289.0) for 
2H3-M3G. All the samples were calculated by the internal standard method with weighing factor 1/(Y
2). The mobile phase consisted of 
0.1% formic acid in water with 3% acetonitril (Lichosolv) (Merck BV, Amsterdam, The Netherlands) as modifier. At a flow rate of 0.5 ml/
min the retention times of morphine, M3G, 2H3-M and 
2H3-M3G were respectively 6.70, 7.18, 6.65 and 5.10 minutes. Total analysis time 
was 10 minutes. All analytes were analyzed within one run.
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abStract
background A volunteer study suggested that taking paracetamol 4 grams daily could 
result in elevated alanine aminotransferase (ALT) plasma levels in a substantial proportion 
of healthy volunteers. The safety of this dose of paracetamol for acute postoperative pain 
remains controversial.
aim To study the incidence of alanine aminotransferase (ALT) elevations after short-term 
use of paracetamol 4 grams daily, as part of the standard pain management protocol, for 93 
consecutive patients after cardiothoracic surgery.
methods ALT-levels and other liver function tests were measured preoperatively as baseline 
and once daily after surgery during the ICU-stay.
results Preoperative ALT-levels of more than 1 time the Upper Limit of Normal (ULN, >40 U/L) 
was observed in 11% (n=10) of the patients but none of these baseline ALTlevels exceeded 3 
times the ULN (>3x ULN). The average daily dose of paracetamol administered was 50 mg per 
kg (standard deviation = 16) after surgery. Postoperative ALTlevels of >1x ULN was observed 
in 17% (n=16), and 4% (n=4) exceeded >3x ULN. The other liver function tests of the latter 
four patients, including AST (range 173-5590 U/L), γ-glutamyltransferase (range 56-103 U/L), 
Lactate Dehydrogenase (range 376-3518 U/L) and the International Normalized Ratio (range 
2.0-6.6), were all abnormal. These four patients all had right ventricular failure or cardiogenic 
shock during the postoperative period which could explain the significant rises in ALT after 
surgery.
conclusion The incidence of significant ALT elevations after using daily paracetamol as an 
analgesic agent for cardiac surgery, at a dose of 4 grams per day, was low and mostly due to 
complications after surgery. Our results, albeit still very limited, provided some reassurance 
about the safety of paracetamol 4 grams daily, as a supplementary analgesic agent for adult 
patients undergoing cardiac surgery.
131
Paracetamol in cardiothoracic patients
introDuction
Paracetamol is the most commonly used analgesic agent to treat mild to moderate postop-
erative pain [1]. For more severe pain, paracetamol in combination with an opioid produces 
a greater analgesic effect than higher doses of the opioid alone [2-4]. Moreover, paracetamol 
has few contraindications or side effects and lacks significant drug interactions [5], which 
makes it a valuable analgesic for postoperative pain management (e.g. after cardiothoracic 
surgery). Severe hepatotoxicity may, however, occur in significant paracetamol overdoses 
(>140 mg/kg) [6] through an increased production of the reactive metabolite N-acetylben-
zoquinoneimine (NAPQI) which reacts with the cysteine group of hepatocellular proteins, 
resulting in hepatic cell death.
Although hepatotoxicity (defined as alanine aminotransferase [ALT] levels >1000 U/L 
[7]) after therapeutic dosages of paracetamol has not been not reported [8-9], Watkins and 
colleagues [10] observed a high incidence of alanine aminotransferase (ALT) elevations 
(31-44%) of more than three times the Upper Limit of Normal (ULN) in paracetamol-treated 
healthy subjects after 3 days of its use. In this clinical trial, a total of 145 healthy subjects 
were randomly assigned into 5 groups (placebo vs. either paracetamol four grams daily, or a 
combination of paracetamol with one of three different opioids). As a result of this publica-
tion, physicians and pharmacists are now well aware of possible liver injury associated with 
therapeutic dosage of paracetamol for the treatment of acute and chronic pain [6,11-12]. 
If an elevated ALT level can be observed in healthy subjects after taking paracetamol four 
grams per day, it is possible that this problem can be more prevalent for critically ill patients 
due to concomitant usage of drugs that may affect the liver and impaired perfusion of the 
liver, especially in postoperative cardiothoracic patients after cardiopulmonary bypass [13]. 
Although other analgesic agents, such as NSAID or opioids, are also available, these agents 
also have significant side effects and may not be safer than paracetamol [6]. As such, it is 
pivotal to evaluate the safety profile of paracetamol as an analgesic agent for critically ill 
patients. Currently the incidence of ALT elevations after using paracetamol, as part of an an-
algesic protocol, after cardiothoracic surgery remains uncertain [14]; in this study we aimed 
to evaluate the profile of ALT levels, in a cohort of postoperative cardiothoracic patients who 
had been treated with rectal or intravenous paracetamol 4 grams daily.
metHoDS anD materialS
Study Design
A prospective observational study was performed in a 30-bed surgical/medical ICU in a 
teaching hospital, St Antonius Hospital, Nieuwegein, The Netherlands. The study was part 
of a clinical trial (registered at ClinicalTrials.gov, identifier NCT00558090), in which the pain 
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management for intervention-related pain was evaluated in postoperative cardiothoracic 
patients. The clinical trial was approved by the local Ethics Committee of the St. Antonius 
Hospital (approval number R0715A, November 7th, 2007). Written informed consent was 
obtained from the patients before the cardiothoracic surgical procedure.
Patients
Between February 18 and November 13 2008, 135 consecutive patients aged between 18 
and 85 years old were admitted to the ICU after cardiothoracic surgery requiring sternotomy 
and cardiopulmonary bypass (CPB). Exclusion criteria were patients with a known morphine 
or paracetamol allergy, planned postoperative admission to the postoperative anaesthesia 
care unit (PACU), pregnancy or breast-feeding, serious neurological deficits (e.g. coma or 
brain death), patients not able to communicate in either Dutch or English, and patients who 
refused informed consent. In 93 of the 135 patients, we were able to collect ALT and AST 
values and were therefore included in this prospective observational study.
Standard pain titration protocol for treatment of pain at rest
According to standard care in our ICU, physicians and nurses were trained in assessing pain 
and in providing adequate analgesia, a patient data management system (PDMS) obliged 
nurses to ask patients for their pain score three times a day, and the preferred analgesic treat-
ment was optimized [15].
For basic pain relief, a standard pain titration protocol was used in all patients, which is 
current practice in the ICU since 2007, consisting of continuous intravenous infusion of 
morphine and a standard dose of rectal or intravenous paracetamol 4 grams daily (Figure 1).
liver function tests
Arterial blood plasma samples (4 ml) for determination of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were taken from the arterial line. Of each patient, samples 
were obtained just after the induction of anaesthesia (baseline) and thereafter once daily at 
15.00 hr as long as the patients were still in the ICU, for a maximum of 10 days. The results of 
the liver function test were available to the attending clinicians. The Upper Limit of Normal 
(ULN) for both ALT and AST was defined as 40 U/L [10], in which 2x ULN equals 80 U/L and 
3x ULN equals 120 U/L. Other liver function tests, such as γ-glutamyl transpeptidase (GGT), 
Lactate Dehydrogenase (LD), International Normalized Ratio (INR) and bilirubin were taken 
as part of their routine clinical care.
Study procedure
On the day of cardiothoracic surgery, patients received one gram of paracetamol orally. 
Thereafter, patients received rectal or intravenous paracetamol upon automatic signals by 
the Patient Data Management System (PDMS) 4 times a day (7 days a week). When patients 
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Contact physician if:
* NRS ≥4 and CO2 ≥7 kPa
* Morphine continuous infusion ≥ 3 mg /hour
* 2x NRS ≥ 5
START pain protocol 
directly on admission
* Start paracetamol 1 gram, 4 times daily
* Start morphine continuous infusion (2mg / hour)
Contra-indication for 
paracetamol 
morphine/ propofol?
1. Decrease/ stop propofol
2. Decrease morphine if: 
- Propofol continuous infusion is stopped > 2-3 hours and
- The patient has no pain (NRS<4), or 
- In case of insufficient breathing 
Alternative medication for pain and sedation  contact
physician
Stable patient? *
Mechanically ventilated patient: 
- bolus of 5 mg morphine intravenously and
- increase morphine continuous infusion with 0.5 mg / hour 
Non-mechanically ventilated patient:
- bolus 2.5 mg morphine intravenously and
- increase morphine continuous infusion with 0.5 mg / hour 
Re-evaluate NRS after 30 minutes.
Don’t change morphine dosage
NRS 0 or 1?
Decrease morphine continuous infusion with 0.5 mg / hour every 
3-4 hours 
NRS ≥4?
Morphine intravenously 
2.5-5 mg, 4 x daily, if necessary 
or
Morphine subcutaneously
7.5-10 mg, 4 x daily, if necessary
* Evaluate NRS and RASS every 6 hours
DISCHARGE ICU
* Morphine continuous infusion stop, administrate 7.5-10 mg of morphine subcutaneously 
* Continue paracetamol 1 gram, 4 x daily
* Check prescriptions of morphine and paracetamol in ICU discharge letter 
* Hemodynamicly stable, acceptable leakage through thoracic drains, adequate time after muscle 
relaxation, adequate core temperature
NRS = numeric rating scale
RASS = Richmond Agitation Sedation Scale
ICU = Intensive Care Unit
Continuous 
infusion of 
morphine?
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
NRS 2 or 3?
Figure 1. Pain titration protocol for pain at rest
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were transferred to the ward, paracetamol one gram four times daily was prescribed in the 
ICU-discharge letter for the ward.
Data-analysis
The SPSS statistical package (version 15.0.1 for Windows; SPSS, Chicago, IL) was used for the sta-
tistical analyses. Descriptive statistics are reported as mean with standard deviation (SD), median 
with range, or proportion. Means were compared using a t-test for normally distributed data or 
the nonparametric Mann Whitney two-sample rank sum test for data not fitting the assumptions 
of parametric testing. Proportions were compared by using chi-square tests or Fisher’s exact test 
when appropriate. A P-value of less than 0.05 was considered statistically significant.
reSultS
Patients and data
Patient demographics of the 93 patients are presented in Table 1. The mean number of 
measured ALT tests performed per patient was 3.4 (range 2-8). Of all the 93 patients included 
in this study, 8 patients (9%) used preoperative paracetamol 4 grams daily. In 69 patients, 
Table 1. Patients’ characteristics 
all patients
Number of patients 93
Male gender, n (%) 69 (74%)
Age (years) 69 ± 11
Body Mass Index (kg/m2) 27 ± 4
Body Weight (kg) 82 ± 14
Median EURO score (range) 8 (0-13)
Type of cardiothoracic surgery, n (%)
 CABG 15 (16%)
 Valve surgery 21 (23%)
 CABG + valve surgery 33 (36%)
 Aortic surgery (+ valve) 24 (26%)
Non-elective surgery, n (%) 5 (5%)
Duration of mechanical ventilation in the ICU (hours) 20 ± 31
Median ICU stay (days) (range) 2 (1-13)
Pre-operative use of paracetamol, n (%) a 8 (9%)
Pre-operative chronic use of alcohol, n (%) b 25 (36%)
Paracetamol received in the ICU
 Dose (mg/kg/day) 50 ± 16
Data are expressed as mean ± standard deviation (SD) or median (range).
a Defined as paracetamol 4 grams daily
b Defined as alcohol >1 IE daily, 24 missing values
EURO score: European System for Cardiac Operative Risk Evaluation score [16]; CABG = coronary artery bypass graft; ICU = intensive care unit
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information on history of alcohol use was available, of whom 36% (n=25) used alcohol (>1 
unit daily) preoperatively. The mean dose paracetamol administered in the ICU per day for all 
patients was 50 mg/kg (± 16 mg/kg).
Preoperative alt levels
Ten patients (11%) had a baseline ALT level of more than one time the upper limit of normal 
(>1x ULN) (mean ALTlevel 66 U/L, range 42-96). In 3 of these 10 patients, the ALT levels were 
elevated to >2x ULN (81 U/L, 90 U/L and 96 U/L). None of the patients experienced a preop-
erative ALT level of >3x ULN (Table 2, Figure 2).
Table 2. (A) Incidence of aminotransferase elevations by multiples of upper limit of normal (ULN) and (B) the incidence of aminotransferase 
elevations by multiples of patient’s preoperative/ baseline (BL).
Preoperative level
n (%)
Postoperative levels
n (%)
a. upper limit of normal
n > 1x uln
(>40 u/l)
> 1x uln
(>40 u/l)
> 2x uln
(>80 u/l)
>3x uln
(>120 u/l)
 alt 93 10 (11%) 16 (17%) 5 (5%) 4 (4%)
 aSt 93 8 (9%) 75 (81%) 40 (43%) 14 (15%)
b. baseline limit
> 1x bl > 2x bl > 3x bl
 alt 93 - 36 (39%) 14 (15%) 5 (5%)
 aSt 93 - 89 (96%) 67 (72%) 37 (40%)
ULN = upper limit of normal (<40 U/L); BL = Baseline; ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase
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Figure 2. Incidence of preoperative and postoperative aminotransferase elevations by multiples of upper limit of normal (ULN)
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Postoperative alt levels
In Table 2 and Figure 2, the incidences of aminotransferase levels (ALT and AST) by multiples 
of the ULN (>40 U/L) (A) and the incidence of aminotransferase levels (ALT and AST) by mul-
tiples of patients’ baseline aminotransferase levels (B) are presented.
Of all the 93 patients included in the study, the incidence of ALT >1x ULN and >2x ULN was 
17% (n=16) and 5% (n=5), respectively. Four male patients (4%) experienced an ALT >3x ULN 
(Table 2, Figure 2).
In the patients experiencing an ALT >1x ULN (n=16), mean dose of paracetamol per day 
was 50 mg/kg (± 22 mg/kg). The mean cumulative dose of paracetamol received in ICU in 
these patients was 205 mg/kg (± 110 mg/kg).
Cases with an ALT >2x ULN (>80 U/L)
In total, 5% (n=5) of the patients experienced an ALT >2x ULN. One of these patients had 
a maximum ALT of 93 U/L, which decreased to normal (< 40 U/L) during follow-up and the 
other 4 patients experienced ALT values of more than 3 times the upper limit of normal (>3x 
ULN).
Cases with an ALT of >3x ULN (>120 U/L)
Table 3 presents an overview of the four cases with an ALT of >3x ULN. In all 4 cases, other 
liver function tests (e.g. AST, GGT, LD, INR), and also creatine kinase (CK) were increased. All 
four cases also had an elevated AST postoperatively (>3x ULN; range 173-5590 U/L).
Case 1 had a preoperative ALT baseline of 60 U/L, which represents >1x ULN. Case 1 experi-
enced an allergic reaction to protamine administered during surgery, thereby also leading to 
right ventricular failure. The postoperative course of this patient was further complicated by 
S. aureus pneumonia. The patient recovered promptly after treatment with inotropic agents 
and antibiotic therapy and left the ICU four days postoperatively.
Cases 2, 3 and 4 had a preoperative baseline ALT level within the reference range (<40 U/L) 
and developed cardiogenic shock and/or sepsis postoperatively, and died 2 to 5 days later. In 
case 4, paracetamol was discontinued when the ALT level was 1011 U/L on day 4 of ICU stay.
One of the 4 cases with an ALT of >3x ULN used paracetamol 4 grams daily preoperatively. 
This case had no serious increased ALT and AST levels at preoperative baseline (60 U/L and 35 
U/L respectively). None of the four cases with an ALT of >3x ULN, used alcohol preoperatively.
DiScuSSion
Our results showed that the incidence of maximum ALT of >3x ULN after paracetamol four 
grams daily in patients after cardiothoracic surgery was low (4%)(n=4) and the significant 
rises in ALT could easily be explained by severe complications after surgery.
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The safety of using 4 grams per day of paracetamol as an analgesic and antipyretic agent 
remains controversial [9]. Increased ALT levels after receiving standard therapeutic doses of 
paracetamol for various indications have been reported [17-20] and, in a systematic review, 
Dart and Bailey [9] reported an overall incidence of 0.4% increase in ALT levels in patients, 
who were treated with therapeutic doses of paracetamol. Furthermore, a remarkably high 
Table 3. Overview of cases with an alanine aminotransferase (ALT) level of >3 x upper limit of normal
case 1 case 2 case 3 case 4
Patient characteristics
Type of surgery CABG + AVR Re-AVR
+ carotid 
endarterectomy
CABG + AVR CABG
+ aneurysm resection
 
EURO- score
4 13 11 12
Pre-operative 
paracetamol?
Yes No No No
Pre-operative alcohol? No No No No
Baseline ALT (U/L) 60 31 20 15
Paracetamol
Dose (mg/kg/day) 40 41 59 50
Cumulative dose (mg/
kg)
150 173 242 236
Route of administration 1 gram IV by ICU arrival, 
followed by rectal 
administration
1 gram IV by ICU arrival, 
followed by rectal 
administration
Rectal administration 1 gram IV by ICU arrival, 
followed by rectal 
administration
liver function tests 
and outcome
Highest ALT (U/L) 293 136 250 2837
Corresponding AST 
(U/L)
264 836 173 5590
Day of ICU stay of 
highest ALT
Day 3 Day 4 Day 3 Day 5
Other liver function 
tests *
Bilirubin 11 μmol/l
CK 2206 U/L
GGT 103 U/L
LD 607 U/L
INR 2.0
Bilirubin 7 μmol/l
CK 176 U/L
LD 376 U/L
INR 5.5
Bilirubin 12 μmol/l
CK 98 U/L
LD 522 U/L
INR 6.6
CK 131 U/L
GGT 56 U/L
LD 3518 U/L
INR 4.1
Progression disease Right ventricle 
failure after allergic 
reaction to protamine 
perioperatively. 
Suspected for 
pneumonia (S. aureus in 
sputum)
Cardiogenic shock, 
sepsis and multi-organ 
failure
Cardiogenic shock and 
multi-organ failure
Cardiogenic shock 
(tamponade)
Outcome
Patient fully recovered, 
left ICU 3 days 
postoperatively
Died 4 days 
postoperatively
Died 2 days 
postoperatively
Died 5 days 
postoperatively
* Reference levels: Bilirubin: <17 μmol/l; Creatinekinase (CK): <175 U/L; γ-glutamyltransferase (GGT): <50 U/L; Lactate hydrogenase (LD): 
<220 U/L; International Normalized Ratio (INR): <1.2. CABG = Coronary Artery Bypass Graft; AVR = Aortic Valve Replacement; EuroSCORE: 
European System for Cardiac Operative Risk Evaluation score [16]; IV = intravenously; ICU = intensive care unit
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incidence of increased ALT levels was also reported in a healthy volunteer study [10]. In some 
reports, the use of therapeutic doses of paracetamol also appeared to have contributed to 
the development of severe liver failure and death [21-23]. Our study was different from these 
previous reports and required careful consideration. First, we had careful documentation of 
the doses of paracetamol administered to all the patients in this study. It is possible that 
some of the previous reports of severe liver toxicity induced by paracetamol may due to 
unintended overdoses because of inaccurate documentation of the doses of paracetamol 
used [9]. In fact, a number of prospective randomised clinical trials on healthy subjects also 
did not observe significant ALT elevations after 4, 6 or 8 grams of paracetamol per day for a 
maximum of 3 days [24-25], even in subjects using alcohol [9,26].
Second, although mild elevations of ALT were not uncommon after therapeutic doses 
of paracetamol after cardiac surgery, severe elevations of ALT (3xULN) were all associated 
with significant complications during or after cardiac surgery. It is known that in critically 
ill patients, the main causes of liver failure are septic shock and a low cardiac output, i.e. 
cardiogenic shock [27]. In cardiac failure, a low cardiac output causes hepatic ischemia due 
to reduced hepatic blood flow and venous congestion of the liver [27]. In sepsis, liver failure 
is mainly the result of insufficient oxygen extraction of the liver despite sufficient or even 
increased splanchnic and hepatic perfusion [27]. In these conditions of liver failure, liver func-
tion parameters like AST, GGT, LD, INR, and bilirubin are often increased similar to those we 
observed in our 4 cases in our study (Table 3). Therefore, the increased ALT levels in these 4 
cases differ from the typical paracetamol induced liver injury, in which an isolated increased 
ALT and AST level within the first 24 hour-period is observed [28].
Third, in the healthy volunteer study conducted by Watkins and colleagues [10], they 
included no data on alcohol consumption, diet or paracetamol use before entering the 
study. We were able to collect these data, and observed that 37% (n=25) and 9% (n=8) of the 
patients regularly consumed alcohol or used paracetamol preoperatively, respectively, in this 
study. Of the four patients with ALT levels of >3x ULN, only one patient used preoperative 
paracetamol 1 to 4 grams daily. However, baseline ALT (60 U/l) and AST (35U/l) levels for this 
patient were not substantially increased.
Apart from an increase in ALT levels in our patients, we also observed an increase in AST 
levels in many of our patients after surgery (AST of >1x ULN: 82%, >2x ULN: 43%, and >3x 
ULN: 15%). Because AST is also a biomarker for myocardial injury, and is formed in the urea 
cycle after cardiac ischemia [29], it is possible that increases in AST were primarily due to 
myocardial ischemia during and after surgery.
This study has some limitations. First, the sample size of this study was still small and was 
underpowered to detect rare adverse events. Second, we did not have a control group in 
our observational study. The safety of paracetamol should ideally be tested in a randomised 
placebo-controlled trial in which selection bias and confounding can be reduced. Third, we 
used different routes to administer paracetamol to the patients during the course of their 
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stay in ICU. Because bioavailability of rectal paracetamol is not the same as intravenous 
or oral paracetamol, it is possible that the incidence of liver dysfunction would be higher 
if only intravenous preparation of paracetamol was used. Finally, we did not have blood 
paracetamol levels both before and after the occurrence of deranged liver function tests. 
As such, we cannot assess whether there was any significant relationship between blood 
paracetamol concentrations and ALT levels in our patients.
In conclusion, in our cohort of postoperative cardiothoracic patients, we found a low 
incidence of substantial ALT elevations, except those who had severe cardiac complication 
during or after surgery, and did not appear to affect the clinical outcomes of our patients. 
With the limited data available, this study provided some reassurance about the safety of 
therapeutic doses of paracetamol in adult cardiac surgical patients.
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Discussion and perspectives
introDuction
The overall goal of the studies described in this thesis was to improve pain management in 
adult patients after cardiac surgery and critically ill patients in the intensive care unit (ICU). 
We focused on pain assessment, pain management at rest and during painful procedures, 
and the efficacy and safety of analgesics, such as paracetamol and morphine.
Despite efforts in improving pain management in intensive care patients from different 
research groups [1-3], 63-77% of the patients still report moderate to severe pain during 
their ICU stay. As pain management programmes may decrease morbidity and mortality, and 
improve the quality of life in intensive care patients [1,4], pain management has increasingly 
been recognized as an essential part of the standard care of patients in the ICU. Moreover, 
pain management became more important as a result of the position statement on sedation 
of intensive care patients that reported restriction to a conscious level whenever possible, 
which enables patients to report pain in an earlier phase of their intensive care stay.
Pain aSSeSSment in intenSiVe care PatientS
Adequate pain management can only be achieved by using effective methods for the recog-
nition, evaluating and monitoring of pain. Both the Society of Critical Care Medicine (SCCM) 
[5] and the Netherlands Society of Intensive Care (NVIC) developed guidelines for analgesia 
and sedation [6], and advice about pain assessment and preferred analgesics and sedatives. 
However, the most optimal method for pain assessment still needs to be determined, as there 
are only few evidence based studies available in this specific patient population.
Every patient in the ICU will pass different stages of consciousness, from a deeply sedated 
state during the first stage of the disease or after surgery, through arousal from sedation to 
a fully conscious and communicative state. Depending of the sedation level of the patient, 
different pain scales are available (Appendix I). Therefore, pain assessment should always be 
in conjunction with assessment of the depth of sedation, for which several sedation scales 
are validated in clinical practice (Appendix II).
In chapter 2, we evaluated three pain rating scales, i.e. the numeric rating scale (NRS), the 
visual analogue scale (VAS), and the behavioral pain scale (BPS) in (non-)ventilated intensive 
care patients, who were conscious sedated or sedated. Furthermore, we determined which 
health care worker (nurse or consultant) should preferably score this pain in case the patient 
was not able to report pain himself.
In conscious patients, self report is the ‘gold standard’ for pain assessment according to 
the guidelines of the International Association for the Study of Pain [7]. However, the NRS 
(range 0-10) and VAS (range 1-100) have been validated for acute pain only, and both pain 
Chapter 10
148
scales were never validated in mechanically ventilated patients in the ICU [8]. In our study, 
66% of the patients were able to score their pain using the numeric rating scale (NRS). The 
visual analogue scale (VAS) appeared less suitable, and could only be scored by 43% of the 
patients. The reduced number of patients who were able to rate the VAS may result from 
the limited ability for abstraction and comprehension of the patients. Furthermore, the VAS 
cannot be used by patients who are injured to the upper limbs. Although the NRS also needs 
a certain level of comprehension and abstraction, the NRS is easier to score as pain is scores 
verbally, with or without some assistance from the attending nurse. The more simple 4-point 
verbal rating scale (VRS-4) may be an alternative for both the VAS and NRS, as the VRS-4 has 
shown good reliability and validity in postoperative patients in previous studies [9], and is 
preferred by patients over the NRS [10]. However, the VRS-4 is less sensitive compared to the 
NRS and VAS [11]. Therefore, the NRS is in our opinion the preferred pain measurement scale 
in conscious patients.
In sedated patients, who are not able to report pain, observers have to use behavioral and 
physiological parameters of the patient. From this point of view, several pain scales were 
developed (Appendix I). The Non Verbal Pain Scale (NVPS) was modified from the FLACC 
(Face, Legs, Activity, Cry, Consolability) scale, consisting of three behavioral indicators and 
four physiological indicators [12]. The NVPS is partly validated for patients after burn trauma 
and not for intensive care patients in general. Before this pain scale can be applied in the 
intensive care unit, it has to be evaluated more extensively, especially in terms of inter-rater 
reliability and psychometric properties.
The Pain Assessment Intervention Notation (PAIN) Algorithm includes behavioral and 
physiological indicators as well, and involves guidelines for analgesic treatment [13]. Al-
though this method may be a useful tool to standardize pain assessment and management in 
the ICU, the length of the pain scale limits the clinical applicability. Furthermore, behavioral 
and physiological indicators of the PAIN Algorithm have not been standardized so far, result-
ing in nurses making clinical judgements or interpretation based on their experiences [14]. 
Moreover, using physiological indicators for estimating patients’ pain may be misleading, as 
these parameters, i.e. heart frequency and blood pressure are influenced by medication, such 
as beta blockers and inotropics. For this reason, the NVPS and PAIN Algorithm may be less 
applicable for pain measurement in intensive care patients.
The Critical Care Pain Observation Tool (CCPOT) was recently developed from three existing 
pain scales (BPS [15], COMFORT [16] en PAIN Algorithm [17]), and consists of four behavioral 
indicators. Gélinas et al. [18] showed that the CCPOT is valid for pain measurement in patients 
after cardiac surgery, with a high sensitivity and specificity during a painful intervention 
[18-20]. An advantage of the scale is that it can be applied even in non-ventilated patients. 
However, the CCPOT is only validated for one painful procedure (turning of the patient), 
with a low specificity during non-painful procedures. Therefore, further research is necessary 
before the CCPOT can be implemented in the ICU.
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At last, the BPS is a pain scale for sedated and mechanically ventilated patients exclusively 
and is based on three behavior parameters [15]. The BPS is validated in a diverse case mix 
population, including surgical patients and patients with respiratory insufficiency, multi-
trauma and sepsis. In our study, the BPS appeared to be a valid tool measuring pain in 
sedated patient, and is most adequately scored by the nurse. The BPS is also quick and simple 
to score, although an important finding of our study is that especially unacceptably high 
patient scores (NRS≥4) were underestimated by the nurses. Thereby, it has to be taken into 
account that the BPS showed a high non-response in deeply sedated patients. The reason for 
this phenomenon may be that the BPS reflects the objective visible behavior at one specific 
time point. In contrast, the NRS represents a global impression of pain, including several 
contextual factors during a longer time period. It seems, therefore, that the BPS should be 
used only in conjunction with the NRS nurse to measure pain levels in intensive care patients.
In conscious sedated patients, the VAS may be not applicable, resulting from immobility 
making it impossible to point to a score on the VAS. Furthermore, the NRS or VAS may be 
unreliable because of limitations in comprehension and abstraction, to capture a range from 
0 to 10, or 0 to 100 mm, respectively. However, self report using the VRS-4 may be useful, 
as this scale consists of only for levels. In chapter 3, we showed that the BPS scored by the 
nurse proved a valid method in conscious sedated patients. Nevertheless, as the BPS was 
found to both overrate and underrate patients’ pain, and the patient’s self-report is not 
always reliable, a combination of the nurse-rated BPS and the patient-rated VRS-4 is perhaps 
ideal for estimating patients’ pain, as each method yields unique information. Self-reporting 
primarily reflects expressive pain behavior that is under control of higher mental processes. 
Observational measures capture behavior that is less subject to voluntary control and more 
automatic [21].
Sedation assessment in intensive care patients
As mentioned before, the choice for a pain measurement instrument for an individual patient 
depends on the patients’ depth of sedation. Sedation assessment can protect patients from 
complications associated with under sedation, such as agitation, anxiety and ventilator 
asynchrony [22], and oversedation on the other hand, which may result in side effects caused 
by sedatives, increased duration of mechanical ventilation and longer length of stay in the 
intensive care unit [23-25]. Several sedation scales are available (appendix II), although a true 
gold standard scale has not been established.
The Ramsay scale is widely used, although the scale attracted criticism because of its 
lack of clear discrimination, and lack of specific descriptors to differentiate between levels 
[5,26]. Because of the limited psychometric testing of the Ramsay scale, new sedation scales 
were developed, i.e. the Sedation Agitation scale (SAS), the Motor Activity Assessment Scal 
(MAAS) and the Richmond Agitation Sedation Scale (RASS). The SAS [27] scores a patient’s 
level of consciousness and agitation from a seven-point list describing patients behavior, 
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and showed excellent inter-rater reliability and validity when compared to other sedation 
scales [27-28]. The MAAS is adapted from the SAS, and has been validated for use in critically 
ill patients [29]. Although the MAAS appeared sensitive to changes in sedation levels and 
was shown a reliable tool, the MAAS does not have sufficient psychometric evaluations, and 
is not significantly different from the SAS. Therefore, the MAAS is not considered a primary 
and unique method for evaluation of sedation levels [26]. The Richmond Agitation Sedation 
Scale (RASS) [30] has been validated to detect changes in sedation status over several days, 
and correlates with doses of sedatives and analgesic medications administered in critically ill 
patients [31]. The RASS has a good inter-rater reliability and correlates well with the Ramsay 
score [30,32]. A disadvantage of the RASS are the lengthy and subjective descriptions of the 
items, which makes the RASS more difficult to interpret for health care workers.
Using the Vancouver Interaction and Calmness Scale (VICS), patients are assessed indepen-
dently for the ability to interact and communicate and for their level of activities or restless-
ness. The scale has been validated for the assessment of sedation in adult critically patients 
[33]. However, the VICS as not been tested to identify optimal sedation endpoints [5].
At last, the ATICE is a sedation scoring system that additionally rates patient agitation and 
ventilator synchrony [34], and includes more scoring parameters compared to the RASS. It 
has demonstrated high internal consistency, inter-rater reliability across disciplines, and va-
lidity. Although more scoring parameters will result in a more complete sedation assessment, 
the ATICE is more difficult to perform in daily practice [6].
Finally, the Bispectral index (BIS) is an objective method for depth of anaesthetic or seda-
tion assessment, based on the patients’ electroencephalogram (EEG). Most reports showed a 
strong correlation between BIS and patient recall or level of hypnosis in the operating room 
[35]. BIS guided anaesthesia is suggested to reduce the risk of awareness in at-risk adult surgi-
cal patients undergoing general anaesthesia [36], although the reliability of these results are 
questionable, as result of the underpowered study and differences in anaesthetic procedure 
between the BIS guided anaesthesia and the control group [37-38]. In the ICU, the use of the 
BIS is limited, as the BIS scores may vary between patients at the same subjective level of se-
dation. Muscle based electrical activity may artificially elevate BIS scores if the patient has not 
received neuromuscular blockade [5], which is the case in almost all intensive care patients 
nowadays. Furthermore, the BIS cannot be evaluated in patients with metabolic impairments 
or structural abnormalities of the brain. At last, there are no prospective comparative studies 
evaluating patient outcomes of using BIS versus subjective sedation scales [5,26,39]. There-
fore, the use of the BIS cannot be recommended until the value and validity are confirmed. 
Both the SCCM and the NVIC, recommends the use of the SAS, MAAS and VICS [5-6]. The NVIC 
recommends also the use of the RASS or the ATICE as useful sedation assessment scale [6].
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Pain management for intenSiVe care PatientS after carDiac Surgery
Pain management at rest
Adequate pain management reflects a high quality in daily patient care and is considered 
an important health care benchmark. Clinical practice guidelines recommend systematic 
evaluation of pain in patients for optimal pain management, but how to implement such a 
protocol is not specified. More specifically, clinical practice guidelines may have limited effect 
on changing the health carers’ behavior, as result of a variety of barriers to guideline adher-
ence, which may include for example lack of knowledge, lack of awareness or environmental 
barriers such as time or resources [40].
In our ICU, at baseline 42% of the pain scores at rest were rated as unacceptable pain by 
patients after cardiac surgery, which is defined as a NRS score of 4 or higher [8]. Although this 
incidence is substantial, it is rather low compared to previous reports, reporting incidences even 
between 63-77% [2]. In order to reduce this incidence of pain at rest, in chapter 4, we introduced 
a pain management system consisting of a pain education programme for nurses and physicians, 
the introduction of systematic pain assessment and registration of the pain scores. Furthermore, 
the standard analgesia protocol was optimized, in which intravenous morphine as a continu-
ous infusion was preferred over subcutaneous use or use on demand, and was combined with 
paracetamol administration directly upon arrival in the ICU. It was shown that this protocol suc-
cessfully reduced the occurrence of unacceptable pain (NRS≥4) in patients after cardiac surgery 
from 42% to 23%. This incidence of unacceptable pain of 23% is comparable with a previous study 
in a diverse group of ICU patients [1], and approximately three times lower than other reports 
[2,41]. In this study, patients in the intervention group received higher morphine doses compared 
with baseline, while morphine was administered to patients with high pain levels (NRS≥4). This 
Conclusions and recommendations
•	 The	method	of	pain	assessment	depends	on	the	patients’	depth	of	sedation	and	
mode of mechanically ventilation.
•	 Pain	 scores	 should	be	obtained	by	 self	 report	of	patients	 as	much	as	possible,	
preferable by using the NRS.
•	 In	sedated	patients,	who	are	not	able	to	communicate,	pain	should	be	rated	by	
the attending nurse, using the NRS in conjunction with the BPS.
•	 In	 conscious	 sedated	 patients,	 a	 combination	 of	 the	 nurse-rated	 BPS	 and	 the	
patient-rated VRS-4 should be used for the estimation of patients’ pain.
•	 Specific	neurobiological	parameters	for	the	evaluation	of	pain	should	be	identi-
fied, which may be used as part of the current pain scales, and may contribute to 
a more objective pain assessment.
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confirms that unacceptable pain is more adequately managed in the intervention group com-
pared to patients in the control group. Additionally, patients in the intervention group received 
more intravenous morphine and less subcutaneous morphine compared to the control group. As 
little is known of the bioavailability of subcutaneously administered morphine in intensive care 
patients with possible impaired perfusion and an altered volume of distribution, the programme 
intended and succeeded in a 38% reduction of the total amount of morphine administered 
subcutaneously. Thus, efforts so far leads to a successful implementation of a guideline concern-
ing pain management, which could in part be achieved by efforts in improving health carers’ 
knowledge and attitude concerning pain management.
However, in the intervention group, still 46% of the patients experienced at least one unac-
ceptable pain score during their stay in the intensive care unit. Therefore, we focused on more 
individually tailored analgesia for pain management at rest. To this effect, we implemented 
a pain titration protocol, consisting of a continuous infusion of morphine and paracetamol 4 
grams daily, as individualized titration of analgesia is associated with shorter ICU- and hos-
pital length of stay and a lower mortality [42]. In chapter 5, in which procedure-related pain 
was studied, all patients were treated according to this pain titration protocol. Within this 
context, we observed a lower incidence of unacceptable pain at rest (16%) in patients treated 
according the pain titration protocol, compared with the situation that only the pain training 
programme was implemented (Chapter 4). The incidence of unacceptable pain of 16% was 
also remarkably lower compared to previous reports, including patients with a comparable 
case mix [1,43]. In this patient group, we observed higher morphine consumption in younger 
patients, and in patients with a low euroSCORE (Chapter 5, Table 1). It is well known that 
older patients need less analgesics for pain relief than younger patients [44]. Patients with a 
high euroSCORE are probably more vulnerable for the effects of medication, due to impaired 
condition of elimination organs, e.g. kidney and liver. This condition may result in a slower 
elimination of morphine, thereby leading to lower morphine consumption in these patients. 
The observed differences in morphine consumption between patients with various back-
ground characteristics suggest that the pain titration protocol leads to an individual dosing 
regimen of analgesics, thereby resulting in a low incidence of unacceptable pain at rest.
Conclusions and recommendations
•	 A	successful	implementation	of	a	pain	training	programme,	in	order	to	achieve	a	signifi-
cant decrease in pain at rest in the ICU can only be realized when health care workers 
are intensively trained in terms of knowledge and attitude in pain management.
•	 In	an	intensive	care	unit,	a	pain	titration	protocol	should	be	implemented,	which	
leads to an individualised dosing regimen of analgesics, thereby resulting in a 
lower incidence of unacceptable pain at rest.
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Procedural pain management
Apart from pain at rest, patients in the ICU may suffer from unavoidable routine care pain-
ful procedures. Procedural related pain is the most common form of health induced pain, 
which has been recalled as strong negative memories of the time in the intensive care unit 
[45-46]. However, a number of reports showed that procedural pain is difficult to treat [1,47]. 
Therefore, one part of the patients will experience unacceptable pain despite treatment [47-
49]. In chapter 5, we studied the efficacy of a bolus of intravenous morphine 2.5 versus 7.5 
mg for procedural pain relief in postoperative patients after cardiac surgery in the ICU, who 
were already treated according to a pain titration protocol for pain at rest. In patients with 
low pain levels for pain at rest (16%), there was no difference in efficacy between a bolus of 
intravenous morphine 2.5 mg or morphine 7.5 mg for pain relief during a painful interven-
tion. As such, a bolus dose of morphine 2.5 mg may be sufficient to prevent procedural pain, 
in case pain at rest is well controlled on the basis on individually tailored analgesia.
During the painful intervention, we found a substantially lower incidence of unaccept-
able NRS scores (25%), compared to previous reports. Incidences of 32% to 62% have been 
reported during endotracheal suctioning and movement in patients with various morbidities 
[47-49]. In these studies, pain was managed with standard doses of analgesics for pain relief 
at rest or during procedural interventions only [50-52], which is in contrast with our study 
in which a pain titration protocol was applied. As such, we suggest that the pain titration 
protocol which is applied during the entire ICU stay may not affect pain scores at rest alone, 
but may also lead to a decrease of pain intensity during painful procedures.
Despite adequate pain management, one part of the patients (25%) experienced unac-
ceptable pain during a painful procedure. Pain levels are known to differ largely between 
patients and may partly be explained by environmental factors such as age, gender or anxi-
ety. Furthermore, some candidate genes genetic polymorphisms have been associated with 
differential pain sensitivity.
Pharmacogenetics
In a sub-study of the randomised controlled trial of chapter 5, in chapter 6 we evalu-
ated the effect of a polymorphism of the catechol-O-methyltransferase (COMT) Val158Met 
polymorphism, which has been shown to affect pain sensitivity upon experimental pain 
stimuli in healthy volunteer studies. COMT metabolizes dopamine, epinephrine and norepi-
nephrine, and is a key modulator of dopaminergic and adrenergic neurotransmission [53]. 
COMT contains a common functional coding polymorphism Val158Met, corresponding to 
a valine-to-methionine substitution at codon 158 (Val158Met). This Val158Met substitution 
has been associated with a three- to four fold decrease in COMT activity [54], which results 
in lower endogenous levels of enkephalins and subsequently exaggerated pain sensitivity 
[55]. In this study, patients received continuous morphine infusions for pain at rest, and a 
bolus of morphine (2.5 or 7.5) before a painful procedure. All patients were genotyped for 
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the COMT Val158Met polymorphism. Morphine-treated patients carrying the Met-variant 
allele experienced both significantly higher overall pain scores and significantly higher pain 
levels during the painful procedure, compared to patients with the Val/Val genotype. More 
specifically, in patients with the Met/Met genotype a statistically significant and clinically 
relevant increase (NRS≥1.3) in pain levels was observed during the painful procedure, which 
was absent in patients with the Val/Val genotype. To our knowledge, this is the first study 
evaluating the COMT Val158Met polymorphism on pain sensitivity within a clinical research 
design in morphine-treated postoperative cardiac patients undergoing an unavoidable pain-
ful stimulus. The COMT Val158Met polymorphism thus explained one part of the variability 
in pain sensitivity. Patients carrying the Met-allele may potentially benefit from another pain 
management strategy, including treatment with analgesics which are independent of en-
dogenous enkephalin levels and the μ-receptor density.
Furthermore, the results of this study suggest that pharmacogenetics may play an impor-
tant role in pain management in the future. It seems that more research is needed, in order to 
determine an adequate set of genes. This set of genes may be of added value in identifying 
patients who are at high risk for pain, or have experienced an ‘abnormal’ pain to usual dos-
ages of analgesics. However, a limitation of such pharmacogenetic studies including several 
polymorphisms at once is the need of extremely large sample sizes in order to detect dif-
ferences between the genotype groups of the polymorphisms. In our study, we did find a 
significant effect in both overall pain levels and pain during the painful procedure between 
the genotype groups of the COMT Val158Met polymorphism. In the future, all patients may 
undergo genotype screening preoperatively, which enables health care workers to adapt 
pain management. Thus, pain sensitivity is influences by many factors, including genetic 
contributions of at least one gene.
Perspectives in procedure-related pain management strategies
In our study, morphine was chosen for the prevention and treatment of postoperative pain 
at rest and during procedures. Morphine is the preferred analgesic for acute pain relief [5], 
as it may provide cardioprotection and anti-inflammatory response in contrast to fentanyl in 
patients after cardiac surgery [56-57]. However, one disadvantage of morphine may be the 
slow onset of action and relatively long half-time compared to other opioids, such as fentanyl 
or remifentanil. In several studies with different patient populations [58-60], no superiority 
for one of the three analgesics, morphine, remifentanil, and fentanyl was found within a pain 
titration model. In two studies on chest drain removal in postoperative cardiac patients, no 
difference in pain scores was observed between subcutaneous bupivacain 0.5%, intravenous 
ketorelac 30 mg or inhaled entonox 50% and intravenous morphine [50,52]. Although an 
intravenous remifentanil bolus of 0.5 μg/kg was shown to be effective for drain removal in 
post-cardiac surgical patients in comparison to placebo (median NRS score [25-75%] 1 [0-2] 
vs. 5 [3-6] respectively), patients received no baseline infusions of opioids [61]. The results 
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are therefore difficult to compare to our situation where standard infusions of morphine are 
given for pain at rest. At last, in most intensive care patients nonsteroidal anti-inflammatory 
drugs (NSAID’s) cannot be used, due to the high risk of provocation in patients with heamo-
dynamic instability and renal dysfunction. An ideal analgesic for procedural related pain is 
thus not yet available. Therefore, we should focus on other strategies for procedural pain 
management. Although beyond our research, we suggest that anxiety management may 
improve pain management.
Pain is based on the perception of the patient, which is influenced by many factors, includ-
ing the patient’s emotional and psychological state, level of anxiety, understanding of the 
procedure [62] and environmental factors, including the setting and person performing the 
procedure [63]. Therefore, the attending nurse may have an important role to decrease pain 
which is caused by one of these factors. Nurses should be trained in an adequate approach 
of patients undergoing a painful procedure, in which good attitude and communication are 
essential. This involves listening to any concerns or anxiety of the patient about the proce-
dure. The patients’ expectations of pain should be explored, in which a realistic view of what 
the patient may experience and the degree of pain relief that may be achieved should be 
discussed, thereby reducing anxiety.
Moreover, in further research, procedural sedation could be considered in patients ex-
pressing concern or distress for the potentially painful procedure. An anxiolytic may induce 
amnesia and increase cooperativeness and willingness to undergo a similar procedure in the 
future. Examples for procedural sedation may include ketamine, propofol and benzodiaz-
epines, such as midazolam.
S-ketamine is often used in children for procedural sedation, and produces a trance-like 
state with both sedation and analgesia while maintaining airway reflexes and an intact respi-
ratory drive [64]. In adult intensive care patients undergoing open wound care procedures, 
S-ketamine in addition to morphine significantly reduced pain scores compared to morphine 
alone [65]. In a recent study including trauma patients in the emergency department [66], 
S-ketamine and propofol were equally effective for procedural related pain, although higher 
ratings of subclinical respiratory depression and recovery agitation were shown in the S-
ketamine group. Recovery agitation, ranging from hallucinations and nightmares to violent 
outburst, limits the use of S-ketamine in adults, with reported incidences as high as 30% [64].
Midazolam and propofol may also be considered for procedural sedation, because of their 
advantageous characteristics, such as their relatively fast onset and short half-time [67]. So 
far, research on midazolam or propofol for procedural sedation is only conducted in patients 
in the emergency department. In these patients, both midazolam and propofol appeared 
equally effective for procedural sedation, without significant adverse effects [68]. In further 
research, midazolam or propofol are suggested agents for procedural sedation in intensive 
care patients. As the anxiolytic provides no analgesia, the anxiolytic should always be used in 
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conjunction with an analgesic [69]. Because fentanyl has a quick onset and short duration of 
action, fentanyl may be considered as analgesic [70].
chronic thoracic pain
Besides acute postoperative pain, chronic thoracic pain after cardiac surgery is a serious 
condition affecting many patients. Pain is described as chronic if it persists three months to 
one year after tissue healing. On the other hand, it has been suggested that chronic postop-
erative pain should be defined as pain persisting two months after surgery, which cannot be 
explained by other causes. In chronic pain management, it is generally accepted to ascertain 
its effect on quality of life and function [71]. Depending on the definition of chronic thoracic 
pain, recent studies report incidences varying from 11 to 56% [48,72].
In order to identify predictors for chronic thoracic pain one year after cardiac surgery 
via sternotomy, in chapter 7, we performed a follow-up study in patients included in the 
randomised clinical trial of chapter 5. Chronic thoracic pain was defined as sternal and/or 
thoracic pain (NRS>0), which the patient identified as related to surgery, which was different 
from angina and which was present in the 2 weeks preceding the interview [73]. As such, in 
our study 35% of the patients reported chronic thoracic pain. Besides age below 69 years 
and a body mass index (BMI) above 28 kg/m2, intraoperative remifentanil appeared an inde-
pendent predictor for chronic thoracic pain, which association was dose-dependent. So far, 
chronic post-surgical pain related to remifentanil during anaesthesia has only been described 
by Salengros et al. [74], who defined chronic pain as a dichotomic variable (pain: yes or no) 
one, three and six months after surgery, combined with questions about the intensity of the 
pain, use of analgesics and type of pain. Remifentanil high dose (0.14-0.26 µg/kg/min) during 
elective thoracotomy combined with postoperative epidural analgesia was not only associ-
ated with a larger area of allodynia around the wound in the first 72 postoperative hours, but 
also with a significant higher incidence of chronic pain compared with a three times lower 
Conclusions and recommendations
•	 To	 prevent	 unacceptable	 pain	 scores	 (NRS≥4)	 during	 painful	 procedures,	 ad-
equate pain management for pain at rest using a pain titration protocol, is crucial.
•	 More	research	is	needed	to	identify	patients	who	are	at	risk	for	unacceptable	pain	
(NRS≥4) during a painful procedure. In this respect, the role of pharmacogenetic 
testing may increase, as a polymorphism of the COMT gene is related to higher 
pain sensitivity.
•	 In	patients	at	risk	for	unacceptable	pain	(NRS≥4)	during	a	painful	procedure	due	
to anxiety, an anxiolytic (e.g. midazolam or propofol) in conjunction with an 
analgesic (e.g. fentanyl) may be a focus in further research.
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dose of remifentanil and epidural analgesia during surgery. Moreover, in patients after major 
abdominal surgery, a higher dose of remifentanil (0.3 ± 0.2 µg/kg/min) has been associated 
with acute opioid tolerance and opioid-induced hyperalgesia compared with a lower dose 
of remifentanil (0.1 ± 0.0 µg/kg/min), suggested by higher postoperative pain scores in the 
first postoperative hour and exaggerated postoperative opioid consumption in the first 24 
postoperative hours [75]. It can be anticipated that hyperalgesia is linked to peripheral and 
central pain sensitization via activation of N-methyl-D-aspartate (NMDA) receptors at spinal 
and central levels, and thereby correlates with the development of postoperative chronic pain 
[76]. This suggests that hyperalgesia due to remifentanil in the early postoperative period 
may explain the higher incidence of chronic pain. In our study, we were not able to evaluate 
this phenomenon, as the patients in our study were sedated in the first postoperative hours. 
Higher postoperative pain scores may however also be due to inadequate postoperative use 
of analgesics, based on the misleading assumption that remifentanil has a prolonged analge-
sic effect. Thus, in this follow-up study, intraoperative remifentanil was predictive for chronic 
thoracic pain in a dose-dependent manner. Randomised studies designed to evaluate the 
influence of intraoperative remifentanil on chronic thoracic pain are needed to confirm these 
results.
morPHine anD Paracetamol analgeSia in intenSiVe care PatientS
In pain management for moderate and severe postoperative pain in the ICU, both morphine 
and paracetamol are commonly used analgesics. Although both analgesics have been used 
for decennia, and have been extensively investigated, there are still questions about the 
use in terms of efficacy and safety, as well as their interaction to diminish pain and need for 
analgesics.
Conclusions and recommendations
•	 There	is	a	need	for	a	uniform	definition	of	chronic	thoracic	pain	to	obtain	more	
reliable and clinically relevant data for research purposes and clinical practice.
•	 To	determine	long-term	outcomes	and	to	clarify	whether	chronic	pain	decreases	
over time, prospective studies should include at least a six months postoperative 
follow-up.
•	 Randomised	 controlled	 trials	 are	 necessary	 to	 confirm	 that	 remifentanil	 is	 as-
sociated with the development of chronic thoracic pain in patients after cardiac 
surgery.
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Pharmacokinetics of morphine
Morphine is the preferred analgesic for moderate and severe (postoperative) pain in the 
ICU [5,6]. However, the clinical use of morphine is characterized by a large inter-individual 
variability in analgesic effect, which may partly be caused by differences in morphine phar-
macokinetics as a result of variability in health status, hepatic metabolic capacity and renal 
clearance, particularly when intensive care patients are concerned. Morphine is mainly 
metabolized in the liver via glucuronidation by phase II metabolism enzyme UDP-glucuro-
nosyltransferase (UGT)2B7 to morphine-3-glucuronide (M3G) and morphine-6-glucuronide 
(M6G). Both metabolites and unchanged morphine are excreted by the kidneys [77]. The 
main metabolite M3G is suggested to have antagonistic or hyperalgesic effects, which may 
potentially result in reduced morphine efficacy. In order to quantify the glucuronidation 
and elimination clearance of morphine in intensive care patients in comparison to healthy 
volunteers, a pharmacokinetic model of morphine and morphine-3-glucuronide (M3G) was 
developed. The analysis included 135 intensive care patients (117 cardiac surgery patients 
and 18 critically ill patients), who received continuous morphine-infusions adapted to indi-
vidual pain levels, and 20 healthy volunteers, who received an intravenous bolus of morphine 
followed by a 1-hour infusion [78]. In intensive care patients, glucuronidation clearance of 
morphine to M3G and elimination clearance of M3G were significantly decreased with 17% 
and 81% respectively, compared to healthy volunteers. Nowadays, no data are available 
on glucuronidation clearance of morphine to M3G in intensive care patients. Studies so far 
focused on patients with cirrhosis, in whom glucuronidation clearance of morphine was 
shown to be decreased, probably due to reduction in hepatic clearance [79]. We hypothesize 
that in intensive care patients, the amount and/or activity of the metabolism enzyme UDP-
glucuronosyltransferase (UGT)2B7 may be (temporarily) decreased. Although no specific 
information is available on the UGT2B7 enzyme in this specific study population, there is 
some evidence that the activity of other liver enzymes, such as cytochrome P-450 enzymes, 
is decreased in case of critically illness [80] or after surgery [81]. However, the decrease of 17% 
in the glucuronidation clearance of morphine in intensive care patients by itself does not 
lead to substantial morphine accumulation upon prolonged infusion. In contrast, we identi-
fied a very large reduction (81%) in elimination clearance of M3G in intensive care patients 
compared to healthy volunteers, which was independent of renal function. Thus, in intensive 
care patients with normal renal function substantially higher M3G levels may be expected 
upon 24 hour continuous infusion, with even higher M3G levels upon renal failure. Although 
controversial, M3G is thought to antagonize the analgesic effect, and to play a role in the 
development of tolerance and hyperalgesia [77]. Most studies arise from animal studies, in 
which M3G has been demonstrated to antagonize morphine and M6G analgesia [82-84]. In 
the study of Mazoit et al. in postoperative patients [85], it was shown that M3G does have an 
antinociceptive effect. The authors discuss that this effect is moderate, and that a significant 
effect of M3G is not though to occur before the 9th – 18th hour after initiation of analgesic treat-
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ment, because of the very long transfer half-time from injection site to effect compartment. 
In our study however, cardiac surgery patients had a mean infusion duration of 21 hours, 
while critically ill patients received intravenous morphine infusions for a mean duration of 
123 hours. Thus, the very large decrease in elimination clearance of M3G in intensive care 
patients resulting in substantially elevated M3G concentrations, may be clinically relevant, in 
particular upon prolonged administration of morphine infusion.
Moreover, serum creatinine concentration was identified as a covariate for both elimina-
tion clearance of M3G within the group of intensive care patients and for non-M3G clearance 
of morphine in both intensive care patients and healthy volunteers. It is well known from 
literature in a diverse patient population that clearance of morphine and its metabolites 
deteriorates as result of renal failure [85-90]. Thus, in intensive care patients with impaired 
renal function, morphine will cumulate compared to intensive care patients without renal 
failure and healthy volunteers. Also for M3G, higher concentrations than those anticipated 
in intensive care patients without renal failure will be reached, while these concentrations 
were already largely increased in intensive care patients without renal dysfunction compared 
to healthy volunteers. A limitation of our study was that we were not able to differentiate 
between the two subgroups of intensive care patients in our study population, i.e. cardiac 
surgery patients versus critically ill patients, even though we realize that there are many 
physiological differences between these two subgroups that may result in different pharma-
cokinetic parameters. Another issue may be the correlation between covariates within the 
study groups. Intensive care patients were older and had on average higher serum creatinine 
concentrations. However, the use of non linear mixed-effects modelling techniques allowed 
to differentiate in part for these correlated covariates, as was demonstrated by the identified 
statistically significant covariates for each of the clearance parameters. In conclusion, gluc-
uronidation of morphine to M3G and elimination clearance of M3G in intensive care patients 
appeared significantly decreased compared to healthy volunteers. As a result, in particular 
elevated M3G concentrations may be anticipated in intensive care patients, which is even 
more pronounced upon increased serum creatinine concentrations. Considering the poten-
tial anti-nociceptive and hyperalgesic activity of M3G, this finding may be clinically relevant, 
and should be taken into account in this special patient group, particularly upon prolonged 
use of morphine infusions.
Safety of paracetamol
Concerning the safety of paracetamol, physicians and pharmacists may be reluctant to use 
paracetamol in intensive care patients, as volunteer study suggested that taking paracetamol 
four grams daily could result in elevated alanine-aminotransferase (ALT) levels in a substan-
tial proportion (31-44%) of healthy volunteers [91]. As such, it can be anticipated that this 
problem can be more relevant in intensive care patients due to concomitant usage of drugs 
that may affect the liver and impaired perfusion of the liver during cardiopulmonary bypass. 
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Severe hepatotoxicity upon paracetamol use may occur through an increased production 
of the reactive metabolite N-acetylbenzoquinoneimine (NAPQI) which reacts with the cys-
teine group of hepatocellular proteins resulting in hepatic cell death, which was shown in 
significant paracetamol overdoses (>140 mg/kg) [92]. In chapter 9, we studied the incidence 
of ALT elevations after short-term use of paracetamol 4 grams daily, as part of the standard 
pain management protocol in 93 consecutive patients after cardiac surgery. Postoperative 
ALT-levels of >1x Upper Limit of Normal (ULN) was observed in 17% (n=16), and 4% (n=4) 
exceeded >3x ULN. These four patients all suffered from right ventricular failure or cardio-
genic shock during the postoperative period which could explain the significant rises in ALT 
after surgery. Thus, the incidence of significant ALT elevations after using paracetamol as an 
analgesic agent for cardiac surgery at a dose of 4 grams per day, was low and most likely due 
to effects of cardiac surgery.
However, the safety of using paracetamol 4 grams daily as an analgesic and antipyretic agent 
remains controversial [93]. In several reports, the use of therapeutic doses of paracetamol 
appeared to have contributed to the development of severe liver failure and death [94-96]. 
Our study was different from these previous reports and requires careful consideration. First, 
we had careful documentation of the doses of paracetamol administered to all the patients 
in this study. It is possible that some of the previous reports of severe liver toxicity induced 
by paracetamol may due to unintended overdoses because of inaccurate documentation of 
the doses of paracetamol used [93]. Thereby, a number of prospective randomised clinical 
trials on healthy subjects did not observe significant ALT elevations after 4, 6 or 8 grams of 
paracetamol per day for a maximum of 3 days [97-98], even in subjects using alcohol [93,99]. 
Second, severe elevations of ALT (3xULN) were all associated with significant complications 
during or after cardiac surgery, i.e. in case of cardiac shock or sepsis. In these conditions of 
liver failure, liver function parameters like AST, GGT, LD, INR, and bilirubin are often increased 
similar to those we observed in our 4 cases. Therefore, the increased ALT levels in these 4 
cases differ from the typical paracetamol induced liver injury, in which an isolated increased 
ALT and AST level within the first 24 hour-period is observed [100]. Third, in the healthy 
volunteer study conducted by Watkins and colleagues [91], they included no data on alcohol 
consumption, diet or paracetamol use before entering the study. We were able to collect 
these data, and observed that 37% (n=25) and 9% (n=8) of the patients regularly consumed 
alcohol or used paracetamol preoperatively, respectively, in this study. However, a limitation 
of our study was that the sample size of this study was small and was underpowered to 
detect rare adverse events. Moreover, we did not have a control group in our observational 
study. The safety of paracetamol should ideally be tested in a randomised placebo-controlled 
trial in which selection bias and confounding can be reduced. Our results, albeit still very 
limited, provided some reassurance about the safety of paracetamol 4 grams daily. As 
paracetamol combined with morphine induced a significant morphine-sparing effect [101-
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102], paracetamol can thus be used as a supplementary analgesic agent for adult patients 
undergoing cardiac surgery.
main concluSionS anD PerSPectiVeS
In this thesis, we focused on pain assessment, pain management at rest and during painful 
procedures, and the efficacy and safety of analgesics, such as paracetamol and morphine.
We identified which pain scale should be used in intensive care patients, depending on 
the level of sedation (Figure 1). In conscious patients, the NRS should be used, reported by 
the patient. In sedated patients, who are not able to communicate, pain should be assessed 
Conscious patient Sedated patient
NRS VRS-4
BPS BPS & NRS
PATIENT’S SELF ASSESSMENT
OBSERVER BASED ASSESSMENT
Figure 1. Pain scales associated with the level of consciousness.
Conclusions and recommendations
•	 In	 intensive	 care	 patients,	 glucuronidation	 clearance	 of	morphine	 to	M3G	 and	
elimination clearance of M3G appeared significantly decreased compared to 
healthy volunteers. As a result, in particular elevated M3G concentrations may 
be anticipated in intensive care patients, which is even more pronounced upon 
increased serum creatinine concentrations. This knowledge is of added value in 
the development of individualized dosing regimens for intensive care patients.
•	 With	the	current	knowledge,	there	is	no	reason	not	to	administer	paracetamol	in	
intensive care patients after cardiac surgery. However, in case of an increased ALT 
level of more than three times the upper limit of normal, paracetamol should be 
reconsidered.
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by the nurse, using the BPS in conjunction with the NRS. Patients who are conscious sedated 
may be able to score their pain on the VRS-4. This pain rating should be combined with a 
pain score of the attending nurse, using the BPS. More research is needed to identify specific 
neurobiological parameters for the evaluation of pain. These parameters may be used as part 
of the current pain scales, and may contribute to a more objective pain assessment.
Pain management at rest was improved in postoperative cardiac patients, using a multiple 
approach. A pain training programme was implemented, consisting of a pain education 
programme for nurses and physicians, the introduction of a systematic pain assessment, and 
registration of the pain scores. These efforts resulted in a successful reduction of unacceptable 
pain scores (NRS≥4) at rest, which could be achieved by improving health carers’ knowledge 
and attitude concerning pain management. Pain scores at rest could be further decreased by 
the implementation of a pain titration protocol, consisting of paracetamol four grams daily 
and a continuous morphine infusion, which was adapted to individual pain levels.
During painful procedures, in a randomised controlled trial there was no difference in ef-
ficacy between a bolus of morphine 2.5 mg or morphine 7.5 for pain relief in patients treated 
according to a pain titration protocol. As such, a bolus of morphine 2.5 mg may be sufficient 
to prevent and treat procedural pain in postoperative cardiac patients. However, despite 
adequate treatment, 25% of the patients experienced unacceptable pain during the painful 
procedure, which may be explained by environmental factors or genetic polymorphisms 
in pain sensitivity. As such, the polymorphism of the COMT Val158Met gene proved associ-
ated with changes in pain sensitivity, as morphine treated patients carrying the Met-allele, 
experienced both significantly higher overall pain scores and significantly higher pain levels 
during the painful procedure, compared to patients with the Val/Val genotype. Although 
this polymorphism explained one part of the inter-individual variability in pain sensitivity, 
more research is needed to identify patients who are at risk for unacceptable pain during 
painful procedures. Unacceptable pain during painful procedures may potentially be further 
decreased by decreasing patients’ anxiety. Hereby, the nurse may play an important role in 
approaching patients undergoing a painful procedure, in which a good attitude and com-
munication are essential. Furthermore, more research is needed to evaluate procedural seda-
tion, for which midazolam or propofol - combined with an analgesic such as fentanyl - are 
suggested agents.
Studying chronic thoracic pain, it appeared that there is a need for a uniform definition, 
which is of added value in obtaining more reliable and clinically significant data on the 
incidence of this phenomenon. In a follow up study of patients included in the randomised 
clinical trial, remifentanil was associated with the development of chronic thoracic pain, in a 
dose dependent manner. These results must be confirmed in a randomised controlled trial.
Both morphine and paracetamol were investigated in terms of efficacy and safety in in-
tensive care patients. In a population pharmacokinetic model, which was developed with 
nonlinear mixed-effects modelling, glucuronidation capacity and elimination clearances of 
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morphine and morphine-3-glucuronide (M3G) were significantly decreased in intensive care 
patients, compared to healthy volunteers. This knowledge is of added value for the develop-
ment of individualized dosing regimens in intensive care patients.
Concerning the safety of paracetamol, physicians and pharmacists may be reluctant 
to use paracetamol in intensive care patients, as a volunteer study suggested that taking 
paracetamol four grams daily could result in elevated alanine-aminotransferase levels in a 
substantial proportion of healthy volunteers. However, with the current knowledge of our 
study, there is no reason not administering paracetamol in intensive care patients. However, 
in case of an increased ALT level of more than three times the upper limit of normal, the use 
paracetamol should be reconsidered.
In conclusion, we significantly improved the pain management in the intensive care unit. 
More specifically, we were able to reduce pain levels which are substantially lower compared 
to other studies. However, despite the efforts for pain management at rest and during pain-
ful procedures, one part of the patients is subject to unacceptable pain levels during their 
intensive care stay. More research is needed to identify objective parameters which may be 
used for pain measurement in case the patient is not able to report pain. Furthermore, there 
is a need of identifying the high risk patient for unacceptable pain scores during painful 
procedures, thereby including pharmacogenetics, potentially in the preoperative evaluation. 
In this way, individual pain treatment regimens can be implemented, and studies can be 
designed to identify the real contribution of genetics in the individual patient. These high 
risk patients may potentially benefit from another pain treatment during painful procedures, 
in which procedural sedation may be useful in the anxious patient. At last, the results of 
pharmacokinetic study, in which the glucuronidation capacity and elimination of morphine 
and M3G was studied, can be used to develop more individualized dosing regimens [103].
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Appendix 1: Overview pain scales for conscious patients and sedated patients in the ICU
Pain scale Dimension total 
range
items range 
items
Pain scales for patients´ self report
Visual Analogue Scale
(VAS) [104]
0 (no pain) -100 (maximal pain) 0-100 - -
Numerical Rating Scale 
(NRS) [105]
0 (no pain) -10 (maximal pain)* 0-10 - -
Verbal Rating Scale
(VRS-4) [106]
1. No pain (NRS=0)
2. Mild pain (NRS 1-3)
3. Moderate pain (NRS 4-6)
4. Severe pain (NRS 7-10)
0-4 - -
objective pain scales scored by the nurse
Non Verbal Pain Scale 
(NVPS) [12]
Sum of 3 behavior indicators +
2 physiological indicators
0-10 Behavior indicators
1.Facial expression
2. Body movement
3. Guarding
Physiological indicators I
4. Changes in vital symptoms in last 4 
hours
Physiological indicators II
5. Changes in skin, pupil diameter or 
body temperature
0-2
0-2
0-2
0-2
0-2
PAIN-Algorithm [13] 0 (no pain) -10 (maximal pain)
Based on 3 behavior indicators + 8 
physiological indicators
0-10 Behavior indicators
facial expression: 1. grimacing
2. Drawn around mouth and eyes.
3. Teary- crying 4. Wrinkled forehead
movements: 5. none 6. Slow
7. Restlessness 8. Seeking attention 9. 
Vocalization
Posturing/guarding: 10. Rigid
11. Splinting 12. Tense, stiff.
Physiological indicators
1. Increased or 2. Decreased Heart rate 3. 
Increased or 4. Decreased blood pressure 
5. Increased or
6. Decreased respiratory rate
7. Perspiration 8. Pallor
Present / 
Absent
Present / 
Absent
Critical Care Pain 
Observation Tool
(CPOT) [18]
Sum of 4 behavior indicators 0-8 1. Facial expression
2. Body movements
3. Muscle tension
4a. compliance with the ventilator or
4b. vocalization for extubated patients
0-2
0-2
0-2
0-2
Behavioral Pain Scale
(BPS)[15]
Sum of 3 behavior indicators 3-12 1. Facial expression
2. Upper limb movements
3.  Compliance with mechanical 
ventilation
1-4
1-4
1-4
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Appendix 2. Sedation scales for intensive care patients
Pain scale Dimension total 
range
items
Ramsay score [107] Six levels, with higher levels 
indicating increased degrees of 
sedation.
1 - 6 Level of sedation: 1. patient anxious, agitated, 
restless, 2. patient cooperative, orientated and 
tranquil, 3. patient drowsy or asleep, responds 
easily to commands, 4. patient asleep, brisk 
response to a light glabellar tap, 5. patient asleep, 
sluggish response to a light glabellar tap and 6. 
patient asleep, no response to a light glabellar tap
Sedation agitation scale 
(SAS) [27]
7 levels with lower levels indicating 
increased levels of sedation
1-7 Level of sedation: 1.Unarousable 2. Very sedated 3. 
Sedated 4. Calm, cooperative, 5. Agitated 6. Very 
agitated 7. Dangerous agitation
Motor activity 
assessment Scale 
(MAAS) [29]
Seven levels, with higher levels 
indicating increased degrees of 
sedation.
0 - 6 Agitation: three levels (4 to 6),
Calm and cooperative level: one level (level 3),
Sedation: 3 levels (levels 0 to 2) All levels are defined 
by multiple criteria.
Vancouver Interaction 
and calmness scale 
(VICS)
Contains two domains (‘interaction’ 
and ‘calmness’).
0-30 per 
domain
Each domain has five questions, and each question 
has six responses from ‘strongly agree’ to ‘strongly 
disagree’. Patient stimulation required for some 
questions. Scores are summed, with higher scores 
for calm and interactive
Richmond Agitation 
Sedation Scale (RASS)
[30]
Ten levels with lower levels 
indicating increased degrees of 
sedation. Levels were defined by 
response to verbal then physical 
stimulation, plus consideration of 
cognition and sustainability
-5 - 4 Level of sedation: 0. Unresponsive 1. Responsive 
only to noxious stimulus 2. Responsive to touch 
or name 3. Calm and cooperative 4. Restless and 
cooperative 5. Agitated 6. Dangerously agitated, 
uncooperative
Adaption to the 
intensive care 
environment (ATICE) [34]
Five tests in two domains: 
consciousness and tolerance 
domains.
0-20 Consciousness domain: (a) awakeness scale (five 
levels from 0 = eyes closed, no mimic, to 5 = eyes 
open spontaneously, based on verbal then physical 
stimulation) and (b) comprehension scale (score 
based on summing 1 point each for positive 
response to five commands). Tolerance domain: 
(a) calmness scale (four levels from 3 = calm to 0 = 
life-threatening agitation), (b) ventilator synchrony 
scale (score based on summing 1 point for each of 
four observed events) and (c) face relaxation scale 
(four levels from 3 = relaxed face to 0 = permanent 
grimacing)
Bispectral index (BIS)
[108]
Objective method for sedation 
assessment, based on the patients’ 
electroencephalogram (EEG)
0-100 100 represents an ‘awake’ clinical state, whereas 0 
denotes an isoelectric state.
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introDuction
In the recent past, pain management has become an essential part of the standard care 
of patients in the intensive care unit (ICU), as these days 63-77% of intensive care patients 
reported pain during their stay in the ICU. Adequate pain management may reduce physi-
ological adversity and emotional stress, and will therefore result in a decrease in morbidity 
and mortality. Adequate pain management reflects a certain quality in daily patient care and 
is considered an important healthcare benchmark. The topic became more important, as 
result of new position statement of the ideal depth of sedation, which is changed away from 
deep sedation in combination with muscle relaxants towards a restricted sedation policy to 
a conscious level whenever possible. Adequate pain management can be achieved only by 
using effective methods for the recognition, evaluating and monitoring of pain. Knowledge 
of the optimal pain measurement instrument and insight which health care worker should 
rate pain in case the patient cannot communicate verbally, are necessary. However, pain 
measurement in intensive care patients can be complicated as result of underlying diseases 
and decreased consciousness.
Analgesic treatment with morphine and paracetamol is the cornerstone of pain manage-
ment. Although both analgesics are commonly used and are extensively investigated, the 
most optimal dose is still not known in terms of efficacy and safety. Especially the morphine 
dose required to produce analgesia for pain relief is characterized by a large inter-individual 
variability.
In this thesis, we studied the most optimal method for measuring pain in intensive care 
patients, in which we evaluated several pain measurement instruments and identified the 
health care worker who should score pain in case the patient is not able to communicate. 
Secondly, we aimed to improve pain management at rest and during routine care procedures 
in patients after cardiothoracic surgery. Moreover, we studied the influence of genetics on 
pain sensitivity during an unavoidable painful procedure, and tried to identify predictors for 
development of chronic thoracic pain in cardiac patients. At last, we studied the pharmaco-
kinetics of morphine in intensive care patients, on the basis of population pharmacokinetic 
modelling and the safety of paracetamol in postoperative patients after cardiac surgery.
Pain aSSeSSment in intenSiVe care PatientS
Various pain measurement instruments are available, but it remains unclear whether they 
can be applied reliably in the diverse patient population of the ICU. Furthermore, it is of inter-
est which health care worker (nurse, physician or consultant) should score pain in case the 
patient cannot communicate verbally.
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In chapter 2, we designed a prospective observational study to compare the visual 
analogue scale (VAS), numeric rating scale (NRS) and the behavioral pain scale (BPS), and to 
compare pain scores of different observers and the patient for measuring pain in patients 
in the ICU. So far, the VAS and NRS were validated for acute pain only, but not for pain mea-
surement in intensive care patients specifically. Furthermore, the BPS was validated for pain 
measurement in sedated and mechanically ventilated patients, but this pain scale still is not 
generally accepted for routine use. This study showed that whenever this is possible, intensive 
care patients should rate their pain using the NRS. In sedated patients, the attending nurse 
involved in daily care should score the patient’s pain, in which the BPS should be used only in 
conjunction with the NRS rated by the nurse to measure pain levels in the absence of painful 
stimuli. Although the different scales show a high reliability, observer-based evaluation often 
underestimates the pain, particularly in case of high NRS values (≥4) rated by the patient.
Apart from conscious patients and sedated patients, a third group of patients can be 
identified, i.e. conscious sedated mechanically ventilated patients. Current intensive care 
practice strives to restrict sedation to a conscious level whenever possible, in agreement with 
the landmark report that showed that ventilated patients benefit from daily interruption of 
sedative infusions. These patients may be communicative, but self-reporting using the NRS 
or VRS-4 may be complicated or unreliable in these patients due to their temporarily limited 
capacities of abstraction and concentration, and lack of comprehension. Therefore, in chap-
ter 3, we evaluated the use of the behavioral pain scale (BPS) in conscious sedated patients in 
comparison to its use in deeply sedated patients, for whom the BPS was developed. Addition-
ally, in conscious sedated patients the combination of the BPS and the patient-rated verbal 
rating scale (VRS-4) was evaluated. In a prospective evaluation study in 80 non-paralyzed 
critically ill adult intensive care unit patients, the BPS appeared a valid tool for measuring 
pain in conscious sedated patients during painful procedures. Thus, for non-communicative 
and mechanically ventilated patients the BPS may be regarded as a bridge between the ob-
servational scale used by nurses and the VRS-4 used by patients who are able to self-report 
pain.
Pain management in intenSiVe care PatientS after carDiac Surgery
In order to improve pain management for patients at rest in the ICU, in chapter 4 the ef-
fect of a pain management programme in the intensive care unit was evaluated, consisting 
of (1) a pain education programme for the health staff, (2) the introduction of systematic 
pain measurement and registration using an automated patient data management system 
(PDMS), and (3) optimization of the analgesia protocol. In this prospective two-phase study, 
pain levels scored by intensive care patients after cardiac surgery through sternotomy were 
compared before and after the implementation of a pain management programme. The 
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intervention programme successfully reduced the occurrence of unacceptable pain (NRS≥4) 
(OR 2.54 [95%CI 1.22 - 5.65; P=0.01] for the control group). Further improvement of pain man-
agement should focus on more individually tailored analgesia and procedural related pain, as 
46% of the patients in the intervention group still experienced at least one unacceptable pain 
event during their ICU stay. Therefore, a pain titration protocol was implemented, consisting 
of paracetamol 4 grams per day, and continuous morphine infusions. In Chapter 5, in which 
procedure-related pain was studied, all patients were treated according to the pain titration 
protocol. Within this context, we observed a lower incidence of unacceptable pain at rest 
(16%) in patients treated according the pain titration protocol, compared with the situation 
that only the pain training programme was implemented (Chapter 4).
In chapter 5 we studied the efficacy of an intravenous bolus of morphine 2.5 versus 7.5 
mg for procedural pain relief in patients after cardiac surgery in the intensive care unit. In a 
prospective double-blind randomised study, all patients were treated according to a pain 
titration protocol for pain at rest. On the first postoperative day, patients were randomised 
to intravenous morphine 2.5 or 7.5 mg before a painful intervention (turning of the patient 
and/ or chest drain removal). This study demonstrated that patients treated according to a 
pain titration protocol show low incidences of pain at rest (NRS≥4; 16%) and during a painful 
intervention (NRS≥4; 25%). Within this context, an intravenous bolus of morphine 2.5 mg is 
sufficient for pain relief during a painful intervention.
Despite adequate treatment, one part of the patients (25%) experiences unacceptable pain 
during the unavoidable painful procedure. Pain sensitivity is known to differ largely between 
patients and may partly be explained by genetic polymorphisms. In chapter 6, we investigate 
whether the catechol-O-methyltransferase (COMT) Val158Met polymorphism influences pain 
sensitivity in 117 morphine-treated intensive care patients undergoing unavoidable routine 
care painful procedures after cardiac surgery. While overall mean NRS score was significantly 
higher in patients carrying the Met-variant allele, also during the painful procedure mean NRS 
score was significantly higher for Met/Met patients compared to Val/Met and Val/Val patients. 
In the Met/Met patients, the increase in NRS scores due to the painful procedure compared 
with baseline NRS score was statistically significant and clinically relevant. So far, the COMT 
Val158Met polymorphism has been shown to affect pain sensitivity in experimental healthy 
volunteer studies. Our results suggest that the COMT Val158Met polymorphism contributes 
to variability in pain sensitivity in morphine treated-patients after cardiac surgery, as Met-
allele carriers were found to be more sensitive to overall pain and procedure related pain. 
As a result, patients carrying the Met-allele may benefit from another pain management 
strategy, including analgesics which are independent of endogenous enkephalin levels and 
the μ-receptor density.
Besides acute postoperative pain, chronic thoracic pain after cardiothoracic surgery is a 
serious condition affecting many patients, with reported incidences varying from 11 to 56%. 
In chapter 7, we aimed to identify predictors for chronic thoracic pain after sternotomy. A 
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follow-up study was performed in 120 patients who participated in the randomised clinical 
trial for procedural pain. In this study, 20% of the 90 responders reported chronic thoracic 
pain one year after cardiothoracic surgery. Besides age below 69 years and a body mass index 
(BMI) above 28 kg/m2, intraoperative use of remifentanil was an independent predictor for 
chronic thoracic pain in a dose dependent manner. Randomised studies designed to evaluate 
the influence of intraoperative remifentanil on chronic thoracic pain are needed to confirm 
these results.
morPHine anD Paracetamol analgeSia in intenSiVe care PatientS
In pain management for moderate and severe (postoperative) pain in the ICU, both morphine 
and paracetamol are commonly used analgesics. Although both analgesics are used for 
decennia, and are extensively investigated, there are still questions about the efficacy and 
safety of morphine and paracetamol.
The clinical use of morphine is characterized by a large inter-individual variability in anal-
gesic effect, which may partly be caused by differences in morphine pharmacokinetics as a 
result of variability in health status, hepatic metabolic capacity and renal clearance, particu-
larly in intensive care patients. Morphine is mainly metabolized in the liver via glucuronida-
tion by phase II metabolism enzyme UDP-glucuronosyltransferase (UGT)2B7 to morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G). Both metabolites and unchanged 
morphine are excreted by the kidneys. As the pharmacokinetics of morphine have not been 
adequately quantified in these patients, in chapter 8 the glucuronidation and elimination 
clearance of morphine was evaluated in intensive care patients in conjunction with healthy 
volunteers. The population pharmacokinetic model with covariate analysis included 135 in-
tensive care patients (117 cardiac surgery patients and 18 critically ill patients), who received 
continuous morphine-infusions adapted to individual pain levels, and 20 healthy volunteers, 
who received an intravenous bolus of morphine followed by a 1-hour infusion. In intensive 
care patients, glucuronidation clearance of morphine to M3G and elimination clearance 
of M3G were significantly decreased with 17% and 81% respectively, compared to healthy 
volunteers. Moreover, serum creatinine concentration was identified as a covariate for both 
elimination clearance of M3G within the group of intensive care patients and for non-M3G 
clearance of morphine in both intensive care patients and healthy volunteers. As a result, 
substantially elevated M3G concentrations may be anticipated in intensive care patients, 
which is even more pronounced upon increased serum creatinine concentrations. Consid-
ering the potential anti-nociceptive and hyperalgesic activity of M3G, this finding may be 
clinically relevant, and should be taken into account in this special patient group, particularly 
upon prolonged use of morphine infusions.
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Considering the safety of paracetamol in intensive care patients, physicians and phar-
macists may be reluctant to use paracetamol in intensive care patients, as a volunteer 
study suggested that taking paracetamol four grams daily could result in elevated alanine 
aminotransferase (ALT) plasma levels in a substantial proportion of healthy volunteers. As 
such, it is possible that this problem can be more prevalent for intensive care patients due 
to concomitant usage of drugs that may affect the liver and impaired perfusion of the liver. 
Therefore, in chapter 9, we studied the incidence of ALT elevations after short-term use of 
paracetamol four grams daily in 93 consecutive patients after cardiac surgery. Postoperative 
ALT-levels of >1x upper limit of normal (ULN) was observed in 17% (n=16), and 4% (n=4) 
exceeded >3x ULN. These four patients all had right ventricular failure or cardiogenic shock 
during the postoperative period. Thus, the incidence of significant ALT elevations after using 
daily paracetamol as an analgesic agent for cardiac surgery, at a dose of four grams per day, 
was low and most likely to complications after surgery. Our results, albeit still very limited, 
provided some reassurance about the safety of paracetamol four grams daily, as a supple-
mentary analgesic agent for adult patients undergoing cardiac surgery.
main concluSionS anD PerSPectiVeS
In this thesis, we focused on pain assessment, pain management at rest and during painful 
procedures, and the efficacy and safety of morphine and paracetamol.
In conclusion, we significantly improved the pain management in the intensive care unit. 
More specifically, we were able to reduce pain levels which are substantially lower compared 
to other studies. However, despite the efforts for pain management at rest and during painful 
procedures, one part of the patients still experience unacceptable pain levels during their 
intensive care stay.
More research is needed to identify objective parameters which may be used for pain 
measurement in case the patient is not able to report pain. Furthermore, there is a need 
of identifying the high risk patient for unacceptable pain scores during painful procedures, 
thereby including pharmacogenetics, potentially in the preoperative evaluation. In this way, 
individual pain treatment regimens can be implemented, and studies can be designed to 
identify the real contribution of genetics in the individual patient. These high risk patients 
may potentially benefit from another pain treatment during painful procedures, in which 
procedural sedation may be useful in the anxious patient. At last, the results of pharmacoki-
netic study, in which the glucuronidation capacity and elimination of morphine and M3G was 
studied, can be used to develop more individualized dosing regimens.
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introDuctie
Pijn op de intensive care is een veel voorkomend probleem, waarbij 63-77% van de patiënten 
pijn rapporteert. De behandeling van pijn vormt daarom een essentieel onderdeel van de 
zorg voor intensive care patiënten. Adequate pijnbehandeling versnelt het fysiologisch her-
stel en verminderd stress, waardoor de morbiditeit en mortaliteit afneemt. Daarnaast draagt 
adequate pijnbehandeling bij aan de dagelijkse standaard patiëntenzorg en is dan ook één 
van de kwaliteitsindicatoren in de Nederlandse ziekenhuizen. Ook werd het belang van een 
goede pijnbehandeling groter, naar aanleiding van het nieuwe standpunt met betrekking 
tot de ideale diepte van sedatie, die is gewijzigd van diepe sedatie in combinatie met spier-
relaxantia naar lichte sedatie.
Adequate pijnbehandeling kan alleen maar worden bereikt door het gebruik van effectieve 
methoden om pijn te herkennen, te evalueren en te monitoren. Het is daarbij noodzakelijk 
kennis te hebben van de meest geschikte pijnschalen, en inzicht te hebben in welke behan-
delaar pijn zou moeten meten indien de patiënt niet in staat is te communiceren. Echter, 
pijnmeting in intensive care patiënten is gecompliceerd als gevolg van onderliggende mor-
biditeit en verminderd bewustzijn, waardoor de pijnscore van de patiënt mogelijk ontbreekt.
Wat betreft analgetica vormen morfine en paracetamol de hoeksteen van de pijnbehande-
ling op de intensive care. Hoewel beide analgetica veel gebruikt worden en al uitgebreid 
onderzocht zijn, de optimale dosering van deze analgetica wat betreft effectiviteit en veilig-
heid is nog niet bekend, waarbij in het bijzonder morfine gekarakteriseerd wordt door een 
grote inter-individuele variabiliteit in analgetisch effect.
In dit proefschrift werd de meest optimale methode voor het meten van pijn bij intensive 
care patiënten onderzocht. Er zijn verschillende pijnschalen geëvalueerd. Tevens is geïden-
tificeerd welke behandelaar pijn zou moeten meten, indien de patiënt zelf hiertoe niet in 
staat is. Als tweede hadden we als doel het pijnbeleid te verbeteren tijdens rust en tijdens 
onvermijdelijke routine procedures bij patiënten na hartchirurgie. Daarbij hebben we de 
invloed van genetica op pijngevoeligheid onderzocht, en hebben we getracht voorspellers 
te vinden voor het ontwikkelen van chronische thoracale pijn bij deze patiënten. Tevens was 
een deel van het onderzoek gericht op de farmacokinetiek van morfine in intensive care 
patiënten, waarvoor een populatie farmacokinetisch model ontwikkeld werd. Tot slot werd 
de veiligheid van paracetamol in postoperatieve patiënten na hartchirurgie geëvalueerd.
Pijnmeting in intenSiVe care Patiënten
Er zijn diverse pijnschalen beschikbaar, maar het is nog onduidelijk in hoeverre ze betrouw-
baar kunnen worden toegepast bij de diverse patiëntenpopulatie op de intensive care. Verder 
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is het van belang te weten welke hulpverlener (verpleegkundige, arts of consultant) pijn kan 
scoren, indien de patiënt niet in staat is te communiceren.
In hoofdstuk 2 werden in een prospectieve studie de visual analoge scale (VAS). De 
numeric rating scale (NRS) en de behavioral pain scale (BPS) vergeleken. Tevens werden 
de pijnscores die gerapporteerd werden door intensive care patiënten vergeleken met de 
pijnscores gerapporteerd door de verschillende waarnemers.
Tot nu toe waren de VAS en de NRS alleen gevalideerd voor acute pijn, maar niet voor 
pijnmeting bij intensive care patiënten. Bovendien was de BPS alleen gevalideerd voor pijn-
meting in gesedeerde en beademde patiënten, en is deze pijnschaal nog niet geaccepteerd 
voor dagelijks gebruik. Deze studie toonde aan dat intensive care patiënten die kunnen com-
municeren, zelf de pijn moeten aangeven met behulp van de NRS. Bij gesedeerde patiënten 
zou de verpleegkundige die betrokken is bij de dagelijkse verzorging de pijn van de patiënt 
moeten scoren met behulp van de BPS in combinatie met de NRS. Hoewel de verschillende 
pijnschalen een hoge betrouwbaarheid vertonen, werd de pijn regelmatig onderschat door 
de verpleegkundige, vooral indien de patiënt hoge NRS waarden (≥4) rapporteerde.
Naast wakkere, communicatieve patiënten en gesedeerde patiënten, kan er nog een 
derde groep patiënten worden geïdentificeerd, namelijk de conscious sedated patiënten. 
Tegenwoordig wordt ernaar gestreefd om waar mogelijk sedatie te beperken tot een lichte 
bewustzijnsdaling. Dit is in overeenstemming met het nieuwe standpunt, waaruit bleek dat 
beademde patiënten baat hebben bij de dagelijkse onderbreking van sedativa. Deze con-
scious sedated patiënten zijn aanspreekbaar, maar zelfrapportage met behulp van de NRS of 
VRS-4 kan ingewikkeld of onbetrouwbaar zijn, als gevolg van hun tijdelijk beperkte capaciteit 
voor abstractie en concentratie, en een gebrek aan bevattingsvermogen.
Daarom is in hoofdstuk 3 het gebruik van de behavioral pain scale (BPS) bij conscious seda-
ted patiënten vergeleken met het gebruik van de BPS in diep gesedeerde patiënten voor wie 
de pijnschaal is ontwikkeld. Bovendien werd in conscious sedated patiënten de combinatie 
van de BPS en de verbal rating scale (VRS-4) geëvalueerd. In een prospectieve observationele 
studie met 80 kritisch zieke volwassen intensive care patiënten, bleek de BPS een waardevol 
instrument voor het meten van pijn tijdens pijnlijke procedures wanneer patiënten conscious 
sedated waren. Samenvattend kan de BPS worden beschouwd als een brug tussen de obser-
vationele schaal die wordt gescoord door verpleegkundige en de VRS-4 gerapporteerd door 
de intensive care patiënt.
Pijn management in intenSiVe care Patiënten na HartcHirurgie
Om de pijn in rust bij intensive care patiënten na hartchirurgie te verbeteren, werd in 
hoofdstuk 4 het effect van een pijnmanagement programma geëvalueerd, dat bestond uit 
(1) een pijneducatie programma voor artsen en verpleegkundigen, (2) de introductie van 
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systematische pijnmeting en registratie, en (3) de optimalisatie van het analgeticaprotocol. 
In deze prospectieve tweefase studie werden de pijnscores die werden gerapporteerd door 
patiënten na hartchirurgie voor en na de implementatie van het pijnmanagement pro-
gramma vergeleken. Het programma bleek succesvol in het voorkomen van onacceptabele 
pijn (NRS≥4) tijdens het intensive care verblijf (OR 2.54 [95%CI 1.22 - 5.65], P=0.01). In verdere 
verbetering van pijnmanagement, zou de focus moeten liggen op de het individualiseren 
van de pijnmedicatie en procedurele pijn, omdat nog steeds een deel van de patiënten onac-
ceptabele pijn ervaart. Daarom werd er een pijntitratieprotocol ingevoerd, dat bestond uit 
vier gram paracetamol per dag en een continue morfine infuus, waarbij de dosering werd 
aangepast op basis van de pijnscores. In hoofdstuk 5, waarin procedurele pijn geëvalueerd 
werd, werden alle patiënten behandeld volgens dit pijntitratieprotocol. In deze studie po-
pulatie werd een lage incidentie van pijn bij rust (16%) waargenomen, vergeleken met de 
situatie dat alleen een pijnmanagement programma geïmplementeerd was (Chapter 4).
Om de incidentie onacceptabele pijn verder te reduceren, werd in hoofdstuk 5 de effecti-
viteit van een intraveneuze bolus morfine 2.5 versus 7.5 mg geëvalueerd voor de preventie 
van procedure gerelateerde pijn bij patiënten na hartchirurgie. In een prospectieve, dub-
belblinde gerandomiseerde studie werden alle patiënten behandeld volgens het pijntitratie 
protocol voor pijn bij rust. Op de eerste postoperatieve dag werden patiënten gerandomi-
seerd naar een intraveneuze bolus morfine van 2.5 of 7.5 mg voor het ondergaan van een 
pijnlijke interventie (draaien van de patiënt, of het verwijderen van thorax drains). Deze 
studie toonde aan dat patiënten die adequaat behandeld worden volgens het pijntitratie 
protocol, een lage incidentie voor pijn tijdens een pijnlijke interventie hebben (NRS≥4; 25%). 
In deze context is een intraveneuze bolus morfine 2.5 mg voldoende voor de pijnverlichting 
tijdens een pijnlijke interventie.
Ondanks adequate behandeling ervaart nog steeds een deel van de patiënten (25%) onac-
ceptabele pijn tijdens een pijnlijke procedure. Het is bekend dat pijn tussen patiënten sterk 
kan verschillen, die deels verklaard kan worden door verschillen in patiëntkarakteristieken, 
zoals geslacht en angst. Daarnaast zijn er enkele genen in verband gebracht met verschillen 
in pijngevoeligheid van patiënten. In hoofdstuk 6 onderzochten we de invloed van het ca-
techol-O-methyltransferase (COMT) Val158Met polymorfisme op de pijngevoeligheid in 117 
intensive care patiënten na hartchirurgie. Deze patiënten werden behandeld met morfine, en 
ondergingen een onvermijdelijke pijnlijke procedure op de eerste postoperatieve dag. Pati-
enten die drager waren van het Met-allel, hadden hogere gemiddelde pijnscores gedurende 
de meetperiode, vergeleken met patiënten met het Val/Val genotype. Tevens rapporteerden 
Met/Met patiënten hogere gemiddelde pijnscores vergeleken met Val/Met patiënten en 
Val/Val patiënten. In de Met/Met patiënten was de toename van de NRS scores ten opzichte 
van de baseline NRS significant en klinisch relevant. Tot nu toe was alleen in experimentele 
studies met gezonde vrijwilligers aangetoond dat het COMT Val158Met polymorfisme de pijn 
gevoeligheid beïnvloedt. Onze resultaten kunnen deze associatie bevestigen bij patiënten 
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na hartchirurgie die reeds met morfine behandeld werden. Hierbij zijn Met-allele dragers 
gevoeliger voor procedure gerelateerde pijn en pijn in het algemeen. Patiënten die het Met-
allele dragen, zouden daarom baat kunnen hebben bij een andere pijnbehandeling, waarbij 
analgetica toegepast worden die niet afhankelijk zijn van endogeen enkephalinen en de 
μ-receptor dichtheid.
Naast postoperatieve acute pijn, is de ontwikkeling van chronische thoracale pijn na 
hartchirurgie een serieus probleem. Afhankelijk van de definitie van chronische pijn, worden 
incidenties tussen de 11 en 56% gerapporteerd. Het doel in hoofdstuk 7 was voorspellers te 
identificeren voor het ontstaan van chronische pijn na hartchirurgie via sternotomie. Er werd 
een follow-up studie uitgevoerd, met de 120 patiënten die tevens aan de gerandomiseerde 
studie deelnamen. Hierbij bleek één jaar na de ingreep, 20% van de 90 responders chronisch 
thoracale pijn te rapporteren. Naast een leeftijd onder de 69 jaar en een body mass index 
(BMI) boven de 28 kg/m2, bleek intra-operatief gebruik van remifentanil een onafhankelijke 
voorspeller te zijn voor het ontwikkelen van chronische thoracale pijn. Deze relatie was do-
seringsafhankelijk. Om deze bevindingen te bevestigen zijn gerandomiseerde trials noodza-
kelijk, die het gebruik van intra-operatief remifentanil in relatie tot chronische pijn evalueren.
morfine en Paracetamol gebruiK bij intenSiVe care Patiënten
Morfine en paracetamol zijn veel gebruikte analgetica voor de behandeling van matige tot 
ernstige (postoperatieve) pijn in de intensive care. Hoewel beide analgetica al decennia lang 
gebruikt worden en uitgebreid zijn onderzocht, zijn er nog vragen over de effectiviteit en 
veiligheid van morfine en paracetamol. Het klinisch gebruik van morfine wordt gekenmerkt 
door een grote inter-individuele variabiliteit in analgetisch effect. Dit kan gedeeltelijk worden 
verklaard door verschillen in de farmacokinetiek van morfine als gevolg van de variabiliteit 
in de gezondheidstoestand, de hepatische metabole capaciteit en de renale klaring van 
een patiënt, met name als het intensive care patiënten betreft. Morfine wordt voornamelijk 
gemetaboliseerd in de lever via glucuronidering door fase II metabolisme enzym UDP-
glucuronosyltransferase (UGT) 2B7 in twee metabolieten; morfine-3-glucuronide (M3G) en 
morfine-6-glucuronide (M6G). Beide metabolieten en de onveranderde morfine worden 
uitgescheiden via de nieren. Tot nu toe is de farmacokinetiek van morfine nog niet gekwan-
tificeerd in intensive care patiënten. Daarom werd bij deze patiënten in hoofdstuk 8 de 
glucuronidering en eliminatieklaring van morfine geëvalueerd, en vergeleken met gezonde 
vrijwilligers. Het populatie farmacokinetisch model omvatte 135 intensive care patiënten 
(117 patiënten na hartchirurgie en 18 kritisch zieke patiënten), die een continue intraveneus 
morfine infuus kregen toegediend, waarbij de dosering morfine werd aangepast op basis 
van de pijn. Hier werd data van een eerdere publicatie aan toegevoegd; deze omvatte 20 
gezonde vrijwilligers die een intraveneuze bolus morfine ontvingen, gevolgd door een 1-uur 
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durend morfine infuus. Het bleek dat de glucuronideringsklaring van morfine naar M3G en 
eliminatieklaring van M3G in intensive care patiënten significant was afgenomen met respec-
tievelijk 17% en 81%, in vergelijking met gezonde vrijwilligers. Bovendien werd het serum 
creatinine concentratie geïdentificeerd als een covariaat voor zowel de eliminatieklaring van 
M3G binnen de groep van intensive care patiënten, als voor niet-M3G klaring van morfine 
bij zowel de intensive care patiënten en gezonde vrijwilligers. Als gevolg hiervan kunnen 
aanzienlijk verhoogde M3G concentraties worden verwacht in intensive care patiënten, die 
nog meer uitgesproken zullen zijn bij verhoogde creatinine concentraties. Gezien de poten-
tiële anti-nociceptieve en hyperalgetische activiteit van M3G, kan deze bevinding klinisch 
relevant zijn. Indien morfine wordt toegepast bij deze patiëntenpopulatie moet hiermee 
rekening worden gehouden, vooral wanneer morfine infusies langdurig worden toegepast.
Wat betreft de veiligheid van het gebruik van paracetamol in intensive care patiënten is 
nog veel discussie, waardoor artsen en apothekers terughoudend zijn bij het gebruik van 
paracetamol bij deze patiënten. Dit als gevolg van een vrijwilliger studie, die suggereerde 
dat het gebruik van 4 gram paracetamol per dag kan leiden tot verhoogde alanine amino-
transferase (ALT) plasma concentraties in een aanzienlijk deel van de gezonde vrijwilligers. 
Dit probleem kan ernstiger zijn bij intensive care patiënten, die meerdere geneesmiddelen 
gebruiken die de lever aandoen, waarbij tevens sprake kan zijn van een verminderde 
perfusie van de lever. Daarom hebben we in hoofdstuk 9 de incidentie van ALT stijgingen 
geëvalueerd bij 93 patiënten na hartchirurgie, die kortdurend 4 gram paracetamol per dag 
gebruikten. Postoperatieve ALT stijgingen van meer dan één keer de Upper Limit of Normal 
(ULN) en drie keer de ULN werden waargenomen bij respectievelijk 17% (n=16) en 4% (n=4) 
van de patiënten. Deze vier patiënten hadden rechter ventrikel falen of een cardiogene shock 
tijdens de postoperatieve periode. Bij kortdurend paracetamolgebruik blijkt de incidentie 
van een significante ALT-stijging zeer laag te zijn, waarbij deze stijgingen zeer waarschijnlijk 
het gevolg waren van complicaties na hartchirurgie. Onze resultaten geven, zij het nog steeds 
zeer beperkt, enige geruststelling over de veiligheid van 4 gram paracetamol per dag, indien 
deze toegepast wordt als analgeticum voor volwassen patiënten na hartchirurgie.
belangrijKSte concluSieS en aanbeVelingen
In dit proefschrift hebben we ons gericht op pijnmeting, pijnbestrijding in rust en tijdens 
pijnlijke procedures, en de effectiviteit en veiligheid van paracetamol en morfine.
De pijnbehandeling voor patiënten op de intensive care is significant verbeterd, en is de 
incidentie van onacceptabele pijn tijdens een verblijf op de intensive care lager vergeleken 
met andere studies die eenzelfde patiëntenpopulatie evalueerden.
Echter, ondanks onze inspanningen om de pijnbehandeling te verbeteren, heeft nog 
steeds een deel van de patiënten onaanvaardbaar veel pijn tijdens een intensive care 
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verblijf. In dit kader is er meer onderzoek nodig om objectieve parameters te identifi ceren 
die gebruikt kunnen worden als pijnmeetinstrument indien de patiënt niet in staat pijn te 
rapporteren. Bovendien moet er onderzoek worden gedaan naar het identifi ceren van hoog 
risico patiënten voor het ontwikkelen van pijn tijdens onvermijdelijke routine procedures. In 
de toekomst kan farmacogenetica hierbij een grotere rol gaan spelen, waarbij het genetica 
profi el mogelijk bij in de preoperatieve setting geëvalueerd kan worden. Op deze manier 
kan de pijnbehandeling geïndividualiseerd worden en kunnen studies ontwikkeld worden 
die de werkelijke bijdrage van genetica in de individuele patiënt kunnen bestuderen. Verder 
kunnen hoogrisico patiënten baat hebben bij een andere behandeling dan opiaten tijdens 
pijnlijke procedures, waarbij wij suggereren dat procedurele sedatie nuttig kan zijn bij de 
angstige patiënt. Tenslotte kunnen de resultaten van de farmacokinetische studie, waarin de 
glucuronidatie en de eliminatie van morfi ne en M3G onderzocht werden, gebruikt worden 
voor het ontwikkelen van geïndividualiseerde doseerschema’s van morfi ne in intensive care 
patiënten.
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De afgelopen jaren heb ik met veel plezier gewerkt aan mijn proefschrift. Natuurlijk was het 
nooit gelukt zonder de hulp en ondersteuning van velen en die wil ik graag bedanken. 
In de eerste plaats Prof. Dr. Tibboel, beste Dick, heel erg bedankt dat je mij de mogelijkheid 
hebt gegeven om onderzoek te doen. Ik weet nog goed dat ik voor het kennismakingsge-
sprek bij je kwam, en er ad-hoc naar een oplossing werd gezocht voor de start van het pro-
motietraject, omdat ik pas een jaar later afstudeerde. Dit was kenmerkend voor de volgende 
bijeenkomsten; inspirerende ideeën, concrete oplossingen en een kritische blik, zodat ik weer 
vol frisse moed en enthousiasme door kon gaan. Bedankt voor de prettige samenwerking.
Prof. Dr. Knibbe, beste Catherijne. Als student farmacie leerde ik je kennen, waarbij ik je al snel 
bewonderde om je enorme enthousiasme voor onderzoek, dat je ook nog combineerde met 
het vak als ziekenhuisapotheker. Je hebt mij voor beide vakgebieden enthousiast gemaakt, 
waarbij jij ook degene bent geweest die mij de kans hebt gegeven beide uit te voeren. Ik 
denk terug aan onze goede, maar ook fijne gesprekken; samen met Laura keek ik altijd uit 
naar de ‘opkikker’-uurtjes van jou. Ik ben trots dat jij mijn promotor bent: bedankt voor de 
afgelopen tijd, bedankt voor alles!  
Mijn copromotor, Dr. van Dongen, beste Eric. Ook jij was er vanaf het eerste uur bij, waarbij 
ik mijn eerste ervaringen opdeed met wetenschappelijk onderzoek. Tevens gaf je mij de 
mogelijkheid klinisch onderzoek te doen, waarbij ik de periode op de intensive care als heel 
bijzonder heb ervaren. Bedankt voor het vele overleg en de leuke gesprekken. 
Mijn collega-onderzoeker, Laura van Gulik. Duizenden bloedmonsters, stopwatches, ijs, cen-
trifugeren, stapels formulieren, samen brainstormen, en gelukkig heel veel groene kikkers 
om het vol te houden. Wat hebben we samen toch een bijzondere tijd gehad; vooral de tijd 
van de patiënten inclusie zal ik niet snel vergeten! Ik vind het enorm knap van je dat je het 
onderzoek wist te combineren met je eigen opleiding tot anesthesioloog en intensivist. Jij 
bent er ook bijna: nog heel veel succes met de laatste loodjes!
Peter Bruins, ook jij hoort ook zeker in dit rijtje thuis. Met bovengenoemde mensen hebben 
we heel wat uren overleg gehad over de opzet van het onderzoek en het bespreken van de 
resultaten. Heel erg bedankt voor het altijd kritisch beoordelen van de manuscripten; ik heb 
veel van je geleerd.
De afdeling Anesthesiologie en Intensive Care en de afdeling cardio-thoracale chirurgie van 
het St. Antonius ziekenhuis wil ik graag bedanken voor de goede samenwerking, de onder-
steuning van het onderzoek en de fijne sfeer. De intensive care verpleegkundigen hebben 
heel erg geholpen met het afnemen van talloze bloedmonsters en het invullen van formu-
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lieren, ook midden in de nacht. Zonder jullie hulp was de OPCIC studie nooit voltooid. Aletta 
van Veen, dank voor je uitleg en nuttige tips over pijnmetingen bij intensive care patiënten.
Ook is mijn dank is groot aan alle patiënten die bereid waren deel te nemen aan ons onder-
zoek; zij vormen de basis van dit proefschrift.
Uit het LUMC wil ik graag Prof Dr. A. Dahan en René Mooren bedanken voor het bepalen 
van de morfine in de vele bloedmonsters. Het Klinisch Chemisch Lab van het St. Antonius 
Ziekenhuis wil ik bedanken voor de goede logistiek rondom de leverfunctie bepalingen. Uit 
het Erasmus MC wil ik graag Ron van Schaik bedanken voor de DNA analyses en zijn input 
hieromtrent.
Graag wil ik alle medewerkers van de Klinische Farmacie en Antonius Apotheek van het St. 
Antonius Ziekenhuis bedanken voor de fijne samenwerking en de belangstelling voor mijn 
onderzoek. De apothekersassistenten; bedankt voor het klaarmaken van de studiemedicatie.
In het bijzonder wil ik mijn opleider, Mathieu Tjoeng, bedanken voor de mogelijkheid het 
onderzoek te combineren met de opleiding tot ziekenhuisapotheker in de vorm van een 
ZAPIKO constructie. Ik ben trots dat ik bij jou in opleiding mag zijn; gelukkig mag ik nog 1,5 
jaar bij de Klinische Farmacie blijven!   
Mijn collega ziekenhuisapothekers Vera Deneer, Arie Van Dijk, Ewoudt van de Garde, Rifka 
Peeters en Ed Wiltink wil ik heel erg bedanken voor de ruimte die jullie mij gaven om het 
onderzoek te voltooien. Rifka en Ewoudt; ook jullie hebben ieder hulp geboden bij studies in 
dit proefschrift; dank daarvoor.
Heel graag wil ik ook mijn (oud-) ZAPIO’s en mede-promovendi bedanken: Ankie Harmsze, 
Tjetske Gerbranda, Jeroen Diepstraten, Roeland Vis, Bas Peters, Tanja ter Brake, Margreke 
Brill en Anne van Rongen. Fijn dat wij collega’s zijn, die altijd voor elkaar klaar staan. Ik kijk 
ook alweer uit naar het volgende (vast niet te evenaren) heel-veel-gangen diner. Tanja, wat 
ontzettend leuk dat jij met mij het vervolgonderzoek gaat doen: ik hoop dat het voor jou net 
zo’n bijzondere ervaring wordt als dat het voor mij was. Margreke & Anne; heel veel succes 
nog met jullie onderzoek, het worden zeker weten stuk voor stuk mooie boekjes! Jeroen; wat 
enorm fijn dat jij op deze dag mijn paranimf bent. Je kunt nu alvast een beetje wennen hoe 
het is om daar te staan; ook jij succes met de afronding van je proefschrift!
De farmacie studenten Zina Brkić, Xue-Mei Guo, Kimberly Sudofsky, Hanna Brouwer en Lies-
beth Verreth, en verpleegkundige studenten Marco van Veelen en Vincent van der Dussen; 
veel dank voor jullie inzet bij de verschillende studies van dit proefschrift. 
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Bij deze zou ik ook graag de leden van de leescommissie (Prof. Dr. A.H.J Danser, Prof. Dr. 
R.J. Stolker en Prof. Dr. L.P.H.J. Aarts) hartelijk willen bedanken voor het beoordelen van het 
manuscript.
Tot slot wil ik graag wil ik mijn alle familie en vrienden bedanken voor hun interesse en steun 
in mijn onderzoek.
Farmacievriendinnetjes en ‘Pitjes’; dank jullie wel voor jullie gezelligheid. Dat er nog veel 
etentjes en weekendjes weg mogen volgen. Andrea, met jou ben ik dit avontuur aangegaan 
tijdens de onderzoeksstage; dank je wel voor de gezellige ‘Antonius-tijd’.
Lieve Veerle, lieve zus. Ik ben zo blij dat jij mijn paranimf bent! Dank je wel voor alle steun 
en vertrouwen in mij de afgelopen jaren, maar bovenal ook voor de ontspannen momenten 
tijdens etentjes, en het afstruinen van verschillende winkelstraten. Ik ben ook trots op jou!
Lieve Pap en Mam, zonder jullie was dit boekje er nooit geweest. Altijd hebben jullie voor 
mij klaar gestaan, en mij gemotiveerd en gestimuleerd om door te gaan. Jullie gaven mij het 
vertrouwen dat ik dit kon. Mam, dank je wel voor je altijd opbeurende woorden wanneer ik 
het even niet zag zitten. Pap, dank je wel voor de altijd stimuleerde woorden, en interesse 
in mijn onderzoek (tot en met de NONMEM analyse!). Dank jullie wel, ik kan mij geen betere 
ouders wensen.
Lieve Micha, niets is genoeg om uit te drukken hoeveel je voor mij betekent. Dank je wel 
voor je vertrouwen, steun, humor en gezelligheid. Ik verheug mij erop samen met jou oud 
te worden. 
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